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ABSTRACT 
Trillions of bacteria live within the gastrointestinal tract and are critical for 
maintaining intestinal homeostasis; however, the mechanisms utilized by specific 
bacterial molecules to contribute to homeostasis are not well understood.  We 
utilize a mouse model in which a single oral dose of the probiotic, Bacillus 
subtilis, protects mice from acute colitis induced by the enteric pathogen 
Citrobacter rodentium.  Our goal is to elucidate the mechanism by which B. 
subtilis prevents inflammation.   
We identified exopolysaccharides (EPS) to be the active molecule of B. 
subtilis, and a single dose of EPS protects mice from disease.  EPS binds 
F4/80+CD11b+ peritoneal macrophages, and adoptive transfer of macrophage-
rich peritoneal cells from EPS-treated mice confers protection from disease to 
recipient mice.  Following EPS treatment, macrophages increase expression of 
CD206, arginase-1, YM-1, FIZZ-1, and IL-4Rα, markers indicative of anti-
inflammatory M2 macrophages.  EPS does not protect TLR4-deficient mice from 
C. rodentium-induced disease, and as expected, M2 macrophages do not develop 
in TLR4-/- mice following EPS treatment.   
CD4+ T cells drive much of the inflammation associated with C. rodentium 
infection, and we hypothesized that EPS-induced M2 macrophages inhibit CD4+ 
T cell responses in vivo.  Accordingly, we measured levels of IFN-γ (Th1), IL-17 
(Th17), and IL-13 (Th2) in splenic T cells following EPS treatment and found 
	xxi	
decreased levels of these cytokines.  In vitro, EPS-induced M2 macrophages 
inhibit activation and proliferation of both CD4+ and CD8+ T cells.  The inhibition 
of CD4+ T cells is dependent on TGF-β, whereas inhibition of CD8+ T cells 
is dependent on both TGF-β and PD-L1.  We suggest that administration of B. 
subtilis EPS can be utilized to broadly inhibit T cell activation and thus control T 
cell-mediated immune responses in numerous inflammatory diseases.   	
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CHAPTER ONE 
LITURATURE REVIEW 
Introduction. 
Humans are home to trillions of bacteria that inhabit virtually all surfaces 
and mucosal tissues of the body.  The gastrointestinal tract (GIT) shares the 
majority of the bacterial load, providing a home to 100 trillion individual 
organisms at a density of 1011 to 1014 cells per gram of luminal contents (Ley et al. 
2008).  Millions of years of co-evolution have interwoven many aspects of the 
microbiota and host; humans provide a nutrient rich environment and safe-
haven and in exchange, bacteria provide paramount benefits to the host.  
Beneficial bacteria aid in food digestion, synthesize vitamins, provide essential 
nutrients, promote angiogenesis and enteric nerve function, defend against 
opportunistic pathogens, and contribute to the development and maintenance of 
the immune system (Hooper, Wong, A. Thelin, et al. 2001).   
Disruption of the normal microbiota which can occur through diet, 
antibiotic use and other environmental factors, contributes to a wide range of 
diseases (Hooper et al. 2012).  Western civilization has brought an era of 
increased sanitation, widespread overuse of antibiotics, and alterations in diet.  
These changes have been accompanied by dramatic increases in allergy and 
asthma, IBD, obesity, and diabetes, all of which are associated with dysbiosis of
2	
	
the microbiota, often in individuals with increased genetic susceptibility to these 
diseases.   
Currently, we have limited knowledge of the mechanisms by which 
bacteria exert beneficial effects or how they can be used to treat disease.  The co-
evolution of the microbiota and the immune system has given rise to very 
complex and intricate mutualistic-symbiotic relationships, while many bacterial 
species may be true commensals.  Of the thousands of different species that 
reside in the GIT, only a handful of organisms have been identified to have 
immunomodulatory functions.  Additionally, several organisms not typically 
thought to be a part of the microbiota, such as those present in fermented foods 
such as yogurt, possess beneficial effects as probiotics.   
Given the complexity of the established interactions, many other species 
undoubtedly exert a wide array of effects not only on the immune system, but 
other physiological processes, as well.  Additionally, some species may promote 
similar pathways to those already identified to maintain homeostasis.  
Outstanding questions: how does the host respond to bacterial colonization?  Do 
bacteria promote normal development of the host? How do different bacteria 
promote immunity? Can beneficial bacteria be used as therapeutics?  All of these 
are important questions in understanding how the microbiota contributes to the 
health of the individual, and importantly, how the microbiota can be used to treat 
disease. 
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Section 1: Role of the Microbiota in the Development of the Immune 
System 
Early-life Microbial Exposure. 
Our current understanding states that the fetal gastrointestinal tract is 
sterile.  At birth, upon passage through the birth canal, the baby is exposed to 
microbes and seeding of the skin and gastrointestinal microbiota begins.  This 
marks the first interaction between the immune system and bacteria, viruses and 
fungi, commencing the training of the immune system to tolerate these microbes.  
In infants born vaginally, Lactobacillus species, similar to the vaginal 
microbiome, comprise the majority of the gut microbiota.  In infants born via 
cesarean section, the gut microbiota resembles the skin microbiome of the 
mother, including Staphylococcus, Streptococcus or Propionibacteria 
(Dominguez-Bello et al. 2010).  Additionally, Pre-term birth is often associated 
with intrauterine infection and a breakdown of maternal-fetal tolerance, leading 
to an altered microbiome (Romero et al. 2014).  By two years of age, the 
microbiota compositions between these groups are fairly similar; however, a 
delay in exposure to certain bacteria during this crucial developmental period for 
the immune system highly correlates with immune disorders later in life 
(Bäckhed et al. 2015; Weng & Walker 2013).  
The tolerogenic environment of the neonate allows colonization of the 
microbes to occur, without eliciting a strong inflammatory response.  Neonates 
have blunted inflammatory cytokine responses and a high percentage of 
regulatory T cells, which help maintain tolerance to the influx of microbes.  This 
4	
	
immunosuppressed state, however, leaves the infant highly susceptible to 
infection and unable to mount protective responses following vaccination.  
Recently, impaired neonatal host defense to bacterial infections has been 
attributed to highly-suppressive erythroid cells (Elahi et al. 2013).  These cells 
actively protect against excessive inflammation triggered by commensal 
microbes, allowing colonization to occur, which seemingly outweighs the risk of 
infection.  
Following birth, nutrition, environmental factors, host genetic factors, and 
antibiotic use impact the developing microbiota.  During this immunosuppressed 
state, breast milk provides nutrients, bacteria and immune protection to the 
infant (Koenig et al. 2011).  Oligosaccharides present in breast milk influence the 
final composition of the infant microbiota to an adult-like state by promoting the 
expansion of Bifidobacteria and Bacterioides species (Marcobal et al. 2010).  
Additionally, maternal IgA in the breast milk shapes the neonatal microbiota by 
binding to nutrients or bacteria, allowing selection of certain bacteria, including 
Bifidobacteria and Bacterioides species, in the GIT (Peterson et al. 2007).   
Bacteria that colonize the infant GIT play a vital role in fine-tuning of the 
developing immune system.  The mode of delivery and host genetics contribute to 
the colonization of the microbiota in infants and development of immune 
responses.  Recent evidence suggests that infants may also be exposed to 
microbial products that cross the placenta (Aagaard et al. 2014), suggesting that 
microbes may begin to shape the immune system prior to birth.  At birth, T 
helper (Th)-2-dominant immune responses prevail, but colonization with 
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Bacterioides spp. contributes to Th1 skewing (Weng & Walker 2013).  In formula-
fed infants compared to breast-fed infants, and more dramatically in infants born 
via cesarean section compared to vaginal delivery, the microbiome is less diverse 
and Th1-skewing does not occur (Dominguez-Bello et al. 2010).  Indeed, many of 
the diseases associated with early-life alterations in the microbiota are Th2-
driven immune disorders.  
Environmental factors also contribute to the maturation of the microbiota.  
In Western civilizations, relatively sterile living environments and good hygiene 
limit early childhood exposure to microbes.  Additionally, the high-prevalence of 
antibiotic use in infants and in early childhood dramatically alters colonization.  
This dysbiosis is associated with increased risk of asthma, atopic dermatitis, 
allergy and autoimmune disorders (Sellitto et al. 2012).  Children with early-life 
exposure to cats and dogs, presumably a less clean environment, have a 
decreased risk of developing asthma and allergy (Ownby et al. 2002).  Further, 
children with siblings or living on or near a farm have lower rates of hay fever and 
atopic disorders compared to children raised in cities (Genuneit et al. 2013).   
These observations and studies in humans demonstrate the importance of 
the microbiota early in life, but have not elucidated the mechanisms by which the 
microbiota shapes the immune system, and in turn, the immune system shapes 
the microbiota.  
Influence of Microbiota on Development of Lymphoid Tissues.  
Animal models have provided mechanistic insights for these correlations 
seen in humans.  Germ-free animals have extensive immune system defects 
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compared to conventionally raised animals.  In rabbits, development of gut 
associated lymphoid tissue (GALT) requires the microbiota (Perey & Good 1968; 
Stramignoni et al. 1969).  Further, interactions between GALT and the intestinal 
microbiota stimulate development and expansion of the preimmune antibody 
repertoire (Lanning et al. 2000; Rhee et al. 2005).  Similarly in mouse GALT, 
Peyer’s patches, mesenteric lymph nodes (MLN), the cecal patch and isolated 
lymphoid follicles (ILF) all show developmental defects in size and function in 
germ-free mice compared to mice housed under normal conditions (specific-
pathogen free (SPF) mice) (Falk et al. 1998; Bouskra et al. 2008).  Although 
lymphoid tissue inducer (LTi) cells (reclassified as RORγt+ Innate Lymphoid 
Cells (ILC)-3, discussed later) induce development of lymph nodes and Peyer’s 
patches prior to birth, selective colonization of germ-free mice restores these 
underdeveloped tissues.  In some cases, such as ILFs, bacterial molecules appear 
to be sufficient.  In contrast to GALT that begins development in a sterile 
environment, ILFs develop from LTi-like cryopatches and recruited B cells in the 
lamina propria (Pabst et al. 2006; Eberl & Littman 2004), and induction of this 
entire process requires the gut microbiota (Hamada et al. 2002; Pabst et al. 
2006; Pabst et al. 2005).  Specifically, peptidoglycan from Gram (-) bacteria 
induces intestinal ILF formation in germ-free mice in a NOD1-dependent manner 
(Bouskra et al. 2008).   
Interactions between the Immune System and Microbiota During 
Development. 
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Humoral immune responses.  Developing lymphoid tissues support 
important cellular responses to the microbiota.  The generation of IgA-producing 
B cells that recognize the microbiota occurs in GALT.  Normally, dendritic cells 
within the Peyer’s patch phagocytose bacteria and promote IgA production by B 
cells.  Secretion of IgA then limits bacterial penetration through the epithelium 
(Macpherson & Uhr 2004; Macpherson et al. 2001).  Germ-free mice have 
decreased antibody responses; in particular, secretory IgA in the colon (Moreau 
et al. 1978).  Colonization with several different bacterial species restores IgA 
production, as well as expression of the polymeric IgA receptor (Moreau et al. 
1978; Hooper, Wong, Thelin, et al. 2001; Macpherson & Uhr 2004).  In the 
absence of class switch recombination, somatic hypermutation and IgA 
production, a 100-fold expansion of anaerobic flora occurs in the small intestine, 
demonstrating a vital role for IgA in promoting homeostasis (Fagarasan et al. 
2002).   
T Helper cell responses: Th1 and Th2 balance.  Bacteriodes fragilis 
is the best-characterized commensal in terms of immune regulatory and 
developmental effects.  Bacteriodes species colonize early in development.  As 
discussed above, these species rapidly proliferate in response to oligosaccharides 
present in breast milk thereby constituting a major portion of the bacteria 
present in the GIT.  B. fragilis is a Gram (-) anaerobic bacteria that produces 
several capsular polysaccharides.  One particular polysaccharide, polysaccharide 
A (PSA), is zwitteronic, possessing both positive and negative charges 
(Mazmanian et al. 2005).  In vitro, antigen-presenting cells (APCs) internalize, 
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process and present PSA, which leads to proliferation of CD4+ T cells (Brubaker 
et al. 1999; Tzianabos & Kasper 2002; Cobb et al. 2004).  Due to these 
immunomodulatory effects, the Kasper lab examined the effects of PSA and B. 
fragilis in germ-free mice.  SPF mice have a greater proportion of CD4+ T cells 
compared to germ-free mice.  Upon mono-colonization of germ-free mice with B. 
fragilis, CD4+ T cells expand and normal development of splenic lymphoid 
follicles occurs.  These effects require PSA production by B. fragilis, and purified 
PSA is sufficient to recapitulate these effects.  In vitro, PSA upregulates the 
production of the cytokine, IFN-γ, in T cells (Mazmanian et al. 2005).   
Naïve CD4+ T cells differentiate into several T helper cell effector subsets 
based on their environment.  Thus far, six subsets have been identified: Th1, Th2, 
Th17, Th9, Th22 and Treg cells, but new subsets of T helper cells are continuously 
being described (Nakayamada et al. 2012).  Th1 cells differentiate in the presence 
IL-12 and IL-18 and produce IFN-γ and TNF-α to protect against intracellular 
pathogens.  Th2 cells are induced by IL-4 and produce IL-4, 5, 6 and 13.  They 
mediate responses to extracellular pathogens such as helminthes, and have been 
implicated in allergy and asthma.  TGF-β and IL-6 promote Th17 cells.  These 
cells are involved in immunity to mucosal pathogens and contribute to 
autoimmune disorders.  Th9 and Th22 cells have recently been identified to 
contribute to tumor and skin/barrier immunity, respectively.  Th9 cells 
differentiate in response to IL-4 and TGF-β, and produce IL-9, whereas Th22 
cells differentiate in the presence of IL-6 and TNF-α and produce IL-22 
(Nakayamada et al. 2012).     
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At the time when Kasper and colleagues determined the involvement of 
PSA in CD4+ T cell development, Th1 and Th2 cytokines were the only well-
established subsets.  Th1 cytokine production suppresses Th2 responses; 
conversely, Th2 cytokine expression inhibits Th1 responses.  Proper balance of T 
helper cell effector responses plays a critical role in human health.  As mentioned 
above, at birth, prior to colonization, humans have a Th2-skewed environment, 
which is also seen in germ-free mice.  Colonization of germ-free mice with B. 
fragilis restores the Th1/Th2 balance to that of SPF mice in a PSA-dependent 
manner (Mazmanian et al. 2005).  These studies demonstrate an essential role 
for PSA in shaping mammalian immune development by stimulating normal 
splenic CD4+ T cell numbers, establishing and maintaining Th1/Th2 balance, and 
thereby directing splenic organogenesis.  Since other T helper subsets have been 
identified, new studies are underway to determine the role of the microbiota in 
the development and maintenance of each subset.   
Invariant natural-killer T cells.  Microbial exposure early in life also 
diminishes excessive responses of inflammatory cells.  Invariant natural-killer 
(iNKT) cells accumulate in the lamina propria and the lung in germ-free mice.  
iNKT cells are implicated in the pathogenesis of ulcerative colitis (UC).  In mouse 
models, iNKT cells mediate oxazolone-induced colitis and germ-free mice have 
exacerbated disease compared to SPF mice (Olszak et al. 2012; An et al. 2014).  
Similar results are seen in asthma models, suggesting that microbiota are 
required to control iNKT cell responses.  Interestingly, colonization of neonatal, 
but not adult mice, with a conventional microbiota alleviates disease.  iNKT cells 
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express CD1d, an MHC class I-like molecule that presents lipid antigens.  The 
protective effects have been attributed to a single sphingolipid produced by the B. 
fragilis.  The sphingolipid GSL-Bf717, purified from B. fragilis, reduces iNKT cell 
proliferation, and neonatal mice treated with this sphingolipid are protected from 
oxazolone-induced colitis later in life (An et al. 2014).  These studies demonstrate 
that early-life exposure to microbes establishes tolerance and without these 
exposures, stimulation of iNKT cells, and perhaps other inflammatory cells, later 
in life can be detrimental to the host.  
Section 2: Maintaining Homeostasis Between the Immune System and 
Microbiota 
Epithelial cells.  Intestinal epithelial cells provide a physical barrier to 
the luminal contents of the GIT.  Although thick layers of mucus separate a vast 
majority of microbial species from direct contact with the epithelium, specialized 
epithelial cells including paneth cells and M cells can directly sense or take up 
bacteria.  Further, dendritic cell protrusions through the epithelial layer sample 
the microbiota and produce cytokines to alter epithelial cell responses.  Germ-
free mice exhibit decreased epithelial cell turnover, altered microvilli formation, 
and decreased expression of cytokines and PRRs, suggesting bacteria contribute 
to epithelial cell responses (Artis 2008).   
Interactions between intestinal epithelial cells and immune cells are 
critical in maintaining homeostasis with the microbiota.  T cell cytokines 
contribute to epithelial barrier integrity by regulating epithelial permeability, 
proliferation, repair, and expression of tight junctions, mucins and anti-microbial 
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peptides (Artis 2008). Distribution of TLRs and other PRRs on epithelial cells 
remains controversial.  Epithelial cells minimally express TLRs on the luminal 
surface, or, in some studies, the expression is below the limits of detection.  In 
contrast, these cells seem to express TLRs on the basolateral side of the cells, 
allowing the innate immune system to rapidly detect bacteria that may breach the 
barrier (Abreu 2010).  Specialized epithelial cells, however, directly sense 
bacteria via innate immune mechanisms.  Paneth cells detect Bacteroides 
thetaiotaomicron, and potentially other bacteria, leading to a MyD88-dependent 
upregulation of the anti-microbial peptide RegIIIγ (Vaishnava et al. 2008; 
Sonnenburg et al. 2006).  In the absence of this pathway, mice are highly 
susceptible to infection with Listeria monocytogenes (Brandl et al. 2007).  
Epithelial cells also contribute to IgA production.  Direct sensing of 
commensal bacteria by TLR upregulates A Proliferation-Inducing Ligand 
(APRIL) expression in epithelial cells, which activates dendritic cells (DCs) to 
promote class switch to IgA2 (He et al. 2007).  It is unclear if these bacteria were 
sensed by TLR in the lumen or if bacteria translocate through M cells and are 
then detected by epithelial cells. 
Immunoglobulin A.  IgA contributes to homeostasis at mucosal 
surfaces and is highly produced in the gut.  As discussed above, the microbiota 
contribute to IgA production during development.  IgA not only functions to 
eliminate pathogens and limit their ability to infiltrate the mucosa, but also 
directs the composition of the microbiota.  IgA contributes to the selection of 
Firmicutes in a complex process: Firmicutes induce expansion of Treg cells, that 
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induce germinal centers and Firmicute-specific IgA, leading to their retention in 
the GIT, demonstrating a feedback loop between the microbiota and adaptive 
immune cells (Kawamoto et al. 2014).  Other studies suggest that location within 
the GIT, rather than specific bacterial species, induced commensal-specific IgA.  
B1b cells that traffic from the peritoneal cavity to the small intestine and B2 cells 
give rise to T-independent IgA-producing plasma cells specific to commensal 
bacteria.  Certain bacteria, including Segmented Filamentous Bacteria (SFB), 
evade T-independent responses and instead induce T-dependent B2 cell 
production of IgA (Bunker et al. 2015).   
Innate lymphoid cells (ILCs).  More recently, ILCs have been 
identified to play a critical role in maintaining intestinal homeostasis through 
direct and indirect interactions with the microbiota.  ILCs are most likely the 
main source of ‘T cell cytokines’ previously established, and discussed above, to 
contribute to intestinal homeostasis.  Development of the three ILC subsets 
appears to occur independently of commensal bacteria, although there are many 
conflicting reports (Monticelli et al. 2011; Vonarbourg et al. 2010; Bouskra et al. 
2008; Tsuji et al. 2008).  More consistently, it seems each subset of ILCs has 
impaired function in the absence of bacteria.  Recently, genome-wide screens of 
intestinal ILCs in SPF mice compared to antibiotic-treated or germ-free mice 
revealed that the microbiota contribute to epigenetic regulation and gene 
expression in intestinal ILCs (Gury-BenAri et al. 2016).   
ILCs and microbiota interactions occur through both direct and indirect 
mechanisms.  Some ILCs have limited expression of TLRs that can respond to 
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viruses and bacteria to enhance anti-viral and bacterial responses.  Additionally, 
metabolic by-products generated by commensals also stimulate ILC responses 
(Stockinger et al. 2011).  ILCs can also shape the microbiota through indirect 
interactions by producing cytokines that influence epithelial cell permeability and 
production of antimicrobial peptides (Clark et al. 2005; Mullin & Snock 1990; 
Monticelli et al. 2011).  Conversely, microbes stimulate cytokine production by 
epithelial cells and myeloid cells that can activate ILCs (Vonarbourg et al. 2010; 
Hughes et al. 2010).   
T helper cell responses: Th17 induction.  Several years after the 
discovery of the immunomodulatory functions of PSA, Th17 cells were identified 
as a new T helper cell subset (Mangan et al. 2006).  These cells produce IL-17A, 
IL-17F and IL-22 and have been implicated in both inflammatory and anti-
inflammatory processes.  During bacterial and fungal infections, these cells 
provide vital mucosal immunity, but excessive activation of these cells 
contributes heavily to autoimmune disorders (Mangan et al. 2006).  Th17 cells 
accumulate in high numbers in the GIT and are notably absent in germ-free mice, 
suggesting their development is induced by the microbiota (Ivanov et al. 2008; 
Ivanov et al. 2009).  Indeed, re-colonization of germ-free mice restores numbers 
of Th17 cells within the lamina propria and colon.  Interestingly, identical mouse 
strains purchased from different commercial vendors had strikingly different 
levels of Th17 cells within the small intestine.  Upon analysis of the microbiota of 
mice from each vendor, mice with no Th17 cells also had undetectable levels of 
SFB compared to mice with Th17 cells from a different vendor (Ivanov et al. 
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2008).  In germ-free mice or in conventional mice lacking Th17 cells, colonization 
with SFB potently induces Th17 cells and associated cytokine production in the 
lamina propria (Ivanov et al. 2009).  SFB are Gram (+) spore-forming anaerobic 
bacteria highly prevalent in the gut microbiota.  SFB colonize the terminal ileum 
of mice, humans, and a variety of other vertebrates including non-human 
primates, birds, frogs and fish (Klaasen et al. 1993), suggesting SFB and the 
immune system have evolved this symbiotic relationship for a vast period of time.  
In fact, SFB colonization appears to be species specific.  Whereas most bacteria 
lie in the upper of two mucus layers, SFB penetrate through the thin upper and 
thick lower mucus layers and intimately attach to epithelial cells, leading to actin 
reorganization.  In response to SFB binding, epithelial cells upregulate serum 
amyloid A and reactive oxygen species, which act on myeloid cells to upregulate 
Th17-inducing cytokines, thereby inducing Th17 cells (Atarashi et al. 2015).  This 
tight adhesion with epithelial cells is species specific in that mouse SFB bind 
specifically to mouse epithelial cells and cannot be transferred to rats, and vice 
versa (Atarashi et al. 2015; Prakash et al. 2011).  These studies suggest that SFB 
have undergone host-specific adaptation.  In exchange for potent immune 
modulation, the host provides the auxotrophic SFB with amino acids and 
nutrients essential for its survival (Sczesnak et al. 2011). 
Prior to the discovery that SFB induce Th17 cells, SFB were identified to 
stimulate secretory IgA production and recruitment of intraepithelial 
lymphocytes (Umesaki et al. 1999; Talham et al. 1999).  Recently, Hirota et al. 
established a link between SFB induction of Th17 cells and IgA production.  In 
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Peyer’s patches, SFB-induced Th17 cells acquire a T follicular helper cell 
phenotype and induce IgA production by germinal center B cells (Hirota et al. 
2013).  These studies highlight nearly thirty years of research on independent 
diverse subjects coalescing into a remarkable mechanism by which a commensal 
bacterium has evolved a highly complex interaction with the host immune 
response.  
The development of tolerance between the colonizing bacteria and the host 
response is pertinent for the health of the host.  The picture of how the immune 
system and commensal bacteria work together to maintain this environment is 
constantly evolving as our understanding of new immune cells and bacteria 
change with newly developed technologies.  What is clear is that defects in any of 
these arms of immunity and host defense leave the host susceptible to an array of 
immune disorders.  
Section 3: Induction of Regulatory Responses by Commensal Bacteria 
 Aberrant immune responses to commensal bacteria are prevented through 
multiple different mechanisms.  The mucus layers and IgA prevent direct 
association of the bacteria with epithelial and immune cells; T helper cells and 
ILCs produce cytokines to reinforce the barrier through antimicrobial peptide 
and mucin production; but what maintains these inflammatory cells from 
excessive responses?  A failure to regulate these responses can lead to diseases 
including IBD, allergies, and metabolic syndromes.   
T Helper Cell Responses: Regulatory T cells. 
 Regulatory T cells (Treg) maintain peripheral and mucosal tolerance.  
16	
	
These cells develop in the thymus (nTreg) under control of the master regulator, 
Foxp3, but can also be induced (iTreg) from naïve CD4+ T cells in the periphery.  
In the absence of Treg cells, the immune system runs rampant, leading to 
exacerbated autoimmune disorders; these mice develop a fatal 
lymphoproliferative disease, leading to multi-organ failure, and die within 3-5 
weeks of age (Brunkow et al. 2001).   
In humans, mutations in Foxp3 lead to IPEX autoimmune syndrome 
(Immunedysregulation, Polyendocrinopathy, Enteropathy, X-linked syndrome), 
and most children die within the first two years of life (Wildin et al. 2001).  Treg 
cells suppress immune responses through the effector molecules CTLA-4, 
Transforming Growth Factor-β (TGF-β) and IL-10.  The latter anti-inflammatory 
cytokines act on a wide array of cells and potently inhibit cell activation and 
proliferation.  In the GIT, Treg cells also promote class switch to IgA via TGF-β 
production, demonstrating another mechanism by which this essential molecule 
is induced (Cong et al. 2009).   
Inducible regulatory T cells (iTreg).  In the gut, iTreg cells play an 
essential role in the induction of tolerance to food and other oral antigens 
(Coombes et al. 2007; Mucida et al. 2005).  The microbiota help generate the 
regulatory environment necessary to induce iTreg cells; Treg cell numbers and 
production of effector cytokines are reduced in germ-free mice.  Gut-resident DCs 
promote iTreg development through TGF-β and vitamin A (Coombes et al. 2007) 
and many of the signals driving the regulatory DCs come from the microbiota.  
Clostridia, which comprise a large portion of the gut microbiota, play an 
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instrumental part in iTreg induction.  The Clostridia clusters IV, XIVa and XVIII 
provide bacterial antigens and induce a TGF-β-rich environment, resulting in 
substantial increases in iTreg cells (Atarashi et al. 2011; Atarashi et al. 2013).  
Induction of regulatory T cells by Bacteroides fragilis.  In 
addition to expanding CD4+ T cell populations within the spleen of germ-free 
mice, B. fragilis also generates iTreg cells in a process requiring PSA.  B. fragilis 
secretes PSA-filled outer membrane vesicles that are taken up by dendritic cells 
in a TLR2-dependent manner.  DCs process and present PSA to T cells via MHC 
class II, thereby inducing IL-10–producing Treg cells (Shen et al. 2012).  PSA can 
also directly induce and expand nTreg cells when administered to germ-free 
mice, or in germ-free mice monocolonized with B. fragilis (Round & Mazmanian 
2010; Mazmanian et al. 2008; Round et al. 2011).  B. fragilis PSA is a single 
bacterial molecule capable of both inducing development of immune responses 
and regulating immune responses.  Although this molecule is the best 
characterized, it is likely not alone; more bacteria and specific bacterial molecules 
are likely to be identified to critically regulate immune responses.   
Induction of regulatory T cells by microbial metabolites.  A long 
understood benefit afforded by the microbiota is aiding in food digestion.  As they 
break down food, the microbiota produces many metabolites, including short-
chain fatty acids (SCFA).  SCFA, and in particular butyrate, not only induce 
differentiation of iTreg cells, but also expand colonic nTreg cells (Smith et al. 
2013; Furusawa et al. 2013), demonstrating that bacterial metabolites as well as 
physiological factors such as polysaccharides contribute to shaping immune 
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responses.  In Westernized countries, plant-based diets have decreased in 
popularity, which may contribute to disregulation of the microbiota and Treg cell 
development, providing a possible link to disease correlations mentioned 
previously.   Although much of the focus on the capacity for the microbiota to 
regulate immunity has been focused on Treg cells, other regulatory cells 
undoubtedly play a part in sustaining this environment.   
Section 4:  Probiotics and Disease 
Clearly, commensal microbes provide integral benefits to the development 
and regulation of the immune system and other bacteria undoubtedly share these 
beneficial properties.  Can we harness the power of these bacteria to treat human 
disease?  Probiotics are live microorganisms considered to benefit the health of 
the host.  The mechanisms by which probiotics benefit the host, and which 
specific bacterial species among the hundreds found in different probiotics 
currently on the market are not well appreciated.  As we grow in our 
understanding of how commensal bacteria influence the immune system, these 
bacteria can be rationally be used as probiotics to treat and prevent different 
ailments.   
History of the Microbiota as a Therapeutic. 
The use of the gastrointestinal microbiota as a therapeutic was first 
documented in ancient Egypt in 1700 BC in papyrus texts, although it most likely 
dates back further (Parkins, 2001).  Excrement of different animals was used for 
a variety of internal and external ailments and thought to magically repel demons 
(Parkins, 2001).  In the 4th century, Chinese physicians treated diarrhea with 
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yellow soup, a broth consisting of dried stool from a healthy individual.  These 
anecdotes continue throughout history, from Antiquity to the Italians during the 
Renaissance.  From these early examples of ‘fecal transplants,’ modern 
physicians and scientists developed invaluable treatments for many more 
diseases.   
Early in the 1900s, Ilya Mechnikov developed the first probiotics in today’s 
understanding of the term.  Fearing toxic biproducts of the GIT poisoned tissues 
and contributed to senility, he believed fermented dairy products possessed 
health benefits.  He hypothesized that the microbiota was the main cause of the 
poisoning and that if consumed regularly, the bacteria in fermented milk would 
replace the damaged microflora by altering the intestinal phagocyte population 
(Metchnikoff & Metchnikoff 1908).     
Decades later, the idea would take hold again, with the return of fecal 
transplants to treat enteric disease.  The first documentation in a modern medical 
journal comes from Dr. Ben Eiseman who used fecal transplants to cure four 
patients suffering from pseudomembraneous colitis induced by Clostridium 
difficile infection in 1958 (Eiseman et al. 1958).  
Clearly the microbiota possessed a powerful therapeutic benefit that took 
modern scientific advances to begin to tease apart.  For years, people speculated 
that the benefits exerted by these transplants were due to antibiotic production or 
metabolites produced by the bacteria.  Today, hundreds of fecal transplants have 
been performed to treat C. difficile infection, and probiotics constitute a multi-
billion dollar industry world-wide.  The numbers of implications are growing, but 
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how the microbiota and specific probiotics contribute to health benefits is not 
understood.  Finally, after significant technological advances, we now understand 
that the mechanisms of the benefits exerted by the microbiota are more complex 
and far-reaching into the immune system than we had ever imagined.   
Prevention of Colitis by Probiotics. 
As we have already discussed, germ-free mice are wrought with problems 
in the immune system.  As expected, germ-free mice are highly susceptible to 
bacterial, viral and fungal infections (Carthew & Sparrow 1980; Taguchi et al. 
2002; Kamada et al. 2012).  These studies suggest that when dysbiosis of the 
microbiota occurs, a normal microbiota or probiotics can be added back to 
restore the normal homeostatic balance between the immune system and the 
microbiota. 
Studies of probiotics in disease prevention, as with fecal transplants, have 
mainly focused on models of inflammatory bowel diseases (IBD), or pathogen-
induced colitis.  IBD are chronic inflammatory disorders of the small intestines 
and colon, in which patients suffer from rectal bleeding, severe diarrhea, 
abdominal pain, fever, and weight loss (Strober et al. 2007).  In many cases of 
IBD, the mucosal barrier to the microbiota breaks down, and the immune system 
mounts improper responses to the microbiota.  Host genetics and dietary 
influences can also contribute to IBD.  All of these factors can lead to a loss of 
tolerance to the microbiota, resulting in excessive inflammation and disease.  
Mouse models of IBD attempt to take into account many of these different facets 
of disease.  Chemically-induced colitis models utilize a variety of chemicals and 
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haptens to cause damage in the intestines and mimic the breakdown of the 
mucosa and homeostasis, similar to what occurs in IBD.  Exacerbated T helper 
cell responses drive many of these models of chemically-induced colitis, including 
2,4,6-trinitro benzene sulfonic acid (TNBS)-, dinitrobenzene sulfonic acid 
(DNBS)-, and oxazolone-induced colitis.  DSS is believed to be directly toxic to 
colonic epithelial cells and induce gut leakiness, allowing the bacterial products 
and bacteria to infiltrate the lamina propria (Wirtz et al. 2007).  Other models 
more directly exploit the T cell-mediated nature of colitis or host genetic 
contributions.  IL-10-/- mice spontaneously develop colitis at 8-10 weeks of age, 
since IL-10 is a main contributor to mucosal tolerance.  Additionally, adoptive 
transfer of naïve T cells into Rag1-/- mice induces a similar pathology to Crohn’s 
disease in humans (Ostanin et al. 2009), as do SAMP1/YitFc (SAMP) mice which 
have chronic Crohn’s Disease-like ileitis (Pagnini et al. 2010).   
 In models of pathogen-induced colitis, pathogens including Helicobacter 
hepaticus, Salmonella enterica, and Citrobacter rodentium induce damage, 
inflammation and disease through complex immune responses, although 
inflammatory T cell responses contribute to much of the inflammation.  Many of 
these are human enteric pathogens or mouse models of human pathogens, and 
give clues as to how probiotics can be used to treat human infections.   
Probiotics can limit disease in several different ways.  First, in the case of 
pathogen infection, they can block colonization of the invading pathogen or 
compete for nutrients, not allowing the pathogen access to the specific niche 
required for infection.  Additionally, probiotics can increase barrier integrity.  
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This can occur by promoting antimicrobial peptide (AMP) production (or 
producing AMPs themselves), increasing mucus production, or upregulating tight 
junctions between epithelial cells, decreasing permeability.  Last but not least, 
probiotics can alter the host immune response, leading to protection from 
disease.  
Colonization.  Many pathogens need to occupy a certain niche within the 
gastrointestinal tract to upregulate production of toxins or virulence factors and 
induce disease.  Many probiotics are thought to block adherence and colonization 
of pathogens, ultimately preventing disease.  Bifidobacterium breve produces 
exopolysaccharide to promote its own colonization within the GIT, which in turn 
prevents colonization with the enteric pathogen C. rodentium (Fanning et al. 
2012).  Although B. breve limits pathogen colonization, it must first modulate the 
immune response to promote its own persistence.  B. breve produces 
exopolysaccharide (EPS) that suppresses B cell responses to B. breve.  In a strain 
of B. breve deficient in EPS production, high titers of antibody to B. breve are 
present in the feces, and colony-forming units (CFUs) of B. breve are drastically 
reduced, indicating that EPS production is crucial for B. breve persistence.  
Further, EPS-deficient strains do not limit C. rodentium colonization, 
demonstrating the importance of EPS production in disease prevention.   
SFB also help to limit infection with C. rodentium by decreasing bacterial 
colonization in the colon.  Induction of Th17 cells by SFB leads to upregulation of 
a signaling cascade that increases expression of IL-23, IL-22 and the AMP 
RegIIIγ that are vital to controlling C. rodentium infection (Ivanov et al. 2009).      
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Commensals and probiotics can also inhibit pathogen colonization by 
competing for nutrients or producing inhibitory molecules including anti-
microbial peptides and antibiotics.  B. thetaiotaomicron competes with C. 
rodentium for carbohydrates (Kamada et al. 2012), directly inhibits toxin 
production by enterohaemorrhagic E. coli (De Sablet et al. 2009), and also 
upregulates RegIIIγ, an anti-microbial peptide that binds Gram (-) bacteria 
(Vaishnava et al. 2008).  Bifidobacterium species produce peptides that serve as 
antibiotics to pathogenic bacteria (Trejo et al. 2006; Gagnon et al. 2004), 
demonstrating that certain species exert a plethora of beneficial effects.   
Antibiotic treatment increases susceptibility to a wide-range of infections 
and allows for proliferation of antibiotic-resistant pathogens such as vancomycin-
resistant Enterococcus species and C. difficile (Stecher et al. 2005; Barthel et al. 
2003; Buffie & Pamer 2013).  Cocktails of probiotics decrease pathogen 
colonization and limit disease (Felley & Michetti 2003; Siggers et al. 2008).  Even 
though these bacteria decrease pathogen colonization, many of the identified 
mechanisms involve innate immune modulation.  More in depth analysis of the 
molecular mechanisms by which probiotics limit pathogen colonization may 
identify novel pathways of immune modulation.    
Epithelial barrier integrity.  Probiotics also promote epithelial barrier 
integrity to prevent colitis; however, similar to prevention of colonization, these 
effects are often due to alterations in innate immune responses.  The probiotic 
cocktail VSL#3 stimulates TNFα production in epithelial cells to promote barrier 
integrity, which prevents ileitis in SAMP mice.  Several studies have 
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demonstrated that probiotics such as E. coli Nissle, Lactobacillus species, and 
VSL#3 increase barrier function and anti-microbial peptide expression in cell-
culture models in vitro (Schlee et al. 2008; Wehkamp et al. 2004; Schlee et al. 
2007).  Lactobacillus species and VSL#3 require MAP kinase, and NF-κB and 
AP-1 pathways, demonstrating that these effects require innate immune sensing 
of bacteria or bacterial products (Schlee et al. 2008).   
Modulation of immune responses.  Probiotics clearly prevent enteric 
diseases by modulating innate immune response, leading to decreased pathogen 
colonization and increased barrier integrity.  But how do probiotics limit IBD?  
Many beneficial microbes appear to enhance anti-inflammatory responses 
through modulation of adaptive immune responses (Table 1.1).   
 
25	
	 
B
ac
te
ri
a 
E
lic
it
ed
 Im
m
un
e 
R
es
po
ns
e 
B
ac
te
ri
al
 M
ol
ec
ul
e 
R
es
po
ns
ib
le
 fo
r 
Pr
ot
ec
ti
on
 
In
fl
am
m
at
or
y 
D
is
ea
se
 
R
ef
 
Ba
ci
llu
s s
ub
til
is
 
TL
R
4-
de
pe
nd
en
t i
nd
uc
tio
n 
of
 M
2 
m
ac
ro
ph
ag
es
  
Ex
op
ol
ys
ac
ch
ar
id
e 
(E
PS
) 
C.
 r
od
en
tiu
m
-in
du
ce
d 
co
lit
is
 
Jo
ne
s e
t a
l. 
 
Ba
ct
er
io
de
s f
ra
gi
lis
 
TL
R
2-
de
pe
nd
en
t i
nd
uc
tio
n 
of
 iT
re
g 
by
 
IL
-1
0+
 D
Cs
 
Po
ly
sa
cc
ha
ri
de
 A
 (P
SA
) 
H
. h
ep
at
ic
us
-in
du
ce
d 
co
lit
is
, T
N
BS
-in
du
ce
d 
co
lit
is
, E
AE
 
M
az
m
an
ia
n 
et
 a
l.;
 
R
ou
nd
 e
t a
l.;
 S
he
n 
et
 a
l.;
 O
ch
oa
-
R
od
ri
ge
z e
t a
l. 
 
Bi
fid
ob
ac
te
ri
um
 
sp
p.
 
In
du
ct
io
n 
of
 T
r1
 a
nd
 T
re
g 
ce
lls
; r
ed
uc
tio
n 
of
 B
. b
re
ve
-s
pe
ci
fic
 a
nt
ib
od
y 
pr
od
uc
tio
n 
 
Po
ss
ib
ly
 
Ex
op
ol
ys
ac
ch
ar
id
e 
 
C.
 r
od
en
tiu
m
-in
du
ce
d 
co
lit
is
 
Je
on
, e
t a
l; 
Fa
nn
in
g,
 e
t a
l. 
	
Ba
ct
er
io
de
s f
ra
gi
lis
 
N
eg
at
iv
e 
re
gu
la
tio
n 
of
 iN
K
T 
ce
lls
 in
 
ne
on
at
al
 m
ic
e 
Sp
hi
ng
ol
ip
id
 G
SL
-B
f7
17
 
O
xa
zo
lo
ne
-in
du
ce
d 
co
lit
is
 
An
 e
t a
l. 
Fa
ec
al
ib
ac
te
ri
um
 
pr
au
sn
itz
ii 
In
hi
bi
tio
n 
of
 N
F-
κB
 in
 in
te
st
in
al
 e
pi
th
el
ia
l 
ce
lls
 
An
ti-
in
fla
m
m
at
or
y 
pr
ot
ei
n 
M
AM
 
D
N
BS
- i
nd
uc
ed
 c
ol
iti
s 
So
ko
l e
t a
l.;
 
Q
ué
vr
ai
n 
et
 a
l. 
Cl
os
tr
id
iu
m
 
bu
ty
ri
cu
m
 
TL
R
2-
de
pe
nd
en
t i
nd
uc
tio
n 
of
 IL
-1
0+
 
F4
/8
0+
CD
11
b+
CD
11
cin
t c
el
ls
 
n/
a 
D
SS
-in
du
ce
d 
co
lit
is
 
H
ay
as
hi
 e
t a
l. 
Cl
os
tr
id
ia
 sp
p.
 
In
du
ct
io
n 
of
 IL
-1
0+
 T
re
g;
 u
pr
eg
ul
at
es
 
IL
-2
2 
by
 IL
C 
n/
a 
D
SS
-in
du
ce
d 
co
lit
is
, 
fo
od
 a
lle
rg
y 
St
ef
ka
 e
t a
l.;
 
At
ar
as
hi
 e
t a
l.;
 C
ao
 
et
 a
l. 
La
ct
ob
ac
ill
us
 sp
p.
 
R
ed
uc
tio
n 
of
 p
ro
-in
fla
m
m
at
or
y 
m
uc
os
al
 
cy
to
ki
ne
s 
n/
a 
H
. h
ep
at
ic
us
-in
du
ce
d 
IB
D
 
Pe
ña
 e
t a
l. 
Se
gm
en
te
d 
fil
am
en
to
us
 b
ac
te
ri
a 
In
du
ct
io
n 
of
 T
h1
7 
ce
lls
; I
gA
 p
ro
du
ct
io
n 
n/
a 
C.
 r
od
en
tiu
m
-in
du
ce
d 
co
lit
is
, T
1D
 
Iv
an
ov
 e
t a
l.;
 
K
ri
eg
el
 e
t a
l. 
VS
L#
3 
In
du
ct
io
n 
of
 T
N
F-
α 
pr
od
uc
tio
n 
by
 
ep
ith
el
ia
l c
el
ls
; I
L-
10
+ 
TG
F-
β+
 T
 c
el
ls
 
n/
a 
Ch
ro
ni
c 
CD
-li
ke
 il
ei
tis
 
(S
AM
P 
m
ic
e)
, T
N
BS
-
in
du
ce
d 
co
lit
is
 
Pa
gn
in
i e
t a
l.;
 D
i 
G
ia
ci
nt
o 
et
 a
l. 
Ta
bl
e 
1.
1.
 C
om
m
en
sa
l B
ac
te
ri
a 
w
it
h 
B
en
ef
ic
ia
l I
m
m
un
om
od
ul
at
or
y 
E
ff
ec
ts
 o
n 
In
fl
am
m
at
or
y 
D
is
ea
se
s.
 
Ab
br
ev
ia
tio
ns
: C
D
- C
ro
hn
’s 
D
is
ea
se
; D
Cs
- D
en
dr
iti
c 
ce
lls
; D
SS
- D
ex
tr
an
 su
lfa
te
 so
di
um
; D
N
BS
- D
in
itr
ob
en
ze
ne
 su
lfo
ni
c 
ac
id
; E
AE
- 
Ex
pe
ri
m
en
ta
l a
ut
oi
m
m
un
e 
en
ce
ph
al
oc
ye
lit
is
; G
IT
- G
as
tr
oi
nt
es
tin
al
 tr
ac
t; 
iT
re
g-
 In
du
ci
bl
e 
re
gu
la
to
ry
 T
 c
el
ls
; I
BD
- I
nf
la
m
m
at
or
y 
bo
w
el
 
di
se
as
e;
 IL
C-
 In
na
te
 L
ym
ph
oi
d 
Ce
ll;
 M
AM
- M
ic
ro
bi
al
 a
nt
i-i
nf
la
m
m
at
or
y 
m
ol
ec
ul
e;
 n
.d
.- 
no
t d
et
er
m
in
ed
; T
N
BS
- 2
,4
,5
-
Tr
in
itr
ob
en
ze
ne
su
lfo
ni
c 
ac
id
; T
1D
- T
yp
e 
1 D
ia
be
te
s 
26	
	
As discussed above, B. fragilis and Clostridia strains help maintain 
homeostasis between the immune system and microbiota through induction of 
Treg cells.  Upon disruption of this homeostatic environment with enteric 
pathogens or in models of chemically induced colitis, administration of B. 
fragilis, or the active component PSA, alleviates disease induced by H. hepaticus 
and TNBS-induced colitis (Mazmanian et al. 2008; Shen et al. 2012).  Further, 
Clostridia strains induce and expand Treg cells through butyrate production, and 
protect mice from DSS- and TNBS-induced colitis, as well as T cell transfer-
induced colitis (Atarashi et al. 2011; Furusawa et al. 2013; Atarashi et al. 2013; 
Smith et al. 2013).  	
Other probiotics, including B. breve and other Bifidobacteria species, 
VSL#3 and Lactobacillus rhamnosus GG, also induce IL-10 or TGF-β producing 
Tr1 cells and iTreg cells that ameliorate disease in several inducible mouse 
models, both pathogen and chemical, of colitis (Jeon et al. 2012; O’Mahony et al. 
2008; Peña et al. 2005; Di Giacinto et al. 2005) .  These studies demonstrate the 
importance of regulatory T cells in maintaining intestinal homeostasis and their 
versatility in limiting inflammation. 
Few Treg cell-independent mechanisms have been established, but 
probiotics potentially modulate other regulatory cells.  The probiotic Clostridium 
butyricum mediates protection from DSS-induced colitis in a Treg-independent 
manner, through TLR2-dependent, IL-10–producing F4/80+CD11b+CD11cint 
macrophages (Hayashi et al. 2013).  Interestingly, inhibition of iNKT cells by B. 
fragilis spingolipids at birth is essential for control of oxazalone-induced colitis 
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in adulthood.  If mice are not exposed to B. fragilis, increased iNKT cells develop, 
leading to exacerbated disease (An et al. 2014).  Faecalibacterium prausnitzii is 
one of the few bacteria for which an inhibitory bacterial molecule has been 
identified and appears to alter innate immune signaling in epithelial cells.  The 
microbial anti-inflammatory molecule (MAM) is a peptide produced by F. 
prausnitzii that prevents DNBS colitis.  MAM is thought to inhibit NF-κB 
signaling in epithelial cells, decreasing inflammation; but the precise molecules 
mediating protection have not been identified (Quévrain et al. 2015; Sokol et al. 
2008).   
The overarching theme of the beneficial effects of probiotics seems to be 
control of inflammation and induction of tolerance.  Indeed, many other 
probiotics, including Lactobacillus species, B. lactis, and E. coli Nissile, have 
been shown to limit experimental colitis by altering the cytokine balance, even 
though the precise mechanisms are undetermined (Peran et al. 2007; Grabig et 
al. 2006; C et al. 2005; Peña et al. 2005).  
Probiotics and Disease Outside the Intestine. 
Pathogens and chemical models of colitis alike, promote pro-inflammatory 
T helper cell responses.  Probiotics promote Treg and Tr1 cells, or other 
regulatory cells, and control exacerbated T cell responses, and restore 
homeostasis to limit disease.  Inflammatory T cells drive many different diseases 
outside of the GIT, but can probiotics be used to treat systemic diseases?  
Antibiotic-mediated disruption of the microbiota accelerates development of 
Type-1 diabetes in mice, and is also linked to increased pathology of numerous 
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systemic diseases including autoimmune diseases, e.g., lupus, arthritis, and 
chronic obstructive pulmonary disease.  These studies and the mechanistic 
studies detailed above suggest that restoring a healthy microbiota with probiotics 
may alleviate disease outside the GIT.   
Many probiotics will likely be useful for treating or preventing other 
inflammatory diseases, including diabetes, allergy and experimental autoimmune 
encephalomyelitis (EAE) (Ochoa-Repáraz et al. 2010; Hu et al. 2015; Stefka et al. 
2014; Cao et al. 2014).  In fact, SFB-induces Th17 cells in the gut and lung that 
regulate immunity to fungal infections (McAleer et al. 2016).  Disruption of IL-17 
receptor signaling, however, results in outgrowth of SFB and enhanced disease 
severity during autoimmune diseases, namely, EAE (Kumar et al. 2016).  This 
study highlights the importance of a balance between the microbiota and the 
immune system in regulating dysbiosis.  SFB-induced Th17 cells can also prevent 
the spontaneous development of type 1 diabetes in non-obese diabetic (NOD) 
mice (Kriegel et al. 2011).  In cases of type 2 diabetes, increased systemic 
inflammation, often associated with obesity, drives insulin resistance and 
metabolic syndrome, promoting the development of diabetes.  Insulin resistance 
in non-diabetic humans and patients with type 2 diabetes is associated with 
increased levels of serum branched-chain amino acids.  The presence of 
Prevotella copri and Bacteroides vulgatus, species with enhanced biosynthetic 
potential for branched-chain amino acids, correlates with insulin resistance in 
humans.  In mice, administration of P. copri increased insulin resistance and 
glucose intolerance, suggesting that detrimental members of the microbiota can 
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expand during dysbiosis (Pedersen et al. 2016).  Restoring a healthy microbiota 
with probiotics or targeting pathogenic bacteria may reduce insulin resistance.   
Oral administration of B. fragilis PSA prevents development of paralysis 
in EAE, a mouse model of multiple sclerosis (MS), by inducing IL-10-producing 
Treg cells (Ochoa-Repáraz et al. 2010).  Further, Clostridia species alter innate 
lymphoid cells to secrete IL-22, which decreases epithelial permeability and 
prevents development of food allergy (Stefka et al. 2014).  Additionally, 
Clostridia species-induced Treg cells prevent allergen-induced diarrhea (Atarashi 
et al. 2011; Atarashi et al. 2013).  These studies are of particular importance given 
the rise of asthma and allergies in children raised in clean enviroments and not 
exposed to a wide range of bacteria to train their immune responses.  As our 
understanding of the mechanisms by which specific commensal bacteria 
modulate the immune system increases, we will likely identify more diseases for 
which these probiotics will be beneficial.  
Purified Bacterial Molecules as Therapeutics. 
B. fragilis PSA and sphingolipids, and F. prausnitzii MAM protein 
(Mazmanian et al. 2005; An et al. 2014; Sokol et al. 2008), are the only bacterial 
molecules identified to have immunomodulatory effects.  B. fragilis PSA and 
sphingolipids have been purified, administered to mice and shown to exert the 
given effects.  MAM protein has been expressed in E. coli and shown to prevent 
colitis; F. prausnitzii superantants containing MAM have anti-inflammatory 
effects, but an active molecule has not been purified.  B. breve modulates IgA 
responses in an EPS-dependent manner, but this molecule has not been purified.  
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Most likely, the majority of bacterial molecule(s) and metabolic products 
responsible for protection have not yet been identified or purified, but perhaps 
some share characteristics of the established molecules described above.  
Undoubtedly, additional molecules from a large number of commensal bacteria 
ware expected to regulate immune responses.  Utilizing purified molecules as 
therapeutics will be a useful alternative to the entire bacteria, especially for 
immune-compromised individuals unable to tolerate or risk the entire organism.  
Fecal transplants and now probiotics seem to be efficacious in treating severe C. 
difficile infection, but many people suffering from recurrent C. difficile are elderly 
or immune-compromised.  These individuals could benefit immensely from an 
anti-inflammatory molecule instead of an entire bacterium that could potentially 
cause detrimental effects not seen in healthy individuals.   
Section 5: Bacillus subtilis: From Soil to Bench to Probiotic 
B. subtilis is a Gram (+), spore-forming bacterium ubiquitous in the 
environment.  B. subtilis has been extensively studied for many years as a model 
organism for Gram (+) physiology, sporulation and biofilm formation.  It is 
highly amenable to genetic engineering, and also has the capacity to secrete large 
amounts of proteins, making it very attractable in biotechnology and industrial 
settings.  Many purified enzymes on the market are produced in B. subtilis.  It is 
also widely used in agricultural and aquaculture to prevent pathogen 
colonization, support bioremediation, and reduce abdominal fat in broiler 
chickens (Samanya & Yamauchi 2002).  New fields of study revolve around the 
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capacity of B. subtilis to serve as a probiotic and a vaccine vector (Duc et al. 2003; 
Jones & Knight 2012).  
Due to its high prevalence in soil, air and drinking water, B. subtilis is 
often found in insects, animals, and humans.  Although vegetative cells would not 
survive transit through the GIT, B. subtilis in spore form is virtually 
indestructible, and would transit unimpeded.  Once in the intestine, spores 
germinate, proliferate, and then resporulate within the GIT (Spinosa et al. 2000; 
Tam et al. 2006).  Although not typically considered a true commensal or 
resident bacteria in the GIT, many studies report Bacillus species present in the 
majority of individuals surveyed, at levels from 103 to 108 CFU/gram of feces 
(Macfarlane et al. 1986; Tam et al. 2006).  Approximately 30% of the 84 Bacillus 
isolates in humans were determined to be B. subtilis (Tam et al. 2006).  
Additionally, B. subtilis is often found in the elderly and breast-fed infants 
(Benno et al. 1986; Benno et al. 1984).  Much importance has been placed on 
Bifidobacteria, Bacteroides and Lactobacillus species since they persist in high 
numbers and can reach 1011 colony-forming units (CFU)/gram of feces.  Less 
prevalent species may play an important role in modulating immune responses, 
and clearly B. subtilis has adapted to living in the gut.   
Bacillus subtilis as a Probiotic. 
B. subtilis is present in high levels in the soil, and as expected, B. subtilis 
and plants have evolved a symbiotic relationship.  Upon infection with the plant 
pathogen Pseudomonas syringae, the leaves of the Arabidopsis plant turn yellow.  
If B. subtilis is added to the soil, the plants are perfectly healthy.  The plant 
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secretes malic acid that acts as a distress signal to attract B. subtilis to the roots, 
where it forms a biofilm.  During biofilm formation, B. subtilis secretes a 
surfactin with antibacterial activity against P. syringae as well as other bacteria 
(Bais et al. 2004).  Innate immune responses are remarkably conserved in 
insects, mammals and plants.  Bacterial infection triggers the plant flagellin PRR, 
leading to activation of the highly conserved MAP kinase signaling pathway and 
innate response genes.  B. subtilis secretes a peptide that suppresses the innate 
immune response of Arabidopsis and over 1000 other plants, allowing itself to 
efficiently colonize the plant roots.  Interestingly, suppression of plant PRR-
stimulated genes is dependent on TasA, the molecule that tethers 
exopolysaccharide to the bacteria’s surface, however epsG and epsO mutants 
deficient in EPS production still exerted suppressive activity (Lakshmanan et al. 
2012).  This immune suppression, however, could potentially leave the plant 
susceptible for a short period of time to pathogens before B. subtilis, and the 
plant itself, can mediate anti-bacterial effects.  
B. subtilis limits pathogen infection in several other species including fish 
and chickens (La Ragione et al. 2001; La Ragione & Woodward 2003; Tactacan et 
al. 2013).  Both of these are highly cultivated for commercial use, and as many 
regulatory agencies begin limiting antibiotic use in animal and fish farming, B. 
subtilis has been widely studied for probiotic potential as an alternative to 
antibiotic treatments.  Administration of B. subtilis to chicks 24 h prior to 
infection with an avian E. coli infection suppresses disease and reduces pathogen 
colonization.  Interestingly, the window of protection is about 5 days (La Ragione 
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et al. 2001).  Pretreatment of chicks with B. subtilis also suppresses colonization 
and persistence of Salmonella enteritidis and Clostridium perfringens, 
demonstrating the versatility of this response (La Ragione & Woodward 2003; 
Tactacan et al. 2013).  In shrimp, B. subtilis controls pathogenic Vibrio species 
through production of a secreted molecule that reduces shrimp mortality in 
shrimp feeding ponds by 90% (Vaseeharan & Ramasamy 2003).  Clearly, Bacillus 
subtilis exerts a wide-range of effects that are beneficial to hosts across kingdoms 
and species.   
B. subtilis has been available as a probiotic in many European countries 
for decades.  The Japanese also regularly consume B. subtilis in the form of 
Natto.  Natto is made by fermenting soybeans with B. subtilis and is believed to 
have probiotic properties, including vitamin synthesis.  Several studies have 
demonstrated that B. subtilis from Natto stimulates the immune system and 
contributes to growth of other commensals (Hosoi et al. 2000; Tsukamoto et al. 
2001; Hosoi et al. 1999).   
Several clinical trials using multiple Bacillus species have shown some 
beneficial effects in several disease states.  B. coagulans has been used 
successfully to prevent antibiotic-associated diarrhea in children (La Rosa et al. 
2003).  In other studies, B. subtilis reduced bacterial load in urine in the elderly 
with urinary tract infections, though the probiotic used, Enterogermina, is 
actually made of B. clausii and not B. subtilis (Coppi et al. 1985).  In a clinical 
trial to determine if B. subtilis improved immunity in the elderly, patients taking 
B. subtilis had increased fecal and salivary IgA compared to placebo controls and 
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decreased respiratory infections, although no changes were seen in 
gastrointestinal disorders (Lefevre et al. 2015).  B. subtlis did prevent antibiotic-
associated diarrhea in a clinical trial in Russia.  Patients receiving B. subtilis and 
antibiotics had a 7.8% occurrence of antibiotic-associated diarrhea compared to 
32% in the placebo group.  Patients receiving B. subtilis also reduced abdominal 
pain, nausea, bloating and vomiting (Horosheva et al. n.d.).  Several other 
Bacillus species are effective in treating symptoms of IBD and diarrhea; however, 
no mechanistic insights have been identified outside of the demonstrated 
antibacterial properties of Bacillus products in other species.    
Immune Modulation by B. subtilis. 
B. subtilis produces a variety of molecules shown to directly target 
pathogenic bacteria and reduce pathogen colonization of the symbiont, but does 
B. subtilis alter immune responses?  
Investigating if specific bacteria mediated the ability of the rabbit 
microbiota to promote GALT development, the Knight Lab determined that B. 
subtilis in combination with B. fragilis promoted B cell proliferation and 
development of the preimmune antibody repertoire (Rhee et al. 2004).  Spores 
are also immunogenic in mice, but the dosing and administration schemes differ 
vastly between studies resulting in a variety of immune responses.  Mice dosed 
three days in a row, every 3 weeks, develop systemic IgG and mucosal IgA 
responses and rapid increases in TNF-α and IFN-γ in the MLN.  Antibodies have 
specificities for both spores and vegetative cells (Duc et al. 2004).  In vitro, B. 
subtilis upregulates APRIL production in intestinal epithelial cells, which 
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promotes IgA class switch by germinal center B cells, providing mechanistic 
insight for changes seen in vivo (He et al. 2007). 
Other cell types have also been shown to respond to B. subtilis.  Murine 
macrophages phagocytose B. subtilis spores in vitro.  Spores germinate within 
the phagosome and may initiate protein synthesis.  However, vegetative cells fail 
to grow and divide and are destroyed within 5 h (Duc et al. 2004).  This amount 
of time however, seems to be enough to trigger innate immune responses.  Cells 
rapidly upregulate IL-6 mRNA upon treatment; minimal changes occur in TNF-α 
and IL-1α.     
Protection from C. rodentium-induced Disease by B. subtilis. 
To further investigate the immune-stimulatory properties of Bacillus 
subtilis, the Knight lab focused on a mouse model of the enteric human pathogen, 
EPEC.  C. rodentium is an attaching and effacing pathogen that induces acute 
colitis.  Disease is characterized by colonic hyperplasia, mucosal infiltration, an 
increase in chemokines and pro-inflammatory cytokines, and diarrhea, similar to 
the pathology of EPEC infection in humans.  During infection, CD4+ T cells 
infiltrate the intestinal mucosa and drive much of the pathology associated with 
disease.  CD4+ T cells increase the proliferation of intestinal epithelial cells and 
deplete mucus-producing goblet cells in an IFNγ-dependent manner (Chan et al. 
2013; Higgins et al. 1999).  Additionally, infected mice display an increase in Th1 
cytokines including IL-12, IFNγ and TNFα in the colon, as well as an increase in 
the Th17 cytokine, IL-17A, in the Peyer’s patches (Li et al. 2014).  These cytokines 
lead to increased production of other chemokines that recruit innate immune 
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cells to the site of infection, furthering the progression of disease.  In most strains 
of immunocompetent mice, C. rodentium is not lethal and is cleared by both 
innate and adaptive immune responses 3 to 4 weeks post-inoculation; pathogen 
clearance requires MyD88-dependent signaling, CD4+ T cells and IgG (Bhinder et 
al. 2013; Kamada et al. 2015).    
To test if B. subtilis protects mice from C. rodentium-induced disease, 
mice were orally administered 109 B. subtilis spores 24 h prior to infection with 
5x108 CFU of C. rodentium by oral gavage.  Jones & Knight then assessed levels 
of serum pro-inflammatory cytokines, colonic hyperplasia, and the development 
of diarrhea 10 days post-infection.  C. rodentium infected mice had increased 
levels of the pro-inflammatory cytokine KC or CXCL1 in serum, mucosal 
infiltration and loss of goblet cells in the colon, and develop soft stool.  In mice 
treated with a single oral dose of B. subtilis prior to infection, mice had no 
evidence of disease.  Serum KC and colonic histology of mice treated with B. 
subtilis prior to C. rodentium infection are comparable to naïve mice.  Further, 
these mice have normal stool, suggesting that B. subtilis prevents C. rodentium-
induced inflammation (Jones & Knight 2012).  In a separate study, D’Arienzo et 
al. found that B. subtilis spores protected suckling mice from C. rodentium-
induced disease, but in adult mice, found no differences in disease progression 
(D’Arienzo et al. 2006).  The doses of B. subtilis and C. rodentium, as well as the 
strains of mice, differed in these studies, which likely contributed to different 
experimental outcomes.   
Jones et al. (2014) first tested if B. subtilis reduces pathogen colonization, 
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thereby limiting disease.  In fact, D’Arienzo et al. did find reductions in C. 
rodentium colonization in both suckling and adult mice following repeated doses 
of B. subtilis.  In our model using a single dose of B. subtilis, we see no alterations 
in pathogen colonization in the lumen or mucosa, demonstrating that the 
pathogen is still present at the same levels, but not causing disease.  Jones et al. 
also tested if B. subtilis alters the localization of C. rodentium in the GIT using a 
luciferase-expressing strain of C. rodentium.  Mice were monitored using an in 
vivo imaging system throughout the course of disease.  Administration of B. 
subtilis did not change the localization or quantity of luminescence of C. 
rodentium (Jones et al. 2014).  These experiments demonstrate that B. subtilis 
does not protect mice by altering the localization, adherence or density of the 
pathogen.   
Jones et al. (2014) also tested if B. subtilis increases epithelial barrier 
integrity to limit disease.  During C. rodentium infection, epithelial cell loss leads 
to gut ‘leakiness’.  We measure this by orally administering FITC-dextran and 
assessing the serum for fluorescence.  If B. subtilis functions by preventing 
epithelial damage, then little to no FITC-dextran should be present in the serum.  
During infection, we find about a two-fold increase in serum FITC-dextran 
compared to PBS-treated mice, regardless of B. subtilis administration or not 
(Jones et al. 2014).  These data suggest that B. subtilis does not protect by 
preventing epithelial barrier damage.  We have not, however, explored the 
possibility of increased IgA in the mucosa due to B. subtilis, as other groups have 
seen, which may help to limit C. rodentium.   
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Dr. Jones then asked which bacterial molecules produced by B. subtilis 
mediate the protective effects, hypothesizing that B. subtilis formed a biofilm 
within the GIT, blocking C. rodentium from attaching to epithelial cells and 
causing damage.  To test this hypothesis, Dr. Jones screened mutants deficient in 
biofilm production, epsH and tasA, for protective effects in the C. rodentium 
model. The epsH mutant did not protect mice from disease, however, the tasA 
mutant, that also cannot form a biofilm, did protect mice from disease (Jones & 
Knight 2012).  These data suggest that the epsH gene product, a 
glycosyltranferase, is required for protection, but formation of a biofilm is not.   
As a negative control, mice were treated with hag mutant spores, which do 
not produce flagella.  Interestingly, the hag mutant also did not protect mice 
from disease, suggesting flagella are required for B. subtilis-mediated protection.  
There are two possibilities by which the flagella could provide protection: first, 
TLR5 recognizes flagella and B. subtilis flagella could potentially stimulate TLR5 
to activate the innate immune response.  The second possibility is that B. subtilis 
needs to localize to a particular niche within the GIT to mediate protection.  To 
test these possibilities, Dr. Jones utilized a motAB B. subtilis mutant, which 
produces structurally intact flagella that cannot rotate.  Therefore, if the bacteria 
need to stimulate TLR5, this mutant will be protective, but if protection requires 
localization of B. subtilis to a given niche, this mutant will not be protective.  The 
motAB mutant did not protect mice from C. rodentium-induced inflammation, 
suggesting protection requires functional flagella (Jones & Knight 2012).  To 
further support this conclusion, mice were administered purified B. subtilis 
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flagella, which did not protect mice from disease (Dr. Sara Jones, unpublished 
observations).  These studies demonstrated that B. subtilis spores germinate 
within the GIT and vegetative cells express functional flagella to localize to a 
certain niche, where cells also express epsH, which together induce a protective 
response during C. rodentium infection.   
Exopolysaccharide. 
EPSs are secreted heterogeneous structures composed primarily of 
carbohydrates that often coat bacteria and are major components of the biofilm 
matrix.  The role of EPS during pathogen infection is well appreciated.  For 
example, pathogenic Staphylococcus aureus are coated with an EPS-containing 
capsule that prevents phagocytosis and allows adherence of the bacteria to host 
tissues and subsequent immune evasion.  Much less is known about EPS from 
commensal bacteria.  EPS might be important for probiotic or commensal 
organisms to establish and maintain an intestinal niche that could prevent 
pathogen colonization, as is the case with B. breve (Fanning et al. 2012).  
Alternatively, gut metabolism of EPS could contribute to short chain fatty acid 
synthesis, a process that regulates intestinal permeability and Treg cell induction 
(Smith et al. 2013). 
The epsH gene is encoded within the 15 gene eps operon required for 
exopolysaccharide (EPS) production.  B. subtilis produces EPS in the transition 
from planktonic cells to cell aggregates known as biofilms.  Biofilms contain non-
motile cells encapsulated within an extracellular matrix often composed of 
polysaccharides, proteins and DNA.  EPS and the amyloid protein TasA are the 
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main components of the B. subtilis biofilm and serve to stabilize the biofilm 
(Romero et al. 2010; Branda et al. 2006; Kearns et al. 2005).  The epsH gene 
encodes one of several glycosyltransferases within the operon, which are most 
likely required for EPS biosynthesis (Guttenplan et al. 2010).  In the absence of 
epsH, B. subtilis does not produce EPS (Guttenplan et al. 2010).   
We tested if B. subtilis EPS is required for protection by purifying EPS 
from B. subtilis.  We collaborated with the laboratory of Dr. Daniel Kearns at 
Indiana University, where they produced a sinRtasA B. subtilis mutant.  The sinR 
gene encodes a DNA binding protein that binds to the promoter region of the eps 
operon, and represses transcription of genes responsible for production of EPS 
(Kearns et al. 2005).  In the sinRtasA mutant, EPS is constantly being produced 
and is no longer tethered to the surface of cells, allowing us to purify EPS from 
culture supernatants.  The Kearns Lab also produced a sinRtasAepsH mutant to 
serve as a negative control, since it would produce all the background 
polysaccharide, but would not produce EPS.  Using these mutants we harvested 
B. subtilis supernatants, digested nucleic acids and protein, and further purified 
the remaining polysaccharide on a size exclusion column.  Mice were injected 
intraperitoneally (i.p.) with EPS or the same volume of material purified from the 
sinRtasAepsH material then infected with C. rodentium 1 day later and disease 
was assessed 10 days post-infection (dpi).  Mice treated with EPS showed no 
evidence of disease, whereas mice treated with the negative control material from 
the EPS-deficient strain had increased levels of serum KC, colonic hyperplasia 
and soft stool (Jones et al. 2014).  These data indicate that EPS mediates 
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protection from inflammation by B. subtilis.  
How does EPS limit C. rodentium-induced inflammation?  Bacterial 
polysaccharides from both pathogens and commensal bacteria are ligands for 
many types of PRRs, including TLRs, NOD-like receptors (NLRs), and C-type 
lectins.  Because many of these PRRs signal through MyD88, an adaptor protein 
that often leads to NF-κB activation, we tested if EPS-mediated protection 
requires MyD88.  MyD88 is essential for controlling C. rodentium-induced 
inflammation and MyD88-deficient mice are highly susceptible to disease 
(Gibson et al. 2008).  Jones et al. (2014) titrated the dose of C. rodentium to a 
level where disease was comparable to that of wild-type (WT) mice, then tested if 
EPS alleviated disease symptoms.  MyD88-/- mice treated with EPS prior to 
pathogen infection develop disease comparable to mice not treated with EPS, 
suggesting EPS requires MyD88 to prevent disease (Dr. Sara Jones, unpublished 
observations).   
We further explored the dependency on MyD88 for protection using cell-
type-specific MyD88-/- mice.  Mice lacking MyD88 in myeloid cells (LysM-cre) 
and mice lacking MyD88 in epithelial cells (villan-cre) were treated with EPS one 
day prior to infection with C. rodentium and disease was assessed 10 dpi.  
Myeloid-specific MyD88-/- mice treated with EPS had elevated serum KC, crypt 
hyperplasia and diarrhea; in comparison, EPS protected epithelial-specific 
MyD88-/- mice from disease (Jones et al. 2014).  These data suggest that EPS 
utilizes MyD88 signaling in a myeloid lineage cell to mediate protection.  Many 
TLRs signal through MyD88.  Other bacterial polysaccharides signal through 
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TLR4, therefore we tested if EPS requires TLR4 signaling for protection.  TLR4-/- 
mice treated with EPS develop C. rodentium-induced disease (Jones et al. 2014).  
These studies suggest that B. subtilis prevents C. rodentium-induced 
inflammation by producing EPS that signals through TLR4 on a myeloid cell to 
elicit a protective response.   
Section 6: Macrophages 
 Metchnikoff identified macrophages over 100 years ago as ‘phagocytes’ 
that phagocytose bacteria and apoptotic cells (Metchnikoff & Metchnikoff 1908; 
Gordon 2008).  He viewed these cells as essential components to maintaining 
homeostasis.  Today, we know that macrophages play a crucial part in 
homeostasis by clearing apoptotic cells and promoting tissue development and 
repair.  Macrophages are also critical for host defense to intracellular and 
extracellular pathogens; these cells produce antimicrobial factors that can 
directly target pathogens within endosomes in the cell (Lawrence & Natoli 2011).  
Additionally, macrophages produce cytokines and chemokines that initiate and 
regulate adaptive immune responses.  
Macrophage Development.  
Tissue-resident macrophages.  Macrophages are present in most 
tissues throughout the body and have important functions in tissue development, 
as well as sensing tissue damage and orchestrating tissue repair.  Each tissue has 
a specialized subset of macrophages, with distinct transcriptional master 
regulators, that contribute to tissue-specific maintenance, even in immune-
privileged sites such as the eye, brain and testes (Okabe & Medzhitov 2016).  
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Tissue-resident macrophages highly express PRRs including TLRs and NLRs, but 
relative amounts of each PRR varies between tissues.  Normal development and 
function of some tissues and organs is dependent on macrophages that reside in 
these organs, but macrophages in every tissue sense tissue damage and 
orchestrate tissue-repair responses.  Microglia, resident CNS macrophages, 
function in synaptic formation and remodeling, which are vital to memory and 
learning (Parkhurst et al. 2013; Blank et al. 2014).  Bone macrophages, or 
osteoclasts, perform bone resorption, which is imperative in bone remodeling 
and tissue repair.  In the liver, Kupffer cells clear pathogens and toxic 
metabolites.  Alveolar macrophages clear bi-products of neighboring cells such as 
surfactins, as well as dust, allergens and microorganisms.  In all tissues, 
macrophages clear apoptotic debris, especially in the spleen where marginal zone 
macrophages suppress immune responses to apoptotic cells and red-pulp 
macrophages clear senescent red blood cells (McGaha et al. 2011).  Intestinal 
macrophages aid in tolerance to food antigens and the microbiota and help to 
remove enteric pathogens (Schreiber et al. 2013).   
Tissue-resident macrophages arise from the yolk sac, fetal liver, and 
hematopoietic stems cells (HSCs) in the bone marrow.  Until recently, 
macrophage dogma dictated that the majority of tissue macrophages 
differentiated from infiltrating blood monocytes.  We now understand that the 
majority of tissue-resident macrophages seed tissues before birth and are 
maintained for the life-span of the organism by self-renewal (Jenkins et al. 2011; 
Jenkins et al. 2013; Yona et al. 2013; Hashimoto et al. 2013).  Judith Allen and 
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colleagues first established the proliferative capacity of tissue-resident 
macrophages during steady state and their increased proliferation in response to 
parasite infection in the pleural cavity (Jenkins et al. 2011).  Fate-mapping and 
parabiosis studies have provided insight into the actual origins of tissue-resident 
macrophages versus macrophages that differentiate from monocytes (Yona et al. 
2013; Hashimoto et al. 2013).  In both of these studies, there was no evidence 
that monocytes contributed to liver, skin, splenic, or alveolar macrophages in 
steady-state conditions.  The majority of peritoneal macrophages appear to arise 
prior to birth, but a small population of monocyte-derived macrophages resides 
within the peritoneum and is discussed in detail below (Ghosn et al. 2010).   
Whether macrophages within different tissues have different rates of 
proliferation and survival has not been established.  In cases of irradiation or 
extreme inflammation, bone marrow-derived macrophages may repopulate 
certain macrophage tissue populations.    
Monocyte-derived macrophages.  Monocytes differentiate from HSCs 
in the bone marrow and circulate in the blood.  Upon infection or acute 
inflammation, monocytes infiltrate the site of damage and differentiate in situ 
into macrophages or dendritic cells.  Within the tissue, monocyte-derived 
macrophages respond to environmental stimuli and contribute to inflammation 
or help to resolve inflammation and promote repair (Schreiber et al. 2013).  
Tumor-associated macrophages also differentiate from monocytes and are highly 
anti-inflammatory.  As discussed, very few macrophages arise from an influx of 
monocytes to a given tissue under steady-state conditions. It is unclear, however, 
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whether monocyte-derived macrophages dissipate with the resolution of 
inflammation or if they persist and self-maintain in the tissue.    
Certain tissues, including the intestine, rely on infiltrating monocytes as 
the main source of macrophages (Little et al. 2014).  The main population of 
CX3CR1hi macrophages in the intestine differentiates from Ly6Chi monocytes that 
expand within the gut lamina propria (Bogunovic et al. 2009; Jaensson et al. 
2008).  These cells have a half-life of roughly 3 weeks.  Intestinal macrophages 
help maintain homeostasis and prevent inflammatory responses to commensal 
bacteria and food proteins (Murai et al. 2009).  During colitis, macrophages 
further infiltrate and accumulate in the gut and drive pathogenesis.  The skin and 
splenic marginal zone also contain resident macrophages that are monocyte-
derived (Tamoutounour et al. 2013; A-Gonzalez et al. 2013).  These tissues, along 
with the gut, are regularly exposed to microbes and microbial products, which 
may explain the need to be regularly replenished by monocytes.   
Peritoneal Macrophages. 
 Macrophages comprise over half the cells within the peritoneal cavity of 
mice.  Due to their large numbers and the easy accessibility of the peritoneum, 
these cells have been extensively studied in characterizing macrophage innate 
immune responses, and for their ability to phagocytose pathogens.  Peritoneal 
macrophages are not a homogeneous population, but rather two distinct 
populations.  Small peritoneal macrophages (SPMs) are bone marrow-derived 
F4/80low, CDllblow, and Ly6C+, and present in small numbers within the 
peritoneal cavity.  During infection, monocytes infiltrate the peritoneal cavity and 
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differentiate into SPMs (Ghosn et al. 2010).  As expected, SPMs highly express 
CCR2, the chemokine receptor critical for monocyte recruitment.  These cells are 
highly phagocytic and produce large amounts of nitric oxide.  Large peritoneal 
macrophages (LPM) are the main population of macrophages within the 
peritoneal cavity.  As are most tissue-resident macrophages, these cells develop 
during embryonic development in the yolk sac and are maintained through self-
renewal.  During infection, these cells undergo rapid proliferation (Jenkins et al. 
2013); however, they are less phagocytic and produce less nitric oxide compared 
to SPMs.  Following peritoneal injection of TLR agonists or even PBS, LPMs 
rapidly disappear from the peritoneal cavity and the influx of monocytes leads to 
an increased percentage of SPMs (Ghosn et al. 2010).  Okabe and Medzhitov 
determined that when macrophages disappear in the peritoneal cavity following 
intraperitoneal injection of LPS, LPMs accumulate within milky spots of the 
omentum, a fatty tissue within the peritoneum (Okabe & Medzhitov 2014).  These 
milky spots are clusters of mostly lymphoid cells and some other leukocytes.  
Here, the omentum provides retinoic acid to macrophages, allowing them to 
migrate back to the peritoneal cavity.  Retinoic acid regulates expression of the 
transcription factor GATA-6.  GATA-6 controls expression of peritoneal 
macrophage-specific genes in LPMs and localization of LPMs within the 
peritoneal cavity under normal conditions and their return following peritoneal 
inflammation (Okabe & Medzhitov 2014).  Among these genes are Tgfb2 and 
other genes related to deposition and activation of the latent form of TGF-β.  
Since TGF-β and retinoic acid promote B cell homing to the gut and induce IgA 
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class switching (Baumgarth 2011), Okabe and Medznikov investigated the 
function of GATA-6 and LPM in gut IgA production.  Interestingly, they 
determined that GATA-6 in macrophages controls IgA production by B1 cells that 
migrate to the lamina propria.  Overall, these studies demonstrate that 
macrophage subsets within the peritoneal cavity have diverse roles in 
maintaining immunity inside and outside of the peritoneum.    
Peritoneal cell trafficking.  In contrast to other tissue-resident 
macrophages, peritoneal macrophages float within the peritoneal fluid that 
circulates toward lymphatics (Avraham-Chakim et al. 2013), allowing them to 
constantly survey abdominal organs.  Trafficking into the peritoneal cavity has 
been much better characterized than cells leaving the peritoneal cavity to travel to 
other parts of the body.  Peritoneal cells are thought to traffic from the peritoneal 
cavity to other organs through two routes.  By one route, cells traffic through 
milky spots in the omentum and into the lymphatics.  Early studies demonstrated 
that capillaries within these lymphoid aggregates are points of cellular traffic for 
multiple cell types, including monocytes (Hodel 1970; Beelen et al. 1980; Doherty 
et al. 1995).  Another route seemingly exists, however, much less is understood.  
Recently, Wang and Kubes identified a non-vascular route by which macrophages 
from the peritoneal cavity directly enter the liver in a model of sterile 
inflammation.  In this model, macrophages rapidly accumulate in the liver by 
upregulating CD44, an adhesion molecule that binds to exposed hyaluronan 
present on liver mesothelium (Wang & Kubes 2016).  Although other organs were 
not examined in this study, it stands to reason that macrophages, and other 
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peritoneal cells, can directly enter other organs covered by the peritoneum, 
including the gut.     
Macrophage Polarization. 
Macrophages polarize into different activation states following microbial 
stimulation or environmental and cytokine stimuli.  Activation phenotypes are 
thought to occur across a spectrum and be fairly plastic, allowing cells to rapidly 
adjust to different environments.  Traditionally, two activation states, classical 
(M1) and alternative (M2) (Figure 1), encompassed most identified macrophages, 
but these subtypes are fairly heterogeneous.  Different transcription factors have 
been identified to regulate classical versus alternative polarization. 
Figure 1.1.  Macrophage Polarization.  Tissue-resident macrophages (MΦ) 
adopt different activation states based on their environment. M1 macrophages 
are induced following LPS and/or IFNγ stimulation and produce pro-
inflammatory cytokines and are highly phagocytic.  M2 macrophages develop in 
the presence of IL-4, IL-13 and potentially other anti-inflammatory factors.  
They induce an anti-inflammatory environment.   
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M1 Macrophages. 
M1, or classical, activation occurs following TLR ligation and/or IFN-γ 
stimulation, and cells express high levels of inducible nitric oxide synthase 
(iNOS).  IFN-γ often comes from natural killer (NK) cells or other innate cells.  
M1 macrophages are pro-inflammatory, highly phagocytic, and mediate host 
defense to bacteria, viruses, and protozoa, and contribute to anti-tumor 
immunity.  Upon phagocytosis of pathogens, the phagosome containing the 
pathogen fuses with the lysosome where nitric oxide, reactive oxygen species, and 
enzymes aid in destruction of intracellular pathogens.  Depending on the 
pathogen, these cells produce large amounts of IL-12p40 and TNF-α that 
promote Th1 effector cell differentiation, or IL-23 that can promote Th17 
differentiation (Italiani & Boraschi 2014).  These effector T cell subsets produce 
cytokines that help to maintain the M1 phenotype.  As the pathogen is eliminated, 
the reduction in M1-stimuli and increase in M2 stimuli are thought to give rise to 
M2 macrophages that promote wound healing and repair tissue damage that 
occurred during inflammation.   
M2 Macrophages. 
M2, or alternatively-activated, macrophages are anti-inflammatory and 
regulate wound healing and tissue repair.  M2 activation primarily occurs in 
response to IL-4 and IL-13 (Dyken & Locksley 2013).  These cytokines are 
produced by granulocytes such as basophils, eosinophils and mast cells, and 
lymphoid cells including Th2 cells, ILC2 and NKT cells (Jenkins & Allen 2010).  
Several other M2 macrophage-inducing stimuli have been described.  Each 
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resulting ‘subtype’ exhibits anti-inflammatory properties, but often differ in 
marker expression and often produce varying effector molecules.  Other M2-
inducing factors include IL-10, TGF-β, immune complexes, and glucocorticoids 
(Cao et al. 2010).  Additionally, TLR stimulation also can drive M2 polarization.  
Another population of macrophages, regulatory macrophages, produce large 
amounts of IL-10 in response to Fc receptor ligation.  Within the tumor 
microenvironment, tumor-associated macrophages (TAMs) and myeloid-derived 
suppressor cells (MDSCs) have been identified and are quite functionally similar 
to M2 macrophages (Mills 2012).   
M2 macrophage markers include arginase-1, CD206, Fizz-1, YM-1, and 
effector cytokines; these molecules are described in detail below.  Table 1.2 
contains a summary of M2 macrophage markers that are upregulated in response 
to different stimuli, however, different studies utilize various combinations of 
these markers or as little as one marker to define these cells.  
 
Molecule Full Name Function 
CD206/
MRC1 
Macrophage mannose receptor, C-
type mannose receptor-1 
C-type lectin, phagocytosis of pathogens 
IL-4Rα --- Dimerizes with the common γ-chain or 
IL-13Rα1 to form IL-4 and IL-13 receptor 
 
Arginase-1 --- Competes with iNOS to catalyze L-arginine 
hydrolysis to urea and ornithine, production of 
prolines and polyamines to promote tissue 
repair/fibrosis 
 
Relmα/
FIZZ-1 
Resistin-like molecule alpha or 
found in inflammatory zone protein 
Cysteine-rich small proteins, not well 
characterized 
Ym-1/
Chi3l3 
chitinase-3-like protein 3 Lectin, chitinase-like molecule, not well 
characterized 
Table 1.2. M2 Macrophage Markers and Functions 
 
 
 
 
 
 
 												
Abbreviations: Chi3l3: chitinase-like 3 ; FIZZ-1:found in inflammatory zone 1 ; IL-4Rα: interleukin-4 
receptor α; IL-13Rα1: interleukin-13 receptor α 1; iNOS: inducible nitric oxide sythase; MRC1: ; Relmα: 
resistin-like molecule α 
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Arginase-1.  Arginase-1 (Arg-1) catalyzes the conversion of L-arginine 
into L-ornithine and urea.  IL-4 and IL-13 upregulate Arg-1 expression in 
macrophages via STAT6, STAT3 and PPAR-γ, supporting the fact that various 
stimuli drive Arg-1+ M2 macrophages.  Arg-1 competes for substrates with iNOS, 
which is induced by M1 stimuli.  These factors, therefore, have become defining 
characteristics in the M2 versus M1 macrophages.  Additionally, Arg-1 
contributes to M2 macrophage-anti-inflammatory functions.  Arg-1 production 
by macrophages inhibits CD4+ T cell proliferation and IFN-γ production, since T 
cells require arginine to proliferate (Pesce et al. 2009; Gobert et al. 2004).   
Mannose receptor.  The mannose receptor, or CD206, is a C-type lectin 
expressed by macrophages in many tissues and upregulated by IL-4/IL-13.  
CD206 binds serum glycoproteins and contributes to their clearance (Lee et al. 
2002).  CD206 also contributes to endocytosis and possibly antigen presentation 
(Gazi & Martinez-Pomares 2009).  Expression of this receptor contributes to 
immunity to fungal and parasitic infections, most likely by serving as a PRR for 
mannosylated ligands.   
Ym-1.  Ym-1, or Chi3l3, is a chi-lectin that is induced in an IL-4/IL-13 and 
STAT6-dependent manner in macrophages.  Chi-lectins, including Ym-1, are 
homologous to chitinases that bind and degrade chitin; chi-lectins bind chitin, 
but lack enzymatic activity.  Chi-lectins bind β-1,4-N-acetylglucosamine that can 
be found on parasites, fungi and dust mites that elicit Type 2 immune responses.  
Although Ym-1 upregulation on M2 macrophages occurs during allergic 
responses and helminth infections and could potentially recognize chitin motifs, 
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Ym-1 accumulates intracellularly.  It is unclear if it can contribute to M2-
mediated anti-inflammatory effects.  
FIZZ-1.  FIZZ-1, found in inflammatory zone (FIZZ-1), or resistin-like 
molecule α (Relmα), is upregulated during helminth infection or allergen-
induced inflammation in epithelial cells, eosinophils and macrophages.  As with 
Ym-1, FIZZ-1 is consistently described as an M2 marker, but the function of this 
molecule is not well understood.  Some evidence suggests that FIZZ-1 is a 
negative regulator of Type 2 inflammation and that recombinant FIZZ-1 can 
directly inhibit Th2 cell cytokine production (Nair et al. 2009), while contrasting 
studies suggest FIZZ-1 promotes allergy-induced lung inflammation (Doherty et 
al. 2012).  Both of these studies use recombinant FIZZ-1.  The actual function of 
FIZZ-1 production by macrophages has not been identified.   
A recent publication discussed the difficulties across the macrophage field 
due to various methods of generating and polarizing macrophages and their 
transient nature (Murray et al. 2014).  Instead of classifying macrophages into M1 
versus M2 macrophages, this large group of macrophage biologists suggest that 
future studies directly reference the stimulus in the name, i.e. M(IFN-γ) or M(IL-
4).  This will undoubtedly be difficult to establish as a new basis of naming 
macrophages.  As our understanding grows of transcriptional programs 
controlling macrophage polarization in different environments and disease 
states, perhaps new nomenclature methods will be identified.   
M2 Macrophages in Health and Disease. 
M2 macrophages have primarily been characterized during helminth 
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infections, and allergy, but recent studies have linked them to an array of normal 
processes including systemic metabolism, cold adaptation and tissue 
homeostasis.  Dysregulation of these normal functions is linked to 
atherosclerosis, osteoporosis, obesity and type 2 diabetes, fibrosis and cancer 
(Martinez et al. 2008).  Interestingly, many of these diseases are also linked to 
disruptions of the microbiota.   
Metabolism.  Immune cells can regulate metabolic homeostasis.  In a 
lean state, Th2 cells, Treg cells, ILCs, and eosinophils promote M2 macrophages 
that all help maintain an anti-inflammatory environment within brown adipose 
tissue, and maintain insulin sensitivity (Carey et al. 2013; Molofsky et al. 2013).  
These cells that maintain adipose tissue homeostasis are dysregulated in obesity 
when fat tissue becomes highly inflamed.  M1 macrophages are highly prevalent, 
as well as Th1 cells, ILC1s and CD8+ T cells (O’Sullivan et al. 2016).  These cells 
secrete proinflammatory cytokines that contribute to insulin resistance and Type 
2 diabetes.   
There are three main types of adipose tissue; white adipocytes store energy 
as lipids and contribute to metabolic disease in obesity, whereas brown 
adipocytes, or ‘healthy fat,’ dissipate chemical energy for heat production in 
response to cold and counteract obesity and metabolic disease.  White fat can 
undergo a ‘beiging’ process, increasing energy expenditure, and become beige 
adipocytes.  Brown and beige adipocytes function to prevent weight gain in mice 
and humans (Feldmann et al. 2009; Carey et al. 2013).  During cold exposure, 
M2 macrophages produce norepinephrine and epinephrine that promote beiging 
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of white adipocytes and decreases adiposity (Wu et al. 2011; Qiu et al. 2014). 
Allergy and asthma.  Allergic disease is caused by the immune system 
inappropriately reacting to innocuous substances.  Allergic reactions occur upon 
exposure to an allergen in pre-sensitized individuals.  Antigen-presenting cells 
(APC), such as dendritic cells (DC), macrophages or B cells, initiate the process of 
allergic sensitization by capturing and internalizing allergen.  APC present 
antigen, especially to T cells which secrete cytokines, interleukin-4 (IL-4), IL-5, 
and IL-13 that help drive the inflammatory response.  IL-4 is critical for class 
switch to IgE, which mediates allergic symptoms (Galli & Tsai 2012).  
Numerous studies have identified roles for M2 macrophages in allergic 
responses driven by IL-4 and IL-13.  However, their function in allergy and 
asthma remains controversial, with some studies suggesting that M2 
macrophages promote allergic inflammation and others indicating a suppressive 
role for these cells.  In several types of allergic inflammation, mice deficient in 
M2 polarization (myeloid-specific IL-4Rα-/-), showed few differences in allergic 
antibody and cytokine production, mucus secretion, and eosinophil infiltration 
that are detrimental during allergic responses (Heller et al. 2007).  Other studies 
have shown that M2 macrophages can contribute to eosinophil recruitment 
(Falcone et al. 2001; Huffnagle et al. 1998).  In cases of asthma, by facilitating the 
uptake and removal of fungal conidia, M2 macrophages have been shown to 
inhibit asthma symptoms associated with chronic fungal infections (Moreira et al. 
2010).  In any event, the upregulation of IL-4 and IL-13 during allergy and 
asthma contributes to accumulation of these cells.   
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Helminth infection.  Helminth infection in the GIT, pleural cavity and 
peritoneal cavity elicit strong Type 2 immune responses that are required to expel 
the worms.  Infection leads to increased IL-4 and IL-13 production, proliferation 
of macrophages, and upregulation of M2 phenotypic markers (Jenkins et al. 
2011).  IL-4 and IL-13 also promote IgE class switch, increased mucus production 
and eosinophilia (Jenkins & Allen 2010).  In the gut, Trichiuris muris infection 
results in monocyte recruitment that ultimately contributes to macrophage 
accumulation and obtain an M2 macrophage phenotype (Little et al. 2014).  
Although robust Type 2 immune responses can be detrimental in the case of 
allergy, these responses are necessary to clear helminth infection and limit 
detrimental responses.  Deficiency of IL-4 receptor α (IL-4Rα)-signaling 
specifically in myeloid cells results in early mortality to Schistosoma mansoni, 
due in part to exacerbated disease pathology from Th1 cells (Herbert et al. 2004), 
and Th2 inflammation and fibrosis, which are limited by Arg-1 (Pesce et al. 
2009).  Infection with other helminthes can impair eosinophil recruitment and 
tissue repair, but worms are cleared normally, suggesting that M2 macrophages 
play different roles in various helminth infection models (Martinez et al. 2008).   
Mechanisms of Inhibition by M2 Macrophages. 
 In addition to Arg-1, M2 macrophages produce several other inhibitory 
molecules including IL-10, PD-L2, and TGF-β.  These molecules can potentially 
inhibit a variety of cell types, but their inhibitory properties have been primarily 
studied with T cells.  
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Interleukin-10.  IL-10 potently inhibits T cell cytokine production and 
proliferation, rendering the T cells unresponsive, or anergic.  IL-10 also 
downregulates MHC class II and co-stimulatory molecules on APCs (A. Taylor et 
al. 2006), and induces immunoregulatory phenotypes, i.e. M2 macrophages, 
iTregs (Murai et al. 2009; Italiani & Boraschi 2014).  Administration IL-10 to 
mice alleviates a plethora of diseases, including colitis, graft-versus-host disease 
(GVHD), and allergic responses to name a few, however clinical trials in humans 
have not been as successful (Min et al. 2007; Murai et al. 2009).  Induction of IL-
10 within a given cell-type or tissue versus administration of recombinant IL-10 
may have better therapeutic effects.   
Programmed death-ligand 1/2.  Immune checkpoints are critical for 
maintaining self-tolerance, and much of this is mediated by membrane receptor-
ligand interactions.  Programmed cell death protein 1, PD-1, is an 
immunooreceptor tyrosine-based inhibitory motif (ITIM)-containing receptors 
expressed on T cells and B cells.  PD-1 is upregulated in activated T cells and 
binds to PD-L1 and PD-L2 (Latchman et al. 2001; Liang et al. 2003).  PD-1 
interacts with its ligands to prevent T cell activation and proliferation by 
promoting apoptosis (Carter et al. 2002).  Interestingly, PD-1/PD-L1 interactions 
also maintain an anti-inflammatory environment by reducing apoptosis in Treg 
cells (Carter et al. 2002).  PD-L1 and PD-L2 are part of the B7 family of co-
stimulatory molecules and are expressed on macrophages and dendritic cells.  IL-
4 upregulates expression of PD-L2 on macrophages in a STAT6-dependent 
manner (Liang et al. 2003).  Inhibition of PD-L2 during infection with the 
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helminth Nippostrongylus brasiliensis enhances Th2 responses in the lung, 
demonstrating that PD-L2 is required to limit an exacerbated Th2 response 
(Huber et al. 2010).  
Transforming growth factor-β.  TGF-β is a pleiotropic cytokine that 
acts on virtually all cell-types.  TGF-β potently inhibits T cells by blocking IL-2 
production, a required growth factor for T cells, via smad3 signaling (A. Taylor et 
al. 2006).  This induces anergy, which is characterized by T cells that fail to 
activate upon antigen-stimulation.  TGF-β contributes to peripheral tolerance by 
promoting Treg cell generation and increasing their suppressive function.  In 
combination with IL-6, TGF-β promotes differentiation to Th17 cells (Mangan et 
al. 2006), whereas TGF-β promotes survival in memory T cells.  In B cells, TGF-β 
suppresses allergen-specific IgE and induces class-switch to allergen-specific IgA 
(Mucida et al. 2005).  Granulocytes, including mast cells and eosinophils, and NK 
cells increase chemotaxis and often survival in the presence of TGF-β, which may 
account for some detrimental effects of TGF-β in allergy models (Gorelik & 
Flavell 2002).  In NK cells, TGF-β also decreases cytokine production and their 
cytolytic activity (Bellone et al. 1995).  Dendritic cells and macrophages decrease 
antigen presentation following TGF-β stimulation, but these cells can obtain 
regulatory phenotypes and inhibit T cells and/or induce Treg cells (Gandhi et al. 
2007; Jaensson et al. 2008).  Several studies demonstrate that TGF-β drives M2 
macrophage polarization and TAM development or mediate the anti-
inflammatory effects of M2 macrophages (Derynck et al. 2001; Calon et al. 2014).  
M2 macrophages induced during infection with the nematode Litomosoides 
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sigmodontis suppress CD4+ T cell proliferation through production of TGF-β (M. 
D. Taylor et al. 2006).   Following phagocytosis of apoptotic cells, macrophages 
upregulate TGF-β to suppress proinflammatory cytokine production that may 
occur in response to the apoptotic bodies (Fadok et al. 1998). Additionally, 
macrophages promote wound healing and repair through TGF-β production.  
TGF-β has three subtypes, TGF-β1, TGF-β2 and TGF-β3, all with similar 
functions, that are synthesized as precursor molecules containing a propeptide 
region and the TGF-β homodimer (Gorelik & Flavell 2002).   TGF-β non-
covalently associates with a latency-associated peptide (LAP).  This complex 
binds to Latent TGF-β-binding Protein (LTBP), forming a large complex that gets 
deposited on the extracellular matrix.  TGF-β can also be expressed on the cell 
surface when associated with LAP; this form mediates TGF-β suppression of T 
cells by Treg cells (Nakamura et al. 2001).  TGF-β remains inactive when bound 
by LAP and LTBP; these molecules must be cleaved to release active TGF-β, but 
the mechanisms by which activation occurs are poorly defined.  Components of 
the extracellular matrix including proteases release active TGF-β, as do pH 
changes, ROS and thrombospondin in serum (Nunes et al. 1995; Hyytiäinen et al. 
2004; Taylor 2009).  Cell-surface bound TGF-β in complex with LAP mediates T 
cell suppression and Treg induction by dendritic cells, but how TGF-β is activated 
on cell surfaces is unknown (Gandhi et al. 2007).  Integrins on epithelial cells also 
cleave LAP from TGF-β and could potentially contribute on cell surfaces (Taylor 
2009).   
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T cell responses in disease.  Maintaining a balance between induction 
and inhibition of T cell responses is vital to the health of the host.  Immunity to 
several pathogens requires Th1 and Th17 responses, but excessive responses can 
contribute to pathology, as is the case in colitis (Giacinto et al. 2005; Higgins et 
al. 1999; Yang et al. 2014).  Similarly, exacerbated Th2 responses, or 
inappropriate responses to antigens, lead to allergy and asthma, but Th2 
inflammation is required to clear helminth infections (Paula et al. 2013).  M2 
macrophages possess the capabilities to dampen excessive immune responses 
through several different mechanisms, and can also promote tolerance through 
induction of Treg cells.   
Unchecked, T cells are main drivers of autoimmune disorders, multiple 
sclerosis (MS) and colitis.  EAE, an animal model of MS, is driven by pathogenic 
Th1 and Th17 responses that target the central nervous system (Langrish et al. 
2005).  The therapeutic agent, fasudil, alleviates the symptoms of EAE by 
promoting M2 macrophages that inhibit pathogenic T cell responses and 
increasing Treg cells (Liu et al. 2013; Liu et al. 2015).  However, many of the 
factors produced by M2 macrophages to inhibit inflammatory responses have 
been implicated in tumorigenesis, demonstrating the importance of the inducible 
and reversible nature of M2 macrophages.  Within the tumor microenvironment, 
M2 macrophages or TAM that develop within the tumor suppress cytotoxic T 
cells and NK cells that could help to eliminate the tumor (Noy & Pollard 2014).  
Further, M2 macrophage functions that normally contribute to wound healing 
and tissue repair promote tumor growth and metastasis through increased 
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stroma remodeling and angiogenesis (Martinez et al. 2008).  Treg cells are also 
increased in the tumor microenvironment.  M2 macrophages may directly induce 
these cells, or enhance their suppressive functions within the tumor.   
 The microbiota alters and induces development of several subsets of T 
cells, and perhaps others that induce inflammation and alter inflammation.  
Understanding the balance of T cell responses during infection and disease will 
help us determine how specific microbes can augment or limit certain responses.   
Concluding Remarks. 
The microbiota is vital to the development of lymphoid tissues and 
immune responses, the induction of tolerance, and disease prevention.  The 
molecular mechanisms by which intestinal bacteria guide these beneficial 
responses are just beginning to be discovered.  Continued research into the 
interactions between specific bacteria and the immune system will undoubtedly 
uncover novel interactions that contribute to homeostasis in the gut, and other 
microbiota/host interfaces such as the skin, eyes, lung, vagina and bladder. 
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CHAPTER TWO 
MATERIALS AND EXPERIMENTAL METHODS 
Mice. 
All animal experiments were performed according to protocols approved 
by the Institutional Animal Care and Use Committee at Loyola University 
Medical Center (Maywood, IL).  Specific pathogen–free (SPF) C57BL/6, TLR4-/-, 
TLR2-/-, CD4-/-, and OT-II transgenic mice founders were purchased from The 
Jackson Laboratory (Bar Harbor, ME) and bred in-house.  Mice lacking MyD88 
in myeloid cells were generated by crossing Lyz2-Cre transgenic mice to MyD88-
floxed mice as described (Gais et al. 2012).  Sterile standard chow and tap water 
were given to mice ad libitum.   
Reagents.  
All base media and supplements were from Life Technologies (Grand 
Island, NY). All antibodies were from Biolegend (San Diego, CA) unless otherwise 
indicated. The fluorescent antibodies used for flow cytometry include anti-
CD16/32 (FC block), anti-F4/80 (BM8), anti-CD25 (PC61), anti-CD4 (GK1.5), 
anti-CD8 (53-6.7), anti-CD11b (M1/70), anti-CD44 (IM7), anti-IL-4Rα (I015F8), 
anti-CD206 (C068C2), anti-CD80 (16-10A1), anti-CD86 (GL-1), anti-PD-L1 
(10F.9G2), anti-CD11c (N418), anti-siglecF (1RNM44N, eBioscience, San Diego, 
CA), anti-Ly6G (1A8), anti-Ly6C (HK1.4), anti-MHCII (M5/114.15.2), anti-PD-L2 
(TY25), anti-IgM (RMM-1), anti-IL-4 (11B11), anti-IL-13 (eBio13A, eBioscience, 
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San Diego, CA), anti-IFN-γ (R4-6A2), anti-LAP (TW7-16B4), anti-Foxp3 (FJK-
16s, eBioscience, San Diego, CA), anti-CD68 (ICFC), anti-CD80 (human, 2D10), 
anti-CD163 (GHI/61), anti-PD-L1 (human, 29E.2A3) and sheep anti-
mouse/human arginase-1 (R&D systems, Minneapolis, MN). Enzyme-Linked 
Immunosorbent Assay (ELISA) reagents for quantitation of IL-10, IFN-γ, TNF-α, 
and KC/CXCL1 were from R&D Systems; IL-17A, IL-2, IL-13 and TGF-β 
matched-pair reagents were from Biolegend.  Clodronate and PBS liposomes 
were from VU medisch centrum (Amsterdam, The Netherlands).  The anti-CD3ε 
(145-2C11) for in vivo experiments was from Leinco Technologies, Inc, (St. Louis, 
MO).  The anti-CD3ε used for in vitro experiments was LEAF-purified anti-CD3ε 
(145-2C11, Biolegend).  Cytochalasin D, NS-398, and SB-431542 were from Sigma 
(St. Louis, MO).  All primers were from IDT (Coralville, IA).  Apoptosis reagents 
were from BioLegend (San Diego, CA).  The MFB-F11 cell-line and RAW264.7 
cell-line were generous gifts from the Iwashima and Weithoff laboratories, 
respectively.  QUANTI-blue reagent was from Invitrogen (Carlsbad, CA).  
Cytokines for in vitro assays were from Peprotech (Rocky Hill, NJ).   
The following neutralizing antibodies were used for in vitro assays:  TGF-β 
inhibition, 5 µg/mL anti-TGF-β  (1D11, R&D Systems, Minneapolis, MN) or 
equivalent concentration of LEAF-purified mouse IgG1 isotype control; PD-L2 
inhibition, 3 µg/mL anti-PD-L2 (TY25) or isotype control LEAF-purified rat 
IgG2a; PD-L1 inhibition, 5 µg/mL anti-PD-L1 (10F.9G2) or isotype control LEAF-
purified rat IgG2b. Experiments with blocking antibody included the addition of 1 
µg/mL LEAF-purified anti-CD16/32 (FcγRII/III) to all wells.  For small molecule 
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inhibitors, the following concentrations were used: Nor-NOHA (12 µM), 
exogenous L-arginine (2 mM), NS-398 (1 µM).  
Purification of Exopolysaccharide.  
Exopolysaccharide was isolated from B. subtilis DS991 (ΔsinRtasA 
mutant), a strain that produces and secretes large amounts of EPS (Guttenplan et 
al. 2010).  The negative control, designated ΔEPS, DS5187 (sinRtasAepsH 
mutant), does not produce EPS and does not protect from C. rodentium-induced 
disease (Jones et al. 2014).  EPS was isolated from stationary phase supernatants 
of bacteria grown in Luria–Bertani (LB), BHI (brain-heart infusion) or MSgg 
medium isolated by 50% EtOH precipitation at -20o C. The precipitate was 
pelleted (15,000xg, 4˚C, 20 min), and resupended in 0.1 M Tris (pH 8.0) and 
samples were treated with DNase (67 mg/ml) and RNase (330 mg/ml) at 37˚C 
for 2 h followed by proteinase K (40 mg/ml) digestion at 55˚C for 3 h.  EPS was 
further purified by gel filtration on an S1000 column.  Dialyzed EPS was 
quantified by dry weight and phenol sulfuric acid assay.  
Generation of EPS-specific Antibodies. 
A New Zealand White rabbit was bled for preimmune serum then 
immunized by intramuscular and subcutaneous injection of 100 µg EPS from 
BHI medium in TiterMax Gold adjuvant. Three weeks post primary 
immunization, the rabbit was boosted with 100 µg EPS in adjuvant.  Eight days 
later, serum was collected.  We assessed antibody recognition of EPS and EPS 
purity by immunoelectrophoresis and western blot.  For immunoelectrophoresis, 
EPS from BHI was electrophoresed in a 0.9% agarose gel, then anti-EPS and 
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preimmune serums were loaded into troughs and incubated o/n in a humidity 
chamber.  The gel was dehydrated and stained with Coomassie brilliant blue to 
visualize antigen/antibody arcs of precipitation.  We found one arc of 
precipitation between anti-EPS serum and EPS and no precipitation occurring 
between the EPS and preimmune serum, or elsewhere on the gel (Figure 2.1A).  
Also, we see little migration of EPS through the gel.  These data demonstrate that 
anti-EPS serum recognizes EPS and neither serum recognizes other material in 
the sample at the level of detection.  For western blot analysis, EPS and ∆EPS 
from BHI were electrophoresed on a 10% SDS-PAGE gel for 3 h at 80 Volts and 
transferred to nitrocellulose overnight at 100 milliamps.  The blot was incubated 
with rabbit anti-EPS serum for 2 h, then the secondary reagent, donkey anti-
rabbit IgG (H&L)-HRP (The Jackson Laboratory, Bar Harbor, ME).  Similar to 
our immunoelectrophoresis results, we find that EPS does not migrate in 
polyacrylamide either, but by western we do see faint bands of contamination in 
EPS (Figure 2.1B).  Importantly, the EPS smeared band is not present in the 
∆EPS sample.  Further, the EPS band is comparable to published results from the 
Kearn’s laboratory of EPS purified from the B. subtilis 991 strain assessed on an 
agarose gel with StainsAll (Guttenplan et al. 2010).  For certain experiments, 
anti-EPS IgG was purified from anti-EPS serum using protein G beads and 
biotinylated using NHS-EZ-Link.   
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B. subtilis Spore Preparation. 
B. subtilis wild-type 3610, DS76 (espH mutant) were germinated via 
exhaustion as described previously (Jones & Knight 2012). On the day of 
administration, B. subtilis spores were washed with ice-cold water, resuspended 
in 100 mL PBS, and administered to mice via oral gavage.  Cells were isolated 4-6 
days post-gavage for analysis.   
EPS Binding and Internalization. 
Peritoneal cells were obtained from mice (4–6 weeks of age) by peritoneal 
lavage with 5 ml DMEM (10% FBS).  It is imperative that these experiments were 
Figure 2.1.  Recognition of EPS by anti-EPS rabbit serum.                      
A. Immunoelectophoresis of EPS.  EPS (BHI) was electrophoresed on 0.9% 
agarose.  Troughs were cut for anti-EPS and pre-immune serum.  Troughs were 
loaded with either serum and incubated in a humidity chamber overnight.  The 
gel was dehydrated and stained with Coommassie blue.  B. Western blot of EPS 
and ΔEPS (BHI).  EPS and ΔEPS were loaded into a 10% SDS-PAGE gel and 
electrophoresed for 3 h at 80 Volts.  The gel was transferred to nitrocellulose o/n 
at 100 milliamps, and blotted the next day with rabbit anti-EPS serum, detected 
using goat-anti-rabbit Ig – HRP.  
ΔEPS EPS 
250 
37 
10 
Anti-EPS Serum 
Preimmune Serum 
A B 
EPS + -	
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performed with cells on ice at all times or at 4oC in the centrifuge for washes. 
After lysing RBCs, cells were incubated with EPS (10 µg) on ice for 1h, washed, 
and then incubated with anti-F4/80 (clone BM8), anti-CD11b (clone M1/70), or 
rabbit anti-EPS serum, followed by donkey anti-rabbit Ig as secondary antibody.  
In some experiments, purified IgG anti-EPS that was biotinylated was used.  For 
internalization experiments, cells were incubated with Cytochalasin D (5 µM) for 
20 minutes on ice. EPS was added to cells, incubated on ice for 30 minutes, then 
experimental tubes were shifted to 37oC for 15 minutes and returned to 4oC to 
stain for EPS, as described.  Fluorescence intensity was assessed by flow 
cytometry.  
Adoptive Transfer Studies. 
For adoptive transfer, peritoneal cells were isolated by lavage (with 
RPMI/50%FCS) from mice 3 days post-treatment with EPS (i.p.).  Cells in the 
granulocyte and lymphocyte gates were FACS-sorted based on forward scatter 
(FSC) and side scatter (SSC) and injected i.p. into mice.  For macrophage 
depletion studies, mice were injected i.p. with 200 µL clodronate-loaded or PBS-
loaded liposomes (Stock 5 mg/mL).  Four to 6 h later, mice were treated with 
EPS, and then 3 days later, peritoneal cells were isolated by PBS lavage.  By flow 
cytometry, less than 1% of the transferred cells were macrophages. 
C. rodentium ATCC 51459 was cultured 16 hr in LB medium and washed 
once in PBS.  An infectious dose (5x108 CFUs) was resuspended in 100 µL sterile 
PBS and administered to mice by oral gavage.  Disease was assessed 11 days post-
infection (dpi).  Serum cytokine levels were assessed by ELISA and distal colons 
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were collected and processed for histological analysis as described (Jones & 
Knight 2012).  To assess diarrhea, feces were examined and scored 1–4 (Jones & 
Knight 2012): 1, no diarrhea (hard, dry pellets); 2, slightly soft stool (mild 
diarrhea); 3, very soft stool (moderate diarrhea); and 4, unformed stool (severe 
diarrhea).  
Flow Cytometry. 
For flow cytometry, cells were treated with anti-CD16/32 Fc Block and 
then stained with surface antibodies.  To assess intracellular cytokines, cells were 
fixed using perm/fix reagents from BD Biosciences according to manufacturer’s 
protocol.  For Foxp3 staining, cells were fixed using Foxp3/ Transcription Factor 
Staining Buffer Set (Ebioscience, San Diego, CA).  Cells were fixed for 16 h, then 
permeabilized as per manufacturer’s protocol.  Anti-Foxp3 antibody was added to 
cells for 1 h at room temperature.  Cells were analyzed on FACSCanto II or 
LSRFortessa flow cytometers; cell sorting was performed on a FACSAria cell 
sorter (BD Biosciences). Analyses were performed using FlowJo software (Tree 
Star, Ashland, OR) by first gating on single cells, and then analyzing each 
population as described. 
In vitro and in vivo Treatment with EPS. 
For in vitro treatment of peritoneal cells, total peritoneal cells were 
isolated by lavage with 5 mL PBS and plated in 24-well plates for 2 h to allow 
macrophages to adhere.  Non-adherent cells were aspirated and washed away.  
The remaining cells were 80-90% F4/80+CD11b+ macrophages.  Peritoneal cells 
or RAW264.7 cells were treated for 16 h with 5 µg/mL EPS purified from DS991 
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B. subtilis grown in MSgg medium. For intracellular cytokine analysis, cells were 
cultured for an additional 2 h with Brefeldin A, and analyzed by flow cytometry. 
For in vivo treatment, mice were injected i.p. with EPS (200 µg) and 3 days later, 
peritoneal cells obtained by lavage as described (Jones et al. 2014).   The level of 
TGF-β production in serum (1:100) was determined by ELISA after activating 
TGF-β with 5 µL 1 N HCL/100 µL for 15 min at RT, followed by neutralization 
with 1 N NaOH.   
T cell Proliferation Assay. 
 Splenocytes were labeled with 5 µM CellTrace Violet (Life Technologies) 
according to manufacturer’s directions and cultured either alone (3x105 cells) or 
with total peritoneal cells (104) or purified macrophages (5x103) in 96-well flat-
bottom tissue culture plates coated with 2 µg/mL anti-CD3.  Plates were coated 
with anti-CD3 using borate buffer pH 8.5 for at least 1 h at 37oC or room 
temperature o/n.  Three days later, non-adherent cells were collected, stained 
and analyzed by flow cytometry.  For Treg cell induction experiments, this same 
assay was performed with the addition of IL-2 (50 µg/mL).  For transwell 
experiments, 1x106 splenocytes were cultured in anti-CD3-coated 24-well plates 
with or without transwell inserts (Corning) containing 5x105 peritoneal cells.  For 
antigen-specific T cell proliferation assay, peritoneal cells were pulsed o/n with 1 
mg/mL ovalbumin (OVA).  CD4+ were purified by positive selection from OT-II 
mouse spleen using magnetic beads (Streptavidin Particles Plus-DM, BD 
Biosciences, San Jose, CA) using biotinylated anti-CD4.  Purified cells were 
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labeled with CTV and incubated with OVA-pulsed peritoneal cells in anti-CD3 (2 
µg/mL)-coated wells with soluble anti-CD28 (5 µg/mL) for 6 d.  
Cell Purification using Magnetic Beads. 
F4/80+ and CD4+ cells were isolated, as indicated, by positive selection 
using magnetic beads, Streptavidin Particles Plus-DM (BD Biosciences, San Jose, 
CA) as per manufacturers protocol.  Total cells were incubated with anti-CD16/32 
(Fc Block) for 15 minutes on ice, then incubated with biotinylated antibodies.  
Cells were then washed twice and magnetic beads were added based on cell 
numbers (15 µL per 5x106 cells) and incubated on ice for 30 minuntes.  Without 
washing, samples are place on the BD IMag Cell Separation Magnet for 8 
minutes.  Negatively-selected cells are collected in the supernatants, and 
positively-selected cells are resuspended in PBS and placed on the magnet two 
more times.   
Real-time Quantitative PCR. 
RNA was isolated from flow cytometry–sorted F4/80+CD11b+ 
macrophages using TRIzol reagent (Invitrogen, Carlsbad, CA), and cDNA was 
prepared. PCR was performed on a C1000 thermal cycler with CFX96 real-time 
detection system (Bio-Rad, Hercules, CA) using the following primers (forward 
and reverse): Arg1, 5′-AGACCACAGTCTGGCAGTTG-3′ and 5′-
CCACCCAAATGACACATAGG-3′; Nos2, 5′-CAGCTGGGCTGTACAAACCTT-3′ 
and 5′-CATTGGAAGTGAAGCGTTTCG-3′; Ym-1, 5’ – 
CATGAGCAAGACTTGCGTGAC-3’ and 5’ – GGTCCAAACTTCCATCCTCCA-3’; 
FIZZ-1, 5’ – TCCCAGTGAATACTGATGAGA-3’ and 5’ – 
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CCACTCTGGATCTCCCAAGA-3’; IL-12p40, 5’ - 
GAAGTTCAACATCAAGAGCAGTAG-3’ and 5’ – AGGGAGAAGTAGGAATGGGG-
3’; Actb (β-actin), 5′-GGCTGTATTCCCCTCCATCG-3′ and 5′-
CCAGTTGGTAACAATGCCATGT-3′. Expression of each target gene was 
normalized to β-actin expression, and data are presented relative to 
F4/80+CD11b+ cells isolated from untreated mice.  
TGF-β Bioassay. 
MFB-F11 cells (2x104) were seeded into 96-well plates in RPMI with 10% 
FCS.  The next day, cells were washed extensively with PBS and co-cultured with 
peritoneal cells (1x105) in serum-free RPMI for 24 h.  Recombinant human TGF-β 
(Biolegend, San Diego, CA) was used as a positive control.  Supernatants (30 µL) 
were mixed with QUANTI-blue reagent (170 µL) and incubated at 37oC for 24 h 
until A630 was measured.  Background absorbance (PBS-treated cell 
supernatants) was subtracted from all samples.  Data are represented as fold-
increase over peritoneal cells from untreated mice.      
Apoptosis Analysis. 
For apoptosis staining, cells were collected from the T cell proliferation 
assay after 1 d of culture.  Following extracellular cell-surface staining, cells were 
resuspended in Annexin V Binding Buffer (BioLegend, San Diego, CA) and 3 µL 
of Annexin V and 3 µL of 7-AAD were added to 1x106 cells for 15 minutes at room 
temperature.  Cells were then analyzed by flow cytometry without washing.   
Statistical Analysis. 
Statistical significance was determined by unpaired two-tailed Student’s t 
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test unless otherwise indicated using Prism software (GraphPad Software; La 
Jolla, CA). A p value <0.05 was considered statistically significant with p<0.001 
denoted as ***, p = 0.001 to 0.01 denoted as **, and p = 0.01 to 0.05 denoted as 
*.  Not significant denoted as ns (p > 0.05).
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CHAPTER THREE 
EXPERIMENTAL RESULTS 
Section 1:  Identification of Cell(s) Required for EPS-mediated 
Protection from Disease 
Binding of EPS to Peritoneal Cells. 
EPS administered via intraperitoneal (i.p) injection prevents disease 
associated with C. rodentium.  Additionally, adoptive transfer of total peritoneal 
cells from EPS-treated mice into recipient mice prevents disease (Jones et al. 
2014).  We therefore hypothesized that EPS modulates a cell within the 
peritoneal cavity to exert a protective effect.  The peritoneal cavity is comprised of 
a large number of innate-like B1 cells, macrophages, and a small percentage of T 
cells, DCs, and eosinophils.  To determine which cell-type is involved in EPS-
mediated protection, we tested which cells bind EPS by incubating peritoneal 
cells from a wild-type (WT) untreated mouse with EPS.  We then identified cells 
bound to EPS using antiserum from rabbits immunized with EPS, detected with 
fluorescent goat anti-rabbit Ig antibody and cell-specific antibodies.  As a 
negative control, cells were incubated with material derived from the mutant B. 
subtilis (ΔEPS) that does not produce EPS.  These strains are described in greater 
detail in Chapters One and Two.  This mutant strain of B. subtilis produces 5 to 
10-fold less total polysaccharide compared to the hyper-producing strain used to
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isolate EPS, but the background polysaccharide levels are the same.  We added a 
volume of ΔEPS equivalent to the volume of EPS added, relative to the starting 
cultures of each strain.  E.g., we purify both EPS and ΔEPS from 500 mL starting 
cultures; if we need 10 µL of EPS for a final concentration of 5 µg/mL, we add 10 
µL of ΔEPS, even though the actual polysaccharide concentration of this material 
is less.  By flow cytometry, we found an increase in EPS binding on 
F4/80+CD11b+ macrophages (Figure 3.1A), with little to no binding to other cell-
types within the peritoneal cavity (Figure 3.1).  As negative controls, we do not 
see any increase in fluorescence intensity by ΔEPS or by preimmune rabbit 
serum.  These data show that EPS binds F4/80+ cells and suggest that 
macrophages may be involved in EPS-mediated protection from C. rodentium-
induced disease.  
Macrophages rapidly internalize antigens that bind to the cell surface, 
leading us to test if macrophages internalize EPS.  To test this, cells were 
incubated with EPS as described above at 4oC, and then experimental tubes were 
shifted to 37oC for 15 minutes; cells were then returned to 4oC.  Purified, 
biotinylated anti-EPS IgG was added to cells and the presence of EPS on the cell 
surface was assessed by flow cytometry.  If macrophages internalize EPS, we 
would expect to see a decrease in surface EPS following incubation at 37oC.
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As expected, we found a decrease in surface EPS in samples incubated at 37oC 
(green line) compared to samples that remained at 4oC (red line) for the duration 
of the experiment (Figure 3.2), suggesting that EPS was internalized by the 
macrophages.  To confirm this idea, we inhibited phagocytosis by adding 
Cytochalasin D (5 µM), a small molecule inhibitor of actin polymerization, to cells 
before incubation with EPS.  We expected that Cytochalasin D would block 
Figure 3.1.  EPS binding to peritoneal cells.  EPS (10 µg) or an equal 
volume of ΔEPS purified from BHI media was added to total peritoneal cells 
from untreated WT mice for 1 h.  EPS binding was detected using anti-EPS 
rabbit serum and goat FITC-anti-rabbit-Ig antibody.  Fluorescence Intensity 
was measured by flow cytometry gated on specific subsets of cells.  A. 
F4/80+CD11b+ macrophages.  B. Lymphocyte gate.  C. CD11c+ dendritic cells.  
D. SiglecF+ eosinophils. E. EPS, total peritoneal cells, and preimmune serum 
gated on F4/80+CD11b+ macrophages.  Representative flow cytometric profiles 
from 5 independent experiments.    
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 internalization of EPS at 37oC, and we would see similar levels of surface EPS 
comparable to samples that remained at 4oC.  As shown in Figure 3.2, 
Cytochalasin D blocks much of the internalization of EPS at 37oC (yellow line), 
although some EPS may still be internalized as surface levels of EPS are not as 
high as cells that remain at 4oC.  Biotinylated anti-EPS IgG with streptavidin-PE 
(present in each tube) alone serves as the negative control (blue line).  These data 
suggest that peritoneal macrophages bind and rapidly internalize EPS.   
Pattern recognition receptors, including Toll-like Receptors, NOD-like 
receptors, and C-type lectins, etc., recognize bacterial and viral products, leading 
to activation or inhibition of innate immune responses. Our lab has previously 
shown that EPS does not protect TLR4-deficient mice from disease (Jones et al. 
2014), suggesting that EPS utilizes TLR4 to induce a protective response.  Since 
Figure 3.2.  Internalization of EPS by peritoneal macrophages.  EPS 
(10 µg) was added to total peritoneal cells and incubated at 4oC for 30 minutes.  
Indicated samples were then shifted to 37oC for 15 minutes.  Binding was 
detected using purified, biotinylated anti-EPS IgG and streptavidin-PE.  
Fluorescence Intensity was measured by flow cytometry of granulocyte-gated 
cells. Representative flow cytometric profiles from 4 independent experiments.    
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+ EPS 37oC + Cytochalasin D 
+ EPS 37oC 
Anti-EPS  
EPS 
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TLRs are highly expressed on peritoneal macrophages, we hypothesized that EPS 
binds to TLR4 on peritoneal macrophages.  To test this hypothesis, we incubated 
peritoneal macrophages from TLR4-/- mice with EPS and anti-EPS IgG, and 
assayed for an increase in fluorescence intensity by flow cytometry.  If EPS binds 
to TLR4 on macrophages, we do not expect to see an increase in fluorescence in 
TLR4-/- macrophages compared to WT macrophages.  Surprisingly, EPS binds 
TLR4-/- F4/80+CD11b+ cells (Figure 3.3A) to the same extent as we see in WT 
F4/80+CD11b+ cells (Figure 3.1A).  We also assessed EPS binding to TLR2-/- 
macrophages and found that EPS binds macrophages in the absence of TLR2 
(Figure 3.3B).  These data suggest that EPS does not directly bind to TLR4 or 
TLR2 and perhaps utilizes a co-receptor of the TLR4 signaling complex, such as 
carbohydrate-binding lectins, to bind to macrophages.
Figure 3.3.  EPS Binding to peritoneal cells from TLR2- and TLR4- 
deficient mice.  EPS was added to total peritoneal cells from untreated mice, 
and binding was detected using rabbit anti-EPS anti-serum and FITC-goat 
anti-rabbit-Ig antibody.  Fluorescence Intensity was measured by flow 
cytometry.  A. F4/80+CD11b+ macrophages from TLR4-/- mice.  B. 
F4/80+CD11b+ macrophages from TLR2-/- mice.  Representative of 4 
independent experiments. 
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77		
	
Requirement of Macrophages for EPS-mediated Protection from C. 
rodentium-induced Disease. 
Since EPS binds to peritoneal macrophages and total peritoneal cells from 
EPS-treated mice prevent disease caused by C. rodentium, we next asked if 
macrophages purified from the peritoneal cavity of EPS-treated mice prevent 
disease.  Macrophages are readily activated by antibodies or magnetic beads; 
therefore, we decided to purify macrophages by FACS-sorting the granulocyte 
gate and the lymphocyte gate based on forward scatter (FSC) and side-scatter 
(SSC) in order to minimally manipulate the cells.  Cells within the granulocyte 
gate are 80-90% macrophages (Figure 3.4), therefore we expect that the 
granulocyte population will prevent disease, but the lymphocyte population will 
not (<5% macrophages, Figure 3.4).  Sorted cells (3x104) were adoptively 
Figure 3.4. F4/80 expression on sorted peritoneal cells.  Peritoneal 
cells were sorted using FACS based on FSC and SSC from the lymphocyte and 
granulocyte gates from untreated or EPS-treated mice.  F4/80 expression on 
total peritoneal cells prior to sort (left), or cells obtained from the sort in the 
lymphocyte gate (center), or granulocyte gate (right).  Representative of 3 sorts 
in each of 2 independent experiments.     
Pre-sort Lymphocyte gate Granulocyte gate 
F4/80 
SS
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transferred to recipient mice -1, +1, and +3 days post-infection (dpi) with C. 
rodentium, and disease was assessed 11 dpi.  The cells in the granulocyte gate 
protected recipient mice from disease, whereas lymphocytes did not, as 
evidenced by increased colonic crypt heights, loose stool, and increased levels of 
serum pro-inflammatory chemokine CXCL1 (Figure 3.5). These data suggest that 
cells in the granulocyte gate, which are predominately macrophages, mediate 
protection by EPS. 
We further assessed the requirement of macrophages in EPS-mediated 
protection using clodronate liposomes.  Macrophages phagocytose the liposomes, 
Figure 3.5.  Assessment of C. rodentium-induced disease following 
adoptive transfer of peritoneal cells from EPS-treated mice.  Crypt 
height (left), diarrhea score (center), and serum CXCL1 (right) on day 11 post C. 
rodentium infection.  Peritoneal cells (3x104) from EPS-treated mice were 
transferred days -1, +1, and +3 relative to C. rodentium infection. (n) PBS-
injected mice, no cell transfer (- control); (☐) EPS-injected mice, no cell transfer 
(+ control);  (					) cells transferred from EPS-injected mice, total unsorted 
(total), granulocytes (Gr), lymphocytes (Lym). Data are from 2 independent 
experiments; N = 5-7 mice total per treatment. Statistical significance 
determined by Student’s t test.  p<0.001 denoted as ***, p = 0.001 to 0.01 
denoted as **, and p = 0.01 to 0.05 denoted as *.	
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releasing clodronate inside the cells, which induces apoptosis (Rooijen & Sanders 
1994).  Intraperitoneal injection of the liposomes results in rapid depletion of 
peritoneal macrophages.  The liposomes gradually disseminate and deplete 
macrophages in the spleen, liver, and bone marrow (van Rooijen & Hendrikx 
2010).   
 Mice were injected with clodronate liposomes to deplete macrophages, or 
PBS liposomes as a control, 4-6 hr prior to EPS treatment.  Three days later, we 
adoptively transferred peritoneal cells (6x104) to naïve recipients -1, +1, and +3 
dpi with C. rodentium; disease was assessed 11 dpi.  If macrophages are required 
for EPS-mediated protection, we would expect that in the absence of 
macrophages, peritoneal cells would no longer protect mice from disease.  As 
expected, all mice that received macrophage-depleted peritoneal cells from EPS-
injected mice had evidence of disease, whereas only 1 of 7 that received peritoneal 
cells from EPS-injected mice treated with PBS liposomes developed disease 
(Figure 3.6). These data indicate that macrophages are required for EPS-
mediated protection from C. rodentium-induced inflammation. 
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How does EPS alter macrophages to induce protection?  Macrophages are 
classified into two main subsets.  M1, classically-activated, macrophages 
differentiate in response to TLR stimulation and IFN-γ, and are pro-
inflammatory and highly phagocytic.  They produce effector molecules including 
IL-12p40 and iNOS.  In contrast, M2, alternatively-activated, macrophages are 
anti-inflammatory, and involved in immunity to parasites and wound-healing 
responses.  They differentiate in response to glucocorticoids, TLR stimulation, 
the anti-inflammatory cytokines IL-10 or TGF-β, or more traditionally, IL-4 and 
IL-13.  We hypothesize that EPS induces M2 macrophages, which prevent disease 
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Figure 5.  Adoptive transfer of Peritoneal Cells Depleted of 
Macrophages into C. rodentium-infected Mice.  Mice were treated with 
clodronate liposomes (Clod-L) or PBS liposomes (PBS-L) 4-6 hr before injection 
with EPS (100 µg); peritoneal cells (6x104) were transferred -1, +1 and +3 relative 
to C. rodentium infection.  Crypt height (left), diarrhea score (center), and serum 
CXCL1 (right) were measured 11 dpi.  Data are from 2 independent experiments 
with N= 7-9 mice total per treatment.  
Figure 3.6.  Adoptive transfer of macrophage-depleted peritoneal cells 
into C. rodentium-infected Mice.  Mice were treated with clodronate 
liposomes (Clod-L) or PBS liposomes (PBS-L) 4-6 hr before injection with EPS 
(100 µg); peritoneal cells (6x104) were transferred to naïve recipients -1, +1 and +3  
days relative to C. rodentium infection.  Crypt height (left), diarrhea score (center), 
and serum CXCL1 (right) were measured 11 dpi.  Data are from 2 independent 
experiments with N= 7-9 mice total per treatment.  Statistical significance 
determined by Student’s t test.  p<0.001 denoted as ***, p = 0.001 to 0.01 denoted 
as **, and p = 0.01 to 0.05 denoted as *.	
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by providing an anti-inflammatory environment that diminishes a hyper-
inflammatory immune response induced by, for example, C. rodentium.  
 Following M2 macrophage polarization, macrophages upregulate 
expression of CD206, IL-4Rα, arginase-1, FIZZ-1, and Ym-1 (Table 1.2).  To 
determine if EPS induces an M2 macrophage phenotype, we took a step back 
from the C. rodentium model and asked how EPS modules the immune system in 
naïve, uninfected mice.  We examined peritoneal cells from mice 3 days after i.p. 
injection with EPS, and we expected to find an increase in M2 macrophages at 
this time point since total peritoneal cells 3 days post-EPS treatment protect 
recipients from disease.  We found increased M2 macrophage marker expression 
on F4/80+CD11b+ cells compared to treatment with the negative control, ΔEPS 
(Figure 3.7A).  Additionally, we FACS-purified F4/80+CD11b+ macrophages from 
EPS-injected mice and found that transcripts of Ym-1 and FIZZ-1 were 
Figure 3.7.  EPS-induced changes in phenotype of peritoneal 
macrophages in vivo.  WT mice were injected with EPS and 3 days later 
peritoneal cells were examined by flow cytometry and qRT-PCR.  A. 
Representative flow cytometric profiles of M2 macrophage marker 
expression (Arg-1, CD206, and IL-4Rα) on F4/80+CD11b+ cells from WT 
mice.  B. Fold change by qRT-PCR of Ym-1, FIZZ-1, IL-12p40 and Nos2 
expression in F4/80+CD11b+ cells in WT mice injected with EPS (relative to 
mice injected with ΔEPS) (average of 4 independent experiments, N = 7 mice 
total per group).  ND = not detectable.  
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upregulated 5-fold and 9-fold, respectively, compared to macrophages from 
ΔEPS-treated mice.  In contrast, no upregulation of the M1 macrophage markers 
IL-12p40 or Nos2 (iNOS) occurs (Figure 3.7B).  We conclude that administration 
of EPS induces cells with an M2 macrophage phenotype in peritoneal 
macrophages. 
 The peritoneal cavity is a dynamic environment with cells continuously 
entering, surveying, and trafficking to other parts of the body.  We sought to 
characterize the distribution of cells in the peritoneal cavity in response to EPS to 
better understand when M2 macrophage induction occurs.  We performed a 
time-course study and analyzed the cells present in the peritoneal cavity 1, 2, and 
3 days following EPS treatment.  Previous reports have shown that regardless of 
what material is administered, an i.p. injection results in an influx of monocytes 
and neutrophils and an efflux of B1 cells (Doherty et al. 1995; Ghosn et al. 2010; F 
et al. 2012).  Similar to these findings, we find a rapid increase in Ly6C+ 
monocytes 1 day after treatment with EPS and ∆EPS (Figure 3.8).  By day 2, the 
percentage of macrophages increases in both treatment groups, which may be 
attributed to the differentiation of infiltrating monocytes into macrophages.  
Further, the majority of F4/80+ cells are CD11b+F4/80lo and have yet to reach full 
differentiation into CD11b+F4/80hi macrophages that bear the M2 phenotype in 
EPS-treated mice (Figure 3.8).  By day three, the peritoneal cell composition in 
∆EPS-treated mice looks similar to an untreated mouse, whereas EPS-treated 
mice display an increase in M2 macrophages, as described in Figure 3.7.  These 
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data suggest that it takes 3 days to fully restore macrophages to the peritoneal 
cavity and induce an M2 phenotype following an i.p. injection.  Although the 
small percentage of macrophages at two days bear the M2 phenotype, the influx 
of other cell types that occurs due to the injection drowns out the number of 
macrophages within the peritoneal cavity.   
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Figure 3.8. Kinetics of macrophage accumulation following i.p. 
injection with EPS.  Macrophages (F4/80+CD11b+), monocytes (Ly6C+) and 
neutrophils (Ly6G+Ly6Clo) present in the peritoneal cavity were assessed in 
untreated (day 0) or days 1-3 post-injection with EPS or an equal volume of 
ΔEPS. Representative of 3 independent experiments, 2 mice per group per 
experiment. 
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Does EPS act directly on macrophages?  Although most reports suggest 
that M2 macrophages develop in response to IL-4 and IL-13 produced by a 
variety of cell types, a diverse set of activators including cytokines, immune 
complexes, and glucocorticoids have been shown to induce an M2 phenotype.  
Since EPS binds to macrophages, we expect EPS to directly induce M2 
macrophage polarization.  We tested if EPS acts directly on macrophages to 
induce the M2 macrophage phenotype in vitro by culturing peritoneal F4/80+ 
cells overnight with EPS (1 µg/mL) or an equal volume of ∆EPS, with the 
expectation that we would see upregulation of the markers listed in Table II in 
EPS-treated cells.  By flow cytometry, we found upregulation of Arg-1, CD206 
and IL-4Rα in EPS-treated cells compared to untreated cells (Figure 3.9A).  
Figure 3.9. EPS-induced changes in phenotype of macrophages in 
vitro. Peritoneal F4/80+ macrophages (A) or RAW264.7 cells (B) were 
incubated 16 h with EPS or ∆EPS in vitro and analyzed by flow cytometry for M2 
marker expression (Arg-1, CD206 and IL-4Rα).  Data are representative of 5 
independent experiments.  
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These data indicate that EPS induces M2 macrophages in vitro by acting directly 
on macrophages.    
To confirm that EPS acts directly on macrophages, we cultured RAW264.7 
cells, a mouse macrophage cell line, with EPS (1 µg/mL) or ∆EPS for 16 h in vitro 
and assessed upregulation of M2 macrophage markers.  By flow cytometry, we 
found that the expression of these markers was upregulated in EPS-treated cells 
compared to cells treated with ∆EPS (Figure 3.9B).  These data further 
demonstrate that EPS acts directly on macrophages to induce M2 macrophages. 
We further characterized the phenotype of M2 macrophages by assessing 
the expression of co-stimulatory or co-inhibitory molecules CD80, CD86, PD-L2 
Figure 3.10. EPS-induced changes in macrophage receptor 
expression.  Peritoneal cells were isolated from untreated, or EPS-treated 
mice 3 days post-treatment (dpt).  Expression of MHC class II, CD80, CD86, 
PD-L1 and PD-L2 on F4/80+ macrophages was assessed by flow cytometry. Data 
are representative of 5 independent experiments.      
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and PD-L1, as well as MHC class II.  These molecules could influence the anti-
inflammatory response of M2 macrophages and interactions with target cells.  
We examined expression of these markers on peritoneal macrophages from EPS-
treated mice 3 days post-treatment (dpt), as well as peritoneal macrophages and 
RAW264.7 cells treated in vitro with EPS.  By flow cytometry, we find 
upregulation of CD80 and PD-L1 on macrophages from mice treated in vivo with 
EPS (Figure 3.10).  In contrast, we find downregulation of CD86 in peritoneal 
macrophages from EPS-treated mice.  MHC class II expression is slightly 
upregulated, but does not occur on all macrophages following EPS treatment.  
We do not find changes in PD-L2 expression.   
Similar to peritoneal macrophages from EPS-treated mice, peritoneal cells 
and RAW264.7 cells treated with EPS in vitro upregulate CD80 and PD-L1 
Figure 3.11. EPS-induced changes in macrophage co-stimulatory 
molecules in vitro.  Peritoneal macrophages (top) or RAW264.7 cells 
(bottom) were incubated 16 h with EPS 5 µg/mL or an equal volume of ΔEPS in 
vitro and analyzed by flow cytometry. Expression of MHC class II, CD80, CD86, 
PD-L1 and PD-L2 on F4/80+ macrophages was assessed by flow cytometry.  
Data are representative of duplicate wells in 4 independent experiments.    
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(Figure 3.11).  EPS decreases expression of CD86 and does not alter MHCII in 
peritoneal macrophages treated in vitro, however, CD86 expression slightly 
increases, as does MHC class II in RAW264.7 cells treated with EPS.  These data 
suggest that peritoneal macrophages respond similarly to macrophages from 
mice treated with EPS, but RAW264.7 cells are slightly altered in their response 
to EPS. 
EPS-induced M2 Macrophage Localization in vivo.  
Thus far, we have examined the generation of M2 macrophages in vitro in 
response to EPS and in vivo in the peritoneal cavity, but does EPS induce 
development of M2 macrophages in other organs and locations of the mouse?  
Further, can M2 macrophages induced in the peritoneal cavity travel to other 
locations, i.e., the colon, to protect from C. rodentium-induced disease?   
To address these questions, we first examined the spleen and MLN of EPS-
treated mice for the presence of M2 macrophages.  The number of macrophages 
Figure 3.12. M2 macrophage development by intravenous injection 
with EPS.  Mice were injected with 100 µg of EPS in 100 µL of PBS, or PBS 
alone, by tail vain injection.  The phenotype of peritoneal macrophages (CD206 
and IL-4Rα) was assessed by flow cytometry 2 dpt.  Representative data of 2 
independent experiments with 2 mice per group in each experiment.   
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is small in both the spleen and the MLN.  Although we sometimes find a slight 
increase in M2 macrophage phenotypic markers on macrophages in these organs 
following EPS treatment, the increases are not reproducible (data not shown).  To 
verify that the injection site did not restrict the development of M2 macrophages, 
we injected mice with EPS by intravenous (i.v.) injection and examined the 
peritoneal cavity 2 dpt for M2 macrophages and found that M2 macrophages still 
develop when using an alternate route of injection (Figure 3.12). 
To determine if EPS-induced M2 macrophages traffic to other organs from 
the peritoneal cavity, we isolated peritoneal cells from EPS-treated mice 3 dpt 
and adoptively transferred them to recipient mice by i.p. injection.  Prior to 
transfer, the cells were labeled with the fluorescent dye, carboxyfluorescein 
succinimidyl ester (CFSE), that covalently binds free amines on the surface and 
within the cell.  This allows us to track the transferred cells in the recipient mice.  
Figure 3.13.  Trafficking of peritoneal macrophages from EPS-treated 
mice.  Peritoneal cells were isolated from EPS-treated mice 3 dpt, labeled with 
CFSE and 106 transferred (i.p.) into naïve mice.  After 24 hours, peritoneal cells, 
spleen and MLN were isolated from recipient mice and analyzed for transferred 
CFSE+F4/80+ macrophages by flow cytometry.  Representative flow cytometric 
profiles from 3 independent experiments.  
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At 24 h post-transfer, we analyzed the presence of CFSE+ cells in various organs 
by flow cytometry.  As is shown in Figure 3.13, we find a small percentage of 
CFSE+F4/80+ cells that remain in the peritoneal cavity following injection, with a 
small percentage trafficking to the MLN at 24 h post-treatment.  Very few 
transferred macrophages are found in the spleen.  The majority of CFSE+F4/80- 
cells in the peritoneal cavity and MLN are IgM+ B cells (data not shown).  Since 
the MLN drains from the colon, we conclude that the macrophages from i.p.-
treated EPS mice can migrate from the peritoneum and traffic to the MLN. 
Future experiments will determine if infection or injury enhance recruitment to 
various organs.     
Mechanism by which EPS Induces M2 Macrophages.  
Previously, we showed that TLR4 is required for EPS protection from C. 
rodentium-induced disease and that transfer of peritoneal cells from TLR4-/- 
mice into WT mice did not prevent disease (Jones et al. 2014).  These findings 
suggest that TLR4 signaling is required for the generation of EPS-induced M2 
macrophages.  To test this, we injected TLR4-/- mice and TLR2-/- mice with EPS, 
with the expectation that M2 macrophages would not develop in TLR4-/- mice but 
would develop normally in TLR2-/- mice.  After injecting TLR4-/- mice with EPS, 
we found no upregulated expression of the M2 markers IL-4Rα, CD206, Arg-1, 
CD80, CD86 or PD-L1 by flow cytometry (Figure 3.14), whereas TLR2-/- mice 
show upregulated expression of M2 macrophage markers, similar to WT mice 
(Figure 3.14, 3.9).  Similarly, little to no upregulation of FIZZ-1 and Ym-1 
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transcripts occurs in macrophages from EPS- injected TLR4-/- mice compared to 
WT mice, as well as no detectable levels of M1 macrophage markers (Figure 3.15).   
 We also tested if upregulation of M2 markers by EPS treatment of 
macrophages in vitro requires TLR4 signaling.  Macrophages from WT, TLR2-/- 
or TLR4-/- mice were culture for 16 h with EPS and IL-4Rα and PD-L1 expression 
was assessed by flow cytometry.  We expected to find upregulation of these 
markers in WT and TLR2-/- macrophages, but not in TLR4-/- macrophages.  As 
expected, EPS upregulated expression of IL-4Rα and PD-L1 on WT and TLR2-/- 
cells, but not on TLR4-/- cells (Figure 3.16).  These data suggest that the induction 
of M2 macrophages by EPS, both in vitro and in vivo requires TLR4 signaling.     
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Figure 3.14.  Induction of M2 macrophages in TLR-deficient mice.  
TLR2-/- and TLR4-/- mice were injected with EPS and 3 days later peritoneal cells 
were examined by flow cytometry.  Representative flow cytometric profiles of M2 
macrophage marker expression (Arg-1, CD206, IL-4Rα, CD80, CD86 and PD-L1) 
on F4/80+CD11b+ cells from TLR2-/- mice (top) or TLR4-/- mice (bottom). 
Representative flow cytometric profiles of 6 independent experiments, at least 
two mice per group in each experiment.  
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TLR4 signals through two downstream adapter molecules: TRIF and MyD88.  
Our lab previously showed that mice lacking MyD88 signaling specifically in 
myeloid cells are not protected from disease by EPS (Jones et al. 2014), which 
supports our conclusions that macrophages, a myeloid lineage cell, mediates 
protection, and that EPS signals through TLR4.  Given these results, we asked if 
EPS induces M2 macrophages in myeloid-specific MyD88-/- mice.  Since these 
mice are not protected from EPS, we would not expect to see induction of 
protective M2 macrophages.  As expected, no M2 macrophages were found in the 
peritoneal cavity of EPS-injected myeloid-specific MyD88-/- mice (Figure 3.17). 
Taken together, these data suggest that both TLR4 and MyD88 in myeloid cells 
are required for the polarization of M2 macrophages by EPS. 
Figure 3.15.  qRT-PCR analysis for M2 macrophage markers on TLR4-/- 
macrophages after i.p. injection of EPS.  Fold change by qRT-PCR of Ym-1, 
FIZZ-1, IL-12p40 and Nos2 expression in F4/80+CD11b+ cells in WT (n) and 
TLR4-/- (☐) mice injected with EPS (compared to mice injected with ΔEPS) 
(average of 4 independent experiments, N = 7 mice total per group).  ND = not 
detectable.  
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Figure 3.17. Flow cytometric analysis of M2 macrophage markers 
on peritoneal macrophages from EPS-treated myeloid MyD88-/- 
mice.  Representative profiles of 4 independent experiments; N = 8 mice 
total per treatment.  
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Figure 3.16. in vitro induction of M2 macrophages by EPS in TLR-
deficient mice.  Peritoneal macrophages from WT, TLR4-/- or TLR2-/- mice 
were incubated 16 h with EPS (5 µg) in vitro and analyzed by flow cytometry. 
Expression of IL-4Rα and PD-L1 were assessed by flow cytometry.  
Representative flow cytometric profiles of duplicate wells in 3 independent 
experiments.   
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Polarization of M2 macrophages often requires IL-4 and IL-13, IL-10, or 
TGF-β.  We find upregulation of IL-4Rα on EPS-induced M2 macrophages, as 
well as increased levels of genes expressed downstream of IL-4 and IL-13 
signaling, including CD206, Ym-1, and arginase-1, leading us to hypothesize that 
EPS induces M2 macrophages by upregulating IL-4 and IL-13 production in 
macrophages.  To test if macrophages express IL-4 and IL-13 in response to EPS, 
we cultured total peritoneal cells with EPS overnight, and then added brefeldin A 
(5 µg/mL) for 3 h to allow for retention of the cytokines intracellularly, and 
analyzed by flow cytometry.  If EPS induces M2 macrophages using IL-4 and IL-
13, we expect to see increased expression of these cytokines in macrophages in 
response to EPS.  Figure 3.18 shows that F4/80+ peritoneal cells upregulate both 
IL-13 IL-4 
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IL-13 IL-4 IL-13 IL-4 
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Figure 3.18. EPS-induced changes in cytokine phenotype of 
peritoneal cells in vitro.  Peritoneal cells were incubated 16 hr with EPS 
in vitro and analyzed by flow cytometry.  IL-13, IL-4, or IFN-γ expression in 
F4/80+ cells (A) IL-13 and IL-4 expression in CD3+ or IgM+ cells (B). Data are 
representative of duplicate wells in 4 independent experiments.  
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IL-4 and IL-13, whereas no increase in cytokine expression is seen in CD3+ T cells 
or IgM+ B cells, (Figure 3.18).  Further, we find no changes in the M1 macrophage 
cytokine, IFN-γ. Consistent with this finding, EPS induces M2 macrophages in 
CD4-/- mice (Figure 3.19), suggesting that macrophages to not require CD4+ T 
cells for M2 polarization in response to EPS.  Taken together, these in vitro and 
in vivo data support the hypothesis that EPS directly drives M2 macrophage 
polarization by upregulating IL-4 and IL-13, although we cannot rule out the 
contribution of other type-2 immunity promoting cells, including ILC2s (innate 
lymphoid cells), DCs, and eosinophils, in helping to maintain these cells in vivo.  
Recent studies have demonstrated that macrophages self-sustain within 
tissues by proliferating (Jenkins et al. 2011; Yona et al. 2013).  Additionally, 
tissue-resident macrophages proliferate in response to M2 macrophage-
polarizing conditions (Jenkins et al. 2013).  We hypothesized that since EPS 
upregulates M2 macrophage-inducing cytokines, EPS will induce macrophage 
PD-L1 IL-4Rα 
Figure 3.19. M2 macrophage induction in CD4-/- mice.  CD4-/- mice 
were injected with 100 µg of EPS and 3 dpt peritoneal F4/80+ macrophages 
were assessed by flow cytometry for M2 macrophage markers.  Data are 
representative flow cytometric profiles of 8 independent experiments, 1-3 mice 
per group per experiment.   
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proliferation within the peritoneal cavity.  To test this hypothesis, we isolated 
peritoneal cells from mice 3 dpt with EPS and labeled them with CellTrace Violet 
(CTV), a highly stable membrane-permeable fluorescent dye.  As cells proliferate, 
CTV dilutes, which can be measured by flow cytometry.  Once labeled with CTV, 
cells were transferred into naïve mice, and 48 h later, peritoneal cells were 
isolated and analyzed for proliferation by flow cytometry.  If EPS stimulates 
macrophage proliferation, we expect to find increased dilution of CTV in 
peritoneal cells from mice treated with EPS compared to cells from untreated 
mice.  As expected, in F4/80+ cells from donor mice treated with EPS, we find 
increased decreased levels of CTV, and hence increased proliferation compared to 
F4/80+ cells from untreated donor mice (Figure 3.20).  CD3+ T cells and CD19+ B 
cells from either group of mice did not proliferate.  In CD11c+ DCs, we find two 
peaks in CTV staining from EPS-treated cells, compared to only one peak from 
untreated cells (data not shown).  Because only a few DCs are present within the 
peritoneal cavity and the population is fairly heterogeneous, it is difficult to draw 
a conclusion about these cells.  In vitro, we do not find increases in macrophage 
proliferation following EPS treatment (data not shown).  Macrophages tightly 
adhere to plastic in tissue-culture dishes; the vastly different environment in 
vitro compared to in vivo conditions, including infiltrating monocytes, may 
explain the differences in proliferation. Further studies are needed to optimize in 
vitro conditions to determine if macrophages proliferate in vitro and if DCs 
proliferate in response to EPS.     
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Conclusions from Section 1. 
EPS induces M2 macrophages.  These macrophages are required for 
protection from C. rodentium-induced disease and transfer of these cells to 
recipient mice prevents disease.  EPS acts directly on macrophages to induce an 
M2 macrophage phenotype and also upregulates IL-4 and IL-13.  Induction of 
M2 macrophages requires TLR4 and MyD88 signaling in myeloid cells.   
Section 2.  Mechanism by which EPS-induced M2 Macrophages Exert 
Anti-inflammatory Effect  
Inhibition of T cell Responses in vitro. 
EPS induces M2 macrophages, and adoptive transfer of these 
macrophages prevents disease associated with C. rodentium.  Further, depletion 
Figure 3.20. Proliferation of peritoneal macrophages following EPS 
treatment.  Peritoneal cells were isolated from untreated or EPS-treated mice 
3 dpt, labeled with CTV, and transferred (i.p.) into untreated recipient mice.  
Two days post-transfer, CTV dilution was assessed in CTV+F4/80+ macrophages 
by flow cytometry.  Data are representative flow cytometric profiles of 2 
independent experiments with 2 mice per group.   
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of macrophages alleviates these protective effects.  How do EPS-induced M2 
macrophages prevent inflammation induced by C. rodentium?  M2 macrophages 
exert anti-inflammatory effects through a variety of different mechanisms, one of 
which is through inhibition of T cells.  Because much of the damage caused by C. 
rodentium is due to a hyper-reactive CD4+ T cell response, as discussed in 
Chapter 1, we hypothesized that EPS prevents C. rodentium-induced 
inflammation by inducing M2 macrophages, which inhibit T cell responses.   
To test this possibility, we developed an in vitro T cell proliferation assay.  
T cells proliferate in vitro in response to anti-CD3 and co-stimulation.  T cells can 
be labeled with CTV for the purpose of tracking proliferation.  Following 
activation with anti-CD3, T cells upregulate activation markers including CD25, 
the IL-2Rα chain, and CD44, a glycoprotein involved in cell-to-cell adhesion, 
cytokine production increases, especially IL-2 and IFN-γ, and then the T cells 
proliferate rapidly.  As the cells proliferate, the fluorescent dye associated with 
each cell is decreased, and this decrease can be measured by flow cytometry.  We 
hypothesized that co-culture of T cells with peritoneal cells from EPS-treated 
mice would result in decreased T cell proliferation.  To test this hypothesis, we 
labeled total splenocytes with CTV and added the cells to anti-CD3ε-coated wells.  
The anti-CD3ε stimulates the TCR, and B cells present in the splenocytes provide 
co-stimulation.  We then added peritoneal cells from EPS- or ΔEPS-treated mice 
and tested for a decrease in T cell proliferation, activation and cytokine 
production.  If EPS-induced M2 macrophages are inhibitory, we expected to see a 
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decrease in CD4+ T cell activation and proliferation in co-cultures with peritoneal 
cells from EPS-treated mice.  By flow cytometry, we found a decrease in activated 
CD4+CD44+CD25+ T cells (Figure 3.21A, C middle) in co-cultures with peritoneal 
cells from EPS-treated mice compared to peritoneal cells from ΔEPS-treated 
mice.  Further, CD4+ T cells do not proliferate when cultured with peritoneal cells 
from EPS-treated mice compared to cultures with peritoneal cells from ΔEPS-
treated mice or splenocytes alone (Figure 3.21B, C left).  Additionally, total IFN-γ 
levels are decreased in the supernatant of the cultures containing peritoneal cells 
from EPS-treated mice compared to peritoneal cells from ΔEPS-treated mice or 
splenocytes alone (no peritoneal cells) (Figure 3.21C right).  These data indicate 
that peritoneal cells from EPS-treated mice inhibit CD4+ T cell responses. 
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 Since peritoneal cells from EPS-treated mice were co-cultured with total 
splenocytes (containing both CD4+ and CD8+ T cells), we also tested if CD8+ T 
cell responses were suppressed.  We found that, like CD4+ T cells, CD8+ T cell 
activation was decreased in co-cultures with peritoneal cells from EPS-treated 
mice compared to peritoneal cells from ΔEPS mice (Figure 3.22A), although the 
Figure 3.21. Inhibition of anti-CD3-stimulated CD4+ T cell 
proliferation by peritoneal cells from EPS-treated mice.  CTV-labeled 
spleen cells were stimulated with anti-CD3, cultured with total peritoneal cells 
from EPS or ΔEPS-treated mice, and analyzed by flow cytometry.  A. 
CD4+CD44+CD25+ Activated T cells.  B. Proliferation of CD4+ T cells; Horizontal 
bar = % proliferating cells.  C. (Left) % proliferating CD4+ T cells; (center) % 
activated CD4+ T cells (CD44+CD25+); (right) concentration of IFN-γ in culture 
supernatants as determined by ELISA.  Average of 10 independent experiments; 
N = 15 mice total per group.  Statistical significance determined by Student’s t 
test.  p<0.05 denoted as *.	
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reduction was not as much as for the CD4+ T cells.  CD8+ T cell proliferation is 
also greatly reduced in co-cultures with EPS-treated mice compared to peritoneal 
cells from ΔEPS mice (Figure 3.22B).  Since IFN-γ was measured in culture 
supernatants, the reduction in IFN-γ production in Figure 3.20C is likely due to 
Figure 3.22. Inhibition of anti-CD3-stimulated CD8+ T cell 
proliferation by peritoneal cells from EPS-treated mice.  CTV-labeled 
spleen cells were stimulated with anti-CD3 and cultured with total peritoneal 
cells from EPS or ΔEPS-treated mice. A. Activated CD8+ T cells (CD44+CD25+) in 
co-cultures with peritoneal cells from ΔEPS-treated mice (left) or EPS-treated 
mice (center); % Activated CD8+ T cells (CD44+CD25+) in 3 independent 
experiments; N = 7 mice total per group.  B. Proliferation of CD8+ T cells; 
Horizontal bar = % proliferating cells; (right) % proliferating CD8+ T cells in 3 
independent experiments; N = 7 mice total per group.  Statistical significance 
determined by Student’s t test.  p<0.001 denoted as ***, p = 0.001 to 0.01 
denoted as **, and p = 0.01 to 0.05 denoted as *.	
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decreased expression by both CD4+ and CD8+ T cells.  Taken together, these data 
demonstrate that peritoneal cells from EPS-treated mice inhibit both CD4+ and 
CD8+ T cell responses.   
Although unlikely that EPS would be present in the peritoneal cavity 3 dpt, 
we verified that EPS doesn’t directly inhibit T cell proliferation by culturing with 
purified CD4+ T cells with EPS or ΔEPS for 16 h, then stimulated the cells with 
anti-CD3 and anti-CD28.  Three days later, we assessed proliferation by flow 
cytometry and found no differences in CD4+ T cell proliferation in cells treated 
with EPS compared to ΔEPS-treated cells (Figure 3.23).  
Anti-CD3 strongly stimulates T cells activation and proliferation.  We 
asked if peritoneal cells from EPS-treated mice inhibit antigen-specific T cell 
proliferation, which is a more physiologically-relevant analysis.  To do this, we 
utilized OT-II transgenic mice in which CD4+ T cells express an ovalbumin-
Figure 3.23.  T cell proliferation following in vitro treatment with EPS.  
CTV-labeled CD4+ T cells were co-cultured with EPS (20 µg/mL) or an equal 
volume of ΔEPS for 16 h, then added to anti-CD3-coated plates with soluble anti-
CD28. Three days later, proliferation was assessed by flow cytometry.  
Representative profile of duplicate wells in 3 independent experiments.   
CTV 
ΔEPS  
EPS 5 µg/mL 
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specific αβTCR. Peritoneal cells were isolated from PBS- or EPS-treated WT mice 
3 dpt and pulsed overnight with ovalbumin (OVA).  CD4+ T cells were purified 
from OT-II mice and co-cultured with OVA-pulsed peritoneal cells for 6 days.  
We found that peritoneal cells from EPS-treated mice inhibit CD4+ T cells 
proliferation compared to proliferation of T cells in culture with peritoneal cells 
from PBS-treated mice (Figure 3.24).  Peritoneal cells from EPS-treated mice also 
inhibitit of OVA-specific T cell prolifeartion using bone marrow-derived dendritic 
cells as the antigen-presenting cell (APC) (data not shown).  This experiment 
demonstrates that reduced proliferation was not due to decreased antigen 
presentation by peritoneal cells from EPS-treated mice, although we have not 
ruled out this possibility.  These data suggest that peritoneal cells from EPS-
treated mice inhibit antigen-specific T cell proliferation.   
CTV 
PBS 
EPS 
Figure 3.24.  Inhibition of antigen-specific T cell proliferation by 
EPS-induced M2 macrophages.  Anti-CD3-stimulated, CTV-labeled CD4+ T 
cells from OT-II transgenic mice were co-cultured with OVA-pulsed peritoneal 
cells from PBS-treated or untreated mice.  Three days later, proliferation was 
assessed by flow cytometry. Representative data from 3 independent 
experiments.   
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Since we hypothesize that EPS-induced M2 macrophages within the 
peritoneal cavity exert this anti-inflammatory effect, we next tested if purified 
macrophages from EPS-treated mice inhibit T cell proliferation.  We FACS-sorted 
F4/80+CD11b+ cells from the peritoneal cavity of EPS-treated or ΔEPS-treated 
mice and co-cultured them in the T cell proliferation assay.  We expected that if 
macrophages mediate the inhibitory activity within the peritoneal cavity in this 
assay, that macrophages would inhibit T cell responses and F4/80- cells would 
not.  As expected, macrophages from EPS-treated mice inhibited CD4+ T cell 
proliferation (18% proliferation), compared to F4/80+CD11b+ cells from ΔEPS-
treated mice, which did not inhibit proliferation (75% proliferation).  Further, 
FACS-sorted T cells (CD3+) and B cells (IgM+) from EPS-treated mice did not 
inhibit T cell proliferation (Figure 3.25).    
Figure 3.25.  Proliferation of CD4+ T cells in co-cultures with FACS-
purified peritoneal cell populations.  CTV-labeled spleen cells were 
stimulated with anti-CD3 in c0-cultures with FACS-purified cells from EPS or 
ΔEPS-treated mice. Proliferation of CD4+ T cells with F4/80+CD11b+ cells (left); 
CD3+ T cells (center) or IgM+ B cells (right).  Horizontal bar = % proliferating 
cells. Representative flow cytometric profiles from 3 independent experiments; 
N = 7 mice total per group.  
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		 To further test if M2 macrophages are required for T cell inhibition, we co-
cultured proliferating T cells with peritoneal cells from EPS-treated mice that 
were depleted of macrophages by clodronate liposomes.  As a control, we co-
cultured T cells with peritoneal cells from EPS-treated mice that were treated 
with PBS liposomes, with the expectation that peritoneal cells from these mice 
would inhibit proliferation.  Further, we expected the cells from mice treated with 
clodronate liposomes and EPS would no longer inhibit proliferation.  As 
expected, peritoneal cells from PBS liposome-EPS-treated mice inhibited CD4+ T  
cell proliferation, whereas peritoneal cells from EPS-treated mice depleted of 
macrophages did not inhibit proliferation (Figure 3.26).  
PBS-L 11% 
Clod-L 85% 
CTV 
Figure 3.26.  Proliferation of CD4+ T cells in co-cultures with 
peritoneal cells from macrophage-depleted mice. Mice were treated 
with EPS 4-6 h post-treatment with PBS liposomes (PBS-L) or clodronate 
liposomes (Clod-L).  Peritoneal cells were co-cultured with CTV-labeled spleen 
cells and stimulated with anti-CD3.  Proliferation of CD4+ T cells, horizontal 
bar = % proliferating cells. Representative flow cytometric profiles from 4 
independent experiments; N = 6 mice total per group.  
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 Similarly, peritoneal cells from EPS-treated TLR4-/- or myeloid MyD88-/- 
mice, which do not generate M2 macrophages, also did not inhibit T cell 
proliferation, whereas peritoneal cells from TLR2-/-, which do develop M2 
macrophages, inhibit proliferation (Figure 3.27).  We conclude that EPS induces 
anti-inflammatory M2 macrophages that inhibit T cell responses in vitro.    
Inhibition of T cell Responses in vivo.   
The data above indicate that EPS-induced M2 macrophages have the 
 
Figure 3.27.  Proliferation of CD4+ T cells in co-cultures with 
peritoneal cells from EPS-treated TLR-deficient mice. CTV-labeled 
spleen cells were stimulated with anti-CD3 and cultured with total peritoneal 
cells from EPS- or ΔEPS-treated mice.  Proliferation of CD4+ T cells cultured 
with peritoneal cells from TLR4-/-
 
 (A), myeloid MyD88-/- (B), or TLR2-/-(C) 
mice.  Horizontal bar = % proliferating cells. None = splenocytes alone.  4-6 
independent experiments with N = 7-10 mice total per group.  Statistical 
significance determined by Student’s t test.  p<0.001 denoted as ***, p = 0.001 
to 0.01 denoted as **, and p = 0.01 to 0.05 denoted as *.	
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capacity to inhibit T cells in vitro, but does this occur in vivo?  Naïve CD4+ T cells 
polarize into different T cell subsets based on their environment.  Upon antigen-
specific interactions, co-stimulation and the surrounding cytokine milieu, T cells 
activate, proliferate, and produce effector cytokines, leading to inflammation.  We 
tested if EPS inhibited T cell responses in vivo by measuring levels of Th1, Th17, 
and Th2 inflammatory cytokines, IFN-γ, IL-17A and IL-13, respectively, in 
cultures of splenocytes from EPS- or ΔEPS-treated mice stimulated with anti-
CD3ε.  The secretion of each of the cytokines was decreased in EPS-treated mice 
compared to ΔEPS-treated mice (Figure 3.28), indicating that EPS induces a 
systemic anti-inflammatory response that broadly suppresses Th1, Th17, and Th2 
cytokine production.	 
  To determine if EPS alters T cell responses during inflammation in vivo, 
we administered EPS to mice and 3 days later, after induction of M2 
Figure 3.28. Inhibition of T cell responses in EPS-treated mice.  
Quantification by ELISA of IFNγ, IL-17A, and IL-13 in culture supernatants of 
anti-CD3-stimulated splenocytes from EPS- or ΔEPS-treated mice. Average of 
4 independent experiments with N = 8 mice total per group. Statistical 
significance determined by Student’s t test.  p<0.001 denoted as ***, p = 0.001 
to 0.01 denoted as **, and p = 0.01 to 0.05 denoted as *.	
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macrophages, injected them i.p. with anti-CD3ε, which induces potent T cell 
activation and release of TNF-α and IL-2 (Ferran et al. 1991). We expected 
decreased production of these cytokines in the blood of EPS-treated mice 
compared to ΔEPS-treated mice.  Indeed, we found a two-fold decrease in 
production of serum TNF-α, IL-2 and IFN-γ in EPS-injected mice compared to 
mice injected with ΔEPS (Figure 3.29).  Together, these data indicate that EPS 
inhibits T cell responses in vivo.   
Mechanism by which EPS-induced M2 Macrophages Inhibit T cells. 
Inhibitory molecules produced by EPS-induced M2 
macrophages.  M2 macrophages inhibit T cell responses by multiple factors, 
including Arg-1, PGE2, IL-10, PD-L1/2 and TGF-β (Taylor et al. 2006; Pesce et al. 
2009; Huber et al. 2010).  In section 1, we established that EPS-induced M2 
macrophages express Arg-1 and PD-L1, but these cells may also express other 
 
Fig. 3.29.  Inhibition of T cell cytokine responses in serum from 
EPS-treated mice.  Quantification by ELISA of serum TNF-α, IFN-γ and 
IL-2 in EPS-treated or untreated (NT) mice 2 h post-i.p. injection of anti-
CD3.  Average of 3 independent experiments with N = 9 mice total per group.  
Statistical significance determined by Student’s t test.  p<0.001 denoted as 
***, p = 0.001 to 0.01 denoted as **, and p = 0.01 to 0.05 denoted as *.	
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inhibitory cytokines, such as IL-10, known to inhibit T cell proliferation.  We used 
ELISA to test if EPS-induced M2 macrophages upregulate IL-10 production, and 
found no increase in IL-10 levels in culture supernatants compared to 
supernatants from untreated macrophages (Figure 3.30A).   
 TGF-β is secreted as a latent pro-peptide, and cannot interact with its 
receptor unless cleaved.  TGF-β associates with latency-associated peptide (LAP) 
in the cytoplasm, but when associated with LAP, can be expressed on the cell 
surface, although the process is not well understood.  Cells and tissues rapidly 
inactivate TGF-β following secretion making it difficult to detect; inactive TGF-β 
can be activated with acid, allowing detection.  To determine if EPS upregulates 
 
Figure 3.30. Identification of inhibitory Molecules Produced by EPS-
induced M2 macrophages.  A. Quantitation of IL-10 in cell supernatants of 
macrophages from untreated or EPS-treated mice. Average of 6 mice in 2 
independent experiments. B. Quantification by ELISA of total TGF-β in serum 
after EPS-treatment or no treatment (NT). N= 4-5 mice total per group.  C. LAP 
expression on F4/80+ macrophages 3 dpt with EPS compared to F4/80+ cells 
from untreated mice.  D. Fold change in TGF-β reporter activity in co-cultures of 
MFB-F11 cells with peritoneal cells from EPS-treated relative to TGF-β activity in 
untreated mice.  rTGF-β= recombinant human TGF-β.  Average of 6 mice from 2 
independent experiments.  Statistical significance determined by Student’s t test.  
p<0.001 denoted as ***, p = 0.001 to 0.01 denoted as **, and p = 0.01 to 0.05 
denoted as *.	
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expression of TGF-β, we activated total TGF-β in serum by acid-treating with 1 N 
HCl, and then neutralizing with 1 N NaOH.  By ELISA, EPS upregulates total 
TGF-β in serum compared to untreated mice (Figure 3.30B).  To test if EPS 
upregulates TGF-β in macrophages from EPS-treated mice, we assessed LAP 
expression on F4/80+ cells from EPS-treated mice and untreated mice.  Since 
LAP, and not TGF-β, has a transmembrane domain, if EPS upregulates cell-
surface TGF-β, we would expect to see LAP upregulated.  We find a very slight 
upregulation of LAP expression on the surface of macrophages following EPS 
treatment. (Figure 3.30C).  
 We further tested for increased TGF-β expression by co-culturing 
peritoneal cells from EPS-treated mice with MFB-F11 cells.  This Tgf-b1-/- 
fibroblast cell line stably expresses a reporter plasmid consisting of TGF-β 
responsive Smad-binding elements coupled to a secreted alkaline phosphatase 
reporter gene.  Smad proteins are part of a signaling cascade activated upon TGF-
β receptor signaling.  Since this cell line originates from a Tgf-b1-/- mouse, the 
assay has limited background activity.  We expected that if EPS-induced M2 
macrophages express TGF-β that we would see an increase in alkaline 
phosphatase activity compared to cells from untreated mice.  Relative to cells 
from untreated mice, we find a 4-fold increase in Smad activity, and therefore 
TGF-β activity, in cells from EPS-treated mice (Figure 3.30D).  The 4-fold 
increase in TGF-β was equivalent to 125 pg/mL of recombinant human TGF-β 
added to MFB-F11 cells.  These data suggest that EPS-induced M2 macrophages 
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produce TGF-β, which is a potent inhibitor of T cell proliferation.   
Since EPS-induced M2 macrophages express multiple inhibitory factors, 
including Arg-1, PD-L1 and TGF-β, we next tested if EPS-induced M2 
macrophages inhibit via a soluble factor or by cell-to-cell contact.  We used 
transwells to separate peritoneal cells from T cells.  We expected that if inhibition 
requires cell contact, the peritoneal cells from EPS-treated mice would no longer 
inhibit T cell proliferation if placed in a transwell, separated from the 
splenocytes.  As is seen in Figure 3.31, EPS-induced M2 macrophages no longer 
inhibited CD4+ or CD8+ T cell proliferation when separated from the T cells, 
indicating that cell-to-cell contact is required for inhibition (Figure 3.31); this 
finding does not rule out the possibility that soluble factors also contribute to the 
inhibition.     
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Figure 3.31. Proliferation of T cells in contact with, or separated 
from peritoneal cells. Proliferation of CD4+ (A) or CD8+ (B) T cells co-
cultured with peritoneal cells from untreated (NT)- or EPS-treated mice in 
direct contact (no transwell, left) or with peritoneal cells in a transwell insert 
(right).  Horizontal bar = % proliferation.  Representative of three independent 
experiments.  
Restoration of CD4+ T cell proliferation by inhibitors of M2 
macrophage function.  To identify the molecule(s) produced by EPS-induced 
M2 macrophages that prevents T cell activation, we added inhibitors to the T cell 
inhibition assay, focusing on PD-L1 and TGF-β.  To test if TGF-β is required for 
inhibition of T cells by EPS-induced M2 macrophages, we added neutralizing 
TGF-β antibody to co-cultures of peritoneal cells and proliferating T cells.  If 
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TGF-β mediates the anti-inflammatory effect of EPS-induced M2 macrophages, 
we expected to find an increase in T cell proliferation in these co-cultures   
compared to co-cultures with isotype control antibody.  Whereas only 14% of 
CD4+ T cells proliferated in cultures with peritoneal cells from EPS-treated mice, 
proliferation was greatly increased by the addition of anti-TGF-β (69% CD4+ T 
cells) (Figure 3.2A, B), indicating that EPS-induced M2 macrophages produce 
TGF-β, which inhibits CD4+ T cell proliferation in vitro.  We further tested the 
importance of TGF-β signaling in EPS-induced M2 macrophage inhibition of T 
cells by using a TGF-β receptor kinase inhibitor.  This inhibitor, SB-431542, 
blocks phosphorylation of Smad proteins, thereby inhibiting TGF-β signaling.  In 
accordance with TGF-β inhibition by antibody, we find a dose-dependent 
restoration of T cell proliferation in the presence of SB-431542. Inhibition using 
this small molecule also restores T cell activation, as expected; however, this 
restoration occurs at all concentrations of the inhibitor (Figure 3.32C, D).  These 
data suggest that TGF-β mediates CD4+ T cell inhibition by EPS-induced M2 
macrophages. 
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In contrast to TGF-β inhibition, addition of neutralizing antibodies to PD-
L2 (Figure 3.33A), PD-L1 (Figure 3.33B), and IL-10 (Figure 3.33C) did not 
restore CD4+ T cell proliferation (Figure 3.34).  Further, inhibition of Arg-1 
activity by Nor-NOHA, or addition of exogenous L-arginine, did not restore T cell 
CTV 
A EPS Peritoneal Cells 
Ms IgG1 15% 
Anti-TGF-β 69% 
Ms IgG1 83.1% 
Anti-TGF-β 92.0% 
CTV 
NT Peritoneal Cells B 
C D 
***	*** ns 
Figure 3.32.  Inhibition of TGF-β in co-cultures of proliferating T 
cells and peritoneal cells.  A. Proliferation of CD4+ T cells of anti-CD3 
stimulated splenocytes cultured with peritoneal cells from untreated mice (left) 
or EPS-treated mice (right) in the presence of neutralizing anti-TGF-β antibody 
or mouse (Ms) IgG1 isotype control.  Horizontal bar = % proliferation.  B.  
Average proliferation in three independent experiments.  C and D. 
Proliferation and activation of CD4+ T cells of anti-CD3 stimulated splenocytes 
cultured with peritoneal cells from untreated mice (left) or EPS-treated mice 
(right) and SB-431542 (C); data from 4 independent experiments (D) using 
decreased amounts of SB-431542.  Average proliferation (left) and activation 
(CD44+CD25+) (right) of T cells.  Statistical significance determined by Student’s 
t test.  p<0.001 denoted as ***, p = 0.001 to 0.01 denoted as **, and p = 0.01 to 
0.05 denoted as *.	
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proliferation (Figure 3.33D, E and Figure 3.34), even though we found increased 
expression of Arg-1 in EPS-induced M2 macrophages (Figure 3.3).  The addition 
of NS-398, a COX2 inhibitor that prevents PGE2 production also had no effect on 
T cell inhibition by EPS-induced M2 macrophages (Figure 3.33F).  These data 
suggest that TGF-β is responsible for the inhibitory effect of M2 macrophages on 
CD4+ T cells (Figure 3.34).   
Figure 3.33. Restoration of T cell proliferation by inhibitors of M2 
macrophage function.  Proliferation of CD4+ T cells cultured with 
peritoneal cells from EPS-treated mice and containing inhibitors of M2 
macrophage function: blocking anti-PD-L2(A); blocking anti-PD-L1(B); 
neutralizing anti-IL-10 (C); Nor-NOHA (D); L-Arginine (E); NS-398, a COX2 
inhibitor (F).  Representative flow cytometric profiles are from 3 independent 
experiments each, N = 6 mice total per group.  
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Restoration of CD8+ T cell proliferation by inhibitors of M2 
macrophage function.  Since TGF-β acts on all T cells, we expected TGF-β to 
mediate EPS-induced M2 macrophage inhibition of CD8+ T cells, as well of CD4+ 
T cells.  Indeed, anti-TGF-β also partially restored CD8+ T cell proliferation 
(Figure 3.35A).  Interestingly, blocking anti-PD-L1 antibody also partially 
restored CD8+ T cell proliferation (Figure 3.35B).  The addition of both anti-PD-
L1 and anti-TGF-β antibodies resulted in complete restoration of CD8+ T cell 
proliferation (Figure 3.35C), indicating that both TGF-β and PD-L1 contribute to 
	
Figure 3.34. Restoration of T cell proliferation by inhibitors of M2 
macrophage function. % Proliferation of CD4+ T cells cultured with 
peritoneal cells from EPS-treated mice and containing inhibitors of M2 
macrophage function.  (n) NT peritoneal cells alone (negative control); (☐) 
peritoneal cells from EPS-treated mice (positive control); (    ) cultures with 
inhibitors of M2 macrophages, anti-TGF-β, Nor-NOHA, L-Arginine, NS-398, 
anti-PD-L2, anti-PD-L1, and anti-IL-10.  Data are from 3 independent 
experiments each, N = 6 mice total per group. Statistical significance 
determined by one-way ANOVA in combination with Bonferroni’s test for 
multiple comparisons.  *** denotes p < 0.0001 by ANOVA.  
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the inhibition of CD8+ T cells.  We conclude that the EPS-induced M2 
macrophages inhibit T cell responses through TGF-β and PD-L1.  
TGF-β and PD-L1 inhibit T cells by inducing apoptosis, among other 
Figure 3.35. Restoration of CD8+ T cell proliferation by inhibitors of 
M2 macrophages.  A-C. Proliferation of CD8+ T cells of anti-CD3 stimulated 
splenocytes cultured with peritoneal cells from EPS-treated mice in the presence 
of neutralizing anti-TGF-β antibody or mouse (Ms) IgG1 isotype control (A); 
blocking anti-PD-L1 or rat (rt) IgG2b isotype control (B); both inhibitory 
antibodies or isotype controls combined (C).  Horizontal bar = % proliferation. D. 
Average % proliferation from 3 independent experiments each, N = 6 mice total 
per group. (n) NT peritoneal cells alone (negative control): (☐) peritoneal cells 
from EPS-treated mice (positive control); (    ) cultures of EPS peritoneal cells 
with inhibitors of M2 macrophages. Statistical significance determined by one-
way ANOVA in combination with Bonferroni’s test for multiple comparisons.  *** 
denotes p < 0.0001 by ANOVA.  
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mechanisms (Gorelik & Flavell 2002; Zou et al. 2016).  We tested if peritoneal 
cells from EPS-treated mice induce apoptosis in co-cultures of proliferating T 
cells by staining for Annexin V and 7-AAD.  Annexin V binds to 
phosphatidylserine that is exposed on the cell surface in cells undergoing 
apoptosis.  During the early stages of apoptosis, cells bind Annexin V, but exclude 
the viability dye, 7-AAD.  Once membrane integrity is lost, cells take up 7-AAD 
and are positive for both stains.  We expected to see an increase in apoptosis in 
CD4+ and CD8+ T cells co-cultured with peritoneal cells from EPS-treated mice 
compared to untreated mice.  After one day of culture with peritoneal cells from 
EPS-treated mice, 37% of CD4+ T cells and 16% of CD8+ T cells are apoptotic, 
compared to only 7.9% and 7.2% of CD4+ and CD8+ T cells, respectively, in co-
cultures with peritoneal cells from untreated mice (Figure 3.36).  These data 
suggest that EPS-induced M2 macrophage induce apoptosis in T cells through 
TGF-β and PD-L1.  The increase in Annexin V and 7-AAD double positive cells 
could possibly due to necrosis, and additional, earlier time points need to be 
examined to address this possibility.  Future experiments will determine if 
induction of apoptosis is dependent on these molecules and if T cells are also 
rendered anergic by EPS-induced M2 macrophages. 
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Conclusions from Section 2. 
 EPS-induced M2 macrophages inhibit T cell responses both in vitro and in 
vivo.  This inhibition is mediated by TGF-β and PD-L1, in a cell contact-
dependent manner.   
 
Figure 3.36.  Apoptosis staining in co-cultures of proliferating T cells 
and peritoneal cells from EPS-treated mice. CTV-labeled spleen cells were 
stimulated with anti-CD3 and c0-cultured with peritoneal cells from untreated or 
EPS-treated mice for one day.  Annexin V and 7-AAD were assessed in CD4+ and 
CD8+ T cells by flow cytometry.  Representative data from 3 independent 
experiments, 1-3 mice in each group per experiment.    
ANNEXIN V 
7-
AA
D
 
CD4+ CD8+ 
NT 
EPS 
120	
		
Section 3.  Induction of Regulatory T cells by EPS-induced M2 
Macrophages 
Induction of T Regulatory Cells in vivo. 
Naïve CD4+ T cells polarize into effector T cell subsets according to 
environmental conditions. In the presence of TGF-β, CD4+ T cells upregulate 
expression of Foxp3 and become inducible Treg cells (iTreg).  Additionally, PD-
1–PD-L1 interactions not only maintain peripheral tolerance by inhibiting 
effector T cells, but also help to maintain iTreg cells.  Since M2 macrophages 
produce TGF-β and PD-L1, which inhibit T cell responses, we hypothesize that 
production of TGF-β could also induce regulatory T cells. We examined Foxp3 
expression in CD4+CD25+ T cells in the peritoneal cavity 3 days post EPS-
treatment and found an increase in the percentage of Foxp3+ cells in EPS-treated 
mice (average of 12%) compared to untreated mice (average of 52%), although 
the percentage of activated T cells (CD4+CD25+) in the peritoneal cavity is 
reduced (Figure 3.37).  We find little difference in the percentage of Treg cells in 
the spleen (27% in untreated vs. 22% in EPS-treated) (Figure 3.38).  The 
percentage of Treg cells is so small, however, that small changes may be difficult 
to quantify by flow cytometry.  To efficiently assess the development and impact 
of EPS in the induction and development of Treg cells in spleen as well as in the 
MLN and GIT, a Foxp3 reporter mouse maybe a useful tool.  
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Figure 3.38.  Induction of Treg cells in spleen of EPS-treated mice.  
Representative example of Foxp3 expression in CD4+CD25+ T cells in the spleen 
of untreated (NT, top) or EPS-treated (EPS, bottom) mice 3 dpt.  B. % 
CD4+CD25+Foxp3+ cells in 5 independent experiments, N = 7 mice per group. 
Statistical significance determined by Student’s t test.  p<0.001 denoted as ***, p 
= 0.001 to 0.01 denoted as **, and p = 0.01 to 0.05 denoted as *.	
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Figure 3.37.  Induction of Treg cells in the peritoneum of EPS-treated 
mice.  A. Representative example of Foxp3 expression in CD4+CD25+ T cells in 
the peritoneal cavity of untreated (NT, top) or EPS-treated (EPS, bottom) mice 3 
dpt. B. % CD4+CD25+Foxp3+ cells in 5 independent experiments, N = 7 mice per 
group.  Statistical significance determined by Student’s t test.  p<0.001 denoted 
as ***, p = 0.001 to 0.01 denoted as **, and p = 0.01 to 0.05 denoted as *.	
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Induction of T Regulatory Cells in vitro by M2 Macrophages. 
We also tested the capacity of EPS-induced M2 macrophages to induce 
iTreg cells in vitro.  Dendritic cells and M2 macrophages co-cultured with naïve 
CD4+ T cells have the capacity to polarize cells to Treg cells in vitro.  We 
hypothesized that in our co-cultures of EPS peritoneal cells and proliferating T 
cells, the M2 macrophages would provide the TGFβ necessary for polarization.  
IL-2 is a growth factor required for Treg cell survival, therefore we also added in 
IL-2 to the co-cultures.  Following co-culture of peritoneal cells from EPS-treated 
mice with anti-CD3 stimulated splenocytes and IL-2, we find an increase in the 
percentage of CD4+CD25+Foxp3+ T cells compared to co-culture with peritoneal 
cells from untreated mice (Figure 3.39).  Taken together, these data suggest that 
M2 macrophages have the capacity to induce Treg cells.   
Figure 3.39.  Induction of Treg cells by EPS-induced M2 
macrophages.  A. CD4+CD25+Foxp3+ T cells found in co-cultures of anti-CD3 
stimulated splenocytes, IL-2 (50 ng/mL), and peritoneal cells from EPS-treated 
or untreated (NT) mice.  B. % CD4+CD25+Foxp3+ T cells (of total CD4+CD25+ T 
cells) in 4 independent experiments with N = 6 mice total per group.  Statistical 
significance determined by Student’s t test.  p<0.001 denoted as ***, p = 0.001 
to 0.01 denoted as **, and p = 0.01 to 0.05 denoted as *.	
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Conclusions from Section 3. 
 EPS-induced M2 macrophages produce TGF-β and PD-L1, which inhibit T 
cell responses and contribute to the development and maintenance of peripheral 
T regulatory cells (Gandhi et al. 2007; Francisco et al. 2009).  We find a slight 
increase in the percentage of Treg cells in the peritoneal cavity of EPS-treated 
mice, and in vitro, EPS-induced M2 macrophages directly induce Treg cells.  
Future experiments will determine if EPS-induced M2 macrophages induce Treg 
cells in other locations in the body.   
Section 4: Potential of B. subtilis to Treat Human Disease 
 Purified EPS has been used to determine the mechanism by which B. 
subtilis spores prevent inflammatory disease induced by an enteric pathogen.  As 
a therapeutic, EPS would be an ideal way to transiently treat different diseases, 
especially in immunosuppressed individuals.  However, since B. subtilis spores 
are already available as a food and as a probiotic in many countries, B. subtilis 
could easily be used therapeutically without the timely regulatory processes 
required for use of purified EPS in humans.  Although we hypothesize that B. 
subtilis spores that protect in an EPS-dependent manner utilize that same 
mechanism as EPS, we sought to determine if spores also induce anti-
inflammatory M2 macrophages.     
Induction of M2 Macrophages by B. subtilis Spores. 
We first tested if like EPS, B. subtilis induces an M2 macrophage 
phenotype.  Mice were treated with WT or epsH B. subtilis mutant spores by oral 
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gavage.  The epsH spores do not produce EPS and do not protect mice from C. 
rodentium-induced disease (Jones & Knight 2012).  On days 4 and 6 post-
treatment, we isolated MLN and peritoneal cells from mice and assessed M2 
macrophage phenotype by flow cytometry.  In the peritoneal cavity at 4 dpt, we 
found an increase in the expression of IL-4Rα, and a slight increase in CD206 on 
macrophages in mice treated with WT B. subtilis spores compared to 
macrophages from epsH B. subtilis spores (Figure 3.40A).  The cells were not 
examined for expression of CD80, CD86 or PD-L1.  At this time-point, we did not 
find changes M2 macrophage markers in the MLN (data not shown).   
Interestingly, although the percentage of macrophages is only 1-4% of the 
MLN, by day 6, we found upregulation of several M2 macrophage markers on 
F4/80+ cells of mice orally gavaged with WT B. subtilis spores compared to mice 
gavaged with epsH B. subtilis spores (Figure 3.40B).  CD206 and PD-L1 are 
upregulated and CD80 expression has a slightly larger peak, but no changes are 
seen in IL-4Rα or CD86.  At day 6, no changes are seen in macrophage phenotype 
in the peritoneum.  These data suggest that B. subtilis induces M2 macrophages 
in the peritoneal cavity at 4 dpt and in the MLN by day 6.  The location of M2 
macrophage induction in B. subtilis-treated mice has not been exhaustively 
studied.  Future studies are needed to determine the dynamics of induction and 
migration of M2 macrophages in these mice.   
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Inhibition of T cell Responses by B. subtilis Spores.  
We further assessed the potential of cells from the peritoneal cavity and 
MLN of mice treated with B. subtilis spores for the capacity to inhibit T cell 
proliferation.  Similar to purified EPS, administration of B. subtilis spores (by 
oral gavage) resulted in the generation of peritoneal cells (4 dpt) that potently 
inhibit T cell proliferation (Figure 3.41A).  In contrast, peritoneal cells from mice 
gavaged with EPS-deficient epsH B. subtilis spores did not inhibit T cell 
proliferation.  Since we hypothesize that macrophages within the MLN of B. 
subtilis-treated mice will inhibit T cells, and macrophages represent such a small 
percentage of the MLN, we purified F4/80+ cells using magnetic beads.  F4/80+ 
MLN cells from WT- or epsH B. subtilis-treated mice isolated 6 dpt were co-
Figure 3.40. Induction of M2 macrophages in MLN and the 
peritoneum of B. subtilis-treated mice.  Mice were gavaged with WT B. 
subtilis spores or epsH B. subtilis spores.  Peritoneal cells (A) and MLN (B) 
were isolated 4 dpt and 6 dpt, respectively, and M2 macrophage markers were 
assessed on F4/80+ cells by flow cytometry.  Data are representative of 5 
independent experiments with 6-8 mice per group.        
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cultured with proliferating T cells and the capacity to inhibit proliferation was 
assessed.  As seen in Figure 3.41B, in cultures with F4/80+ cells from WT 
B.subtilis-treated mice, we find reduced T cell proliferation (48% CD4+ T cells) 
compared to proliferation in co-cultures with F4/80+ cells from epsH-treated 
mice (94% CD4+ T cells).  These reductions in proliferation are reproducible; 
however, they are not statistically significant (p=0.06), potentially due to 
variability in proliferation between experiments.  From these data, we conclude 
that both B. subtilis, like EPS, induces cells that inhibit T cell proliferation, 
indicating that both B. subtilis and EPS induce systemic anti-inflammatory 
responses.  Further studies are needed to determine if the inhibitory cells 
induced by B. subtilis are M2 macrophages, as is the case for EPS.  
 
Figure 3.41. Inhibition of T cell proliferation by peritoneal and MLN 
cells from B. subtilis treated mice. Proliferation of CD4+ T cells in cultures 
of anti-CD3 stimulated splenocytes and peritoneal cells from mice gavaged with 
WT or epsH B. subtilis spores. A. Representative flow cytometric profile of co-
cultures of peritoneal cells isolated 4 dpt (Left), and % proliferating T cells in 4 
independent experiments; N = 6 mice per group (right). B. Magnetic bead-
purified F4/80+ cells from MLN 6 dpt. Representative flow cytometric profile 
(Left); % proliferating CD4+ T cells in three independent experiments, with N = 
5 mice total per group (right). Horizontal bar = % proliferating cells; none = 
splenocytes alone.  Statistical significance determined by Student’s t test.  
p<0.001 denoted as ***, p = 0.001 to 0.01 denoted as **, and p = 0.01 to 0.05 
denoted as *.	
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Induction of M2 Macrophages in Human Cells.    
B. subtilis appears to induce M2 macrophages in an EPS-dependent 
manner, similar to the effects seen with purified EPS, although we have not 
determined if the inhibitory peritoneal cell type is a macrophage.  To further 
demonstrate if the model could be relevant to treat human disease, we asked if 
EPS induces an M2 macrophage phenotype in human macrophages.  Many of the 
M2 macrophage markers we utilize, Arg-1, Ym-1 and FIZZ-1 are expressed in 
mouse, and not human macrophages.  The scavenger receptor, CD163, is 
routinely used as a human M2 marker, and we used this marker to assess the 
capacity of EPS to induce M2 macrophages.  We also assessed CD80 and PD-L1 
expression, because these markers are upregulated in mouse macrophages, and 
they have homologs in humans.  We generated human macrophages from human 
cord blood by first allowing monocytes to adhere to plastic and washing away 
non-adherent cells.  We then treated the enriched monocyte population with M-
CSF (10 ng/mL) for 5 d.  After treating the macrophages with 5 µg EPS or an 
equal volume of ΔEPS for 3 d, the expression of CD80, PD-L1 and CD163 was 
assessed on CD68+ cells, the human macrophage marker, by flow cytometry.  If 
EPS induces M2 macrophages in humans, we expect to find an increase in CD163 
expression in CD68+ cells treated with EPS compared to untreated or ΔEPS-
treated cells.  Indeed, we found an increase in CD80+CD163+ cells within CD68+ 
cells from EPS-treated cultures compared to CD68+ cells from untreated cultures, 
or cultures treated with ΔEPS (Figure 3.42).  Further, EPS-treated cells 
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upregulate PD-L1 (Figure 3.42, right), consistent with observations in mouse 
macrophages.  These data suggest that EPS induces M2 macrophages in human 
cells.  Future studies will be needed to determine if these M2 macrophages 
generated in human also inhibit T cell responses.   
 
Conclusions from Section 4. 
 These studies show that B. subtilis, like EPS, induces an anti-inflammatory 
state and is a potential treatment for inflammatory disorders in humans until we 
identify the structure of EPS.  Additionally, we found that EPS induces an M2 
macrophage-like phenotype in human macrophages.
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Figure 3.42.  M2 macrophage induction in human cells.  Macrophages 
were generated from cord blood monocytes using M-CSF (10ng/mL) for 5 d.  
Cells were treated with 5 µg/mL EPS or an equal volume of ΔEPS for 3 d; 
CD68+ macrophages were assessed for CD80, CD163 and PD-L1 expression by 
flow cytometry.  Representative of 3 independent experiments, each from a 
different cord blood donor.   
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CHAPTER FOUR 
DISCUSSION 
Introduction. 
 Bacteria contribute to the development of many organ systems and 
physiological processes.  The microbiota is essential to train the immune system 
to tolerate foreign and self-antigen and develop regulated immune responses.  
Our health relies on maintaining a robust and diverse microbiota within our 
gastrointestinal tract.  Failure to establish a healthy microbiome at birth leaves 
individuals with increased susceptibility to numerous diseases.   
Not only are bacteria required for the proper development of the immune 
system, but specific bacterial molecules appear to be essential to mediate these 
effects.  Studies of bacterial products that modulate the immune system have, 
until recently, focused primarily on pathogenic molecules that elicit pro-
inflammatory responses or contribute to evasion of the immune system.  These 
studies identified host pattern recognition receptors, such as TLRs and NODs 
and their cognate ligands (e.g. LPS, lipoteichoic acid and flagellin) along with the 
downstream signaling pathways.  Less understood are the mechanisms by which 
commensal bacteria and commensal-derived products circumvent pro-
inflammatory responses, allowing select bacteria to live in homeostasis with the 
host.  The work in this thesis seeks to understand how commensal bacteria 
protect the host from disease.
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We found that a single oral dose of the probiotic B. subtilis or a single i.p. 
injection of B. subtilis EPS prevents inflammatory responses against the enteric 
pathogen, C. rodentium.  Additionally, we have identified that EPS from B. 
subtilis exerts this anti-inflammatory response by inducing M2 macrophages.  
This is the first demonstration of a probiotic molecule exerting anti-inflammatory 
effects through M2 macrophages. 
Mechanism by which B. subtilis Induces Anti-inflammatory 
Response. 
EPS binding to macrophages.  Peritoneal macrophages bind and 
rapidly internalize EPS (Figure 4.1).  Macrophages throughout the body and 
especially peritoneal macrophages highly express pattern recognition receptors.  
Since, EPS does not protect TLR4-/- mice from disease caused by C. rodentium, 
we suspected that EPS binds to TLR4, however, we find that EPS binds to 
peritoneal macrophages in mice deficient in TLR4 and TLR2.  We hypothesize 
that EPS utilizes a co-receptor of the TLR4 signaling complex, similar to LPS, 
which binds to the co-receptors CD14 and MD2 (Da Silva Correia et al. 2001).  In 
addition, EPS could bind C-type lectins or scavenger receptors, which serve as 
carbohydrate-binding pattern recognition receptors, and can associate with TLR4 
(Stewart et al. 2009; Mukhopadhyay et al. 2011; Amiel et al. 2009; Yu et al. 
2012).   
 Based on binding, we think that EPS acts strictly on macrophages, 
however, EPS may be internalized or phagocytosed by other cell types and elicit a 
response.  Some efforts to biotinylate EPS have been sucessful, however, the 
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process seems to render the EPS inactive and may alter the structure.  Once we 
understand the composition of EPS, we can more rationally determine a way to 
label EPS based on the polysaccharide chemistry, and effectively expore the effect 
of EPS on other cell types that perhaps bind EPS at low levels.  In fact, we have 
observed alterations in dendritic cells function following EPS treatment.  
Dendritic cells pulsed with ovalbumin stimulate CD4+ T cell proliferation in OVA-
specific T cells.  Following EPS treatment, OVA-pulsed dendritic cells no longer 
stimilate T cells to proliferate.  Although we don’t observe many alterations in the 
expression of co-stimulatory or co-inhibitory molecules, we find increased 
expression of IL-10 and TGF-β.  Whether this is due to the upregulation of IL-10 
and TGF-β following EPS treatment, or if EPS alters antigen presentation and co-
stimulation has not been determined.  Further studies will determine the 
mechanism by which EPS modulates dendritic cells.  Dendritic cells and 
macrophages express many of the same PRRs and therefore, the signaling 
cascade induced following EPS binding and internalization may be similar in 
both cell types.  In both cases, EPS seems to induce a regulatory phenotype.   
What is EPS?  Our lack of understanding of the basic biology of EPS 
complicates our search for the ‘EPS receptor’.  EPS is essential for B. subtilis 
biofilm formation.  Within the eps operon are four genes, epsH-K, required for 
synthesis of β-1,6-linked N-acetylglucosamine, identified to be a major 
component of EPS and thereby the B. subtilis biofilm.  The epsH and epsJ genes 
encode glycosyltransferases.  The B. subtilis mutant used as a negative control for 
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EPS production in all of our experiments is an epsH mutant, suggesting that N-
acetylglucosamine may comprise some of our immunomodulatory EPS.  If an 
EPS mutant outside of the epsH-K locus does not protect mice from disease, EPS 
is likely made up of an additional carbohydrate component.  
In initial analyses of EPS composition, we determined that EPS purified 
from B. subtilis grown in LB medium was comprised of 88.0% mannose, 11.9% 
glucose, and 0.1% N-acetylglucosamine (Complex Carboydrate Research Center, 
University of Georgia).   In collaboration with Dr. Neil Price at the USDA, we 
have determined that high amount of mannose in our EPS preparations was due 
to yeast extract mannan present in LB broth that co-purifies with EPS.  A small 
amount of EPS preparation purified from LB broth, although active in vivo, is 
actual EPS.  To obtain a higher and more pure yield of EPS, we grew B. subtilis in 
MSgg minimal medium to minimize polysaccharide background contamination.  
Using EPS purified from MSgg medium, we find the same immunomodulatory 
effects in vivo that we see with EPS purified from LB broth or BHI media, which 
we had used in early binding experiments (Table 4.1).  Interestingly, we can use 
10-fold less EPS from MSgg to induce the same response observed with EPS 
purified from LB broth.  The only functional difference identified thus far 
between EPS purified from LB and MSgg is that EPS from MSgg (and from BHI) 
induces M2 macrophages in vitro, whereas no in vitro changes were ever 
detected using the less-pure EPS from LB broth (Table 4.1).  Although we have 
yet to determine the composition of EPS prepared from MSgg, it is possible that 
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the mannose and N-acetylglucosamine observed to be a small percentage 
previously are the actual, functional EPS.  Once we determine the composition 
and structure of EPS, we can identify macrophage receptors that bind to the 
identified polysaccharide.   
 
 
Induction of M2 macrophages.  Even though EPS does not bind 
directly to TLR4, induction of M2 macrophages requires this PRR.  Canonical 
TLR4 signaling through MyD88 leads to NF-κB activation, however this pathway 
Experiment  
BHI 
 
LB 
 
MSgg 
EPS binding + +/- + 
M2 induction (in vivo) + + + 
M2 induction (in vitro) + - + 
T cell inhibition by EPS-
induced M2 macrophages 
+ + + 
Anti-CD3 challenge in vivo n.d. + + 
Splenic T cell responses n.d. + + 
Induction of Treg cells n.d. + + 
Growth Medium 
Key: (+): EPS purified from specified medium functions in this assay; (-): 
EPS purified from this medium does not function in this assay; (+/-): 
Variable results.  List of abbreviations: BHI – brain heart infusion media; 
EPS – exopolysaccharide; LB – Luria-bertani; n.d. – not determined. 
Table 4.1. Functional properties of EPS 
purified from different culture conditions 
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is often thought of as an inflammatory pathway.  M1 macrophage induction often 
occurs by LPS signaling through TLR4.  How then, does EPS drive an anti-
inflammatory response and induce anti-inflammatory M2 macrophages?          
The dependency on TLR4 is not likely due to LPS because B. subtilis is 
Gram (+) and produces little to no LPS.  In contrast to other bacterial 
polysaccharides, notably PSA from B. fragilis that signals through TLR2, EPS is 
unlikely to function through TLR2 because EPS induces M2 macrophages in 
Figure 4.1.  Model of induction of M2 macrophages by EPS.  EPS 
binds to macrophages and is rapidly internalized. EPS upregulates 
expression of M2 macrophage markers in a TLR-4 dependent manner.  
These cells also upregulate IL-4 and IL-13 that further enhances activation of 
M2-dependent genes.  STAT6, PPAR-γ, or NF-κB potentially drive this 
process.   
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TLR2-/- mice.  We hypothesize that EPS binding to TLR4 co-receptors recruits 
TLR4 and initiates a signaling cascade, directly modifying macrophages and 
induces M2 macrophage-specific transcription factors (Figure 4.1).  EPS binding 
to these receptors could upregulate M2 macrophage-inducing transcription 
factors such as STAT6, IRF4 and peroxisome proliferator-activated receptor 
gamma (PPAR-γ), which regulate transcription of Arg-1 and CD206 (Lawrence & 
Natoli 2011; Shirey et al. 2010).  IL-4 and IL-13 activate STAT6 signaling through 
IL-4Rα to induce M2 macrophages.  Since we see increased IL-4 and IL-13 
production by	macrophages following EPS treatment, EPS may activate the 
STAT6 pathway.  An intriguing study by Shirey et al. determined that respiratory 
syncytial virus (RSV) activates PPAR-γ to induce M2 macrophages.  Similar to 
EPS-induced M2 macrophages, RSV-induced M2 cells upregulate FIZZ-1, Ym1, 
CD206 and Arg-1 in a TLR4-dependent manner, that also requires STAT6 (Shirey 
et al. 2010).  This study identifies TLR4-dependent transcription factors that 
drive M2 induction that EPS could potentially utilize.   
We have preliminary evidence that EPS treatment upregulates NF-κB 
signaling in RAW264.7 cells that stably express an NF-κB luciferase reporter 
(Wonbeom Paik).  IL-10 activates STAT3 signaling in macrophages, leading to 
M2 macrophage generation in a process that also activates NF-κB, but EPS does 
not upregulate IL-10 in the conditions tested thus far.  Interestingly, STAT3 
activation in dendritic cells upregulates PD-L1 expression, similar to what we see 
in macrophages in response to EPS (Wölfle et al. 2011).  We have not yet 
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determined the timing of NF-κB activation, or if it occurs in primary 
macrophages.  It is possible that NF-κB activation occurs downstream of the 
initial signaling events induced by EPS.  Further, the phenotype of RAW264.7 
cells following EPS treatment is somewhat different than primary macrophages 
treated with EPS.  Studies of the signaling cascades induced by EPS will have to 
be completed in both cell types to verify that the correct signaling cascade is 
identified.  
An intriguing alternate hypothesis is that EPS antagonizes TLR4 signaling 
to induce an anti-inflammatory response.  In adipose tissue, the absence of TLR4 
drives macrophages towards an M2 phenotype (Orr et al. 2012).  M2 
macrophages present in adipose tissue highly express suppression of 
tumorigenicity 2 (ST2), a negative regulator of TLR4 signaling (Westcott et al. 
2009).  Other negative regulators of TLR4 signaling, such as AP-1 (activator 
protein 1), are stimulated by TLR4 activation (Patel et al. 2006).  EPS could 
activate M2 macrophage polarization by upregulating a negative regulator of the 
inflammatory TLR4 signaling cascade.   
EPS acts directly on macrophages to upregulate M2 macrophage markers.  
Other cell types, however, potentially contribute to the maintenance of M2 
macrophages within the peritoneal cavity.  Type 2 immune responses are 
characterized by IL-4, IL-5, IL-10 and IL-13 production.  ILC2s, Th2 cells, B cells 
and eosinophils are all activated by these cytokines, which leads to even greater 
production of these cytokines (Figure 4.2).  Although M2 macrophages may 
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initiate the response to EPS, these other type 2 immune cells are present in the 
dynamic environment of the peritoneal cavity and may be activated by 
macrophage cytokines.   
Induction of M2 macrophages by other probiotics.  Our work is 
the first to identify a probiotic molecule that suppresses pro-inflammatory 
responses through M2 macrophages.  Many bacterial species have been shown to 
induce the generation of Treg cells to suppress inflammation, however it is 
Figure 4.2. Dynamics of EPS-induced type 2 Immunity within the  
peritoneal cavity. 
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unclear how much M2 macrophages facilitate this induction.  The Mazmanian lab 
identified DCs as the cell type driving Treg induction by PSA, and DCs likely 
induce Treg cells in other probiotic models.  Other bacteria potentially induce 
anti-inflammatory macrophages and these cells may induce Treg cells in many 
models, as well as DCs.  One study on Clostridium butyricum identified a 
population of IL-10+ macrophages in the GIT of mice treated with this probiotic.  
This mechanism of induction is unique to that of B. subtilis EPS, given that C. 
butyricum utilizes TLR2 signaling and upregulates IL-10 production.  These cells 
are required for protection from DSS-induced colitis, and Treg cells seem to be 
partially required, however a direct connection between macrophages and Treg 
cells in this model has not yet been established.   
Trafficking of EPS-induced M2 macrophages.  EPS induces M2 
macrophages within the peritoneal cavity following intraperitoneal injection of 
EPS.  Increases in M2 macrophages are found both in the peritoneum after i.p. or 
i.v. injection of EPS, as well as after oral administration of B. subtilis spores.  
Does EPS travel systemically following injection, and/or do M2 macrophages 
traffic to other locations in the body?  Macrophages are highly prevalent in the 
peritoneum and because they bind and internalize EPS, we expect a limited 
amount of EPS leaves the peritoneal cavity.  Once we can label EPS, we will be 
able to track where EPS travels after injection.   
The peritoneum contains two populations of macrophages: LPMs and 
SPMs.  These cells differ in size and CD11b expression, and other markers, but 
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EPS binds to both LPMs and SPMs.  We hypothesize that EPS induces an M2 
phenotype in LPMs and SPMs.  Following non-specific i.p. injection, the majority 
of LPM traffic to milky spots in the omentum, but cytokines still interact with 
peritoneal cells (Okabe & Medzhitov 2016).  Meanwhile, monocytes infiltrate the 
peritoneal cavity and differentiate into macrophages (Ghosn et al. 2010).  
Although these infiltrating cells may not directly interact with EPS, the cytokine 
environment induced by initial EPS binding to LPMs and SPMs polarizes these 
new macrophages to an M2 macrophage phenotype.  In fact, supernatants from 
EPS-induced M2 macrophages polarize naïve macrophages to an M2 macrophage 
phenotype (unpublished observations).  F4/80+ cells proliferate in response to 
EPS, but we have not determined if this population of proliferating cells is LPMs, 
SPMs, or both.  Further, these studies were done by adoptive transfer of EPS-
induced M2 macrophages into naïve mice.  An important study will be to 
determine if the macrophages of mice fed Bromodeoxyuridine, BrdU, (in order to 
label proliferating cells) proliferate in response to EPS.   
 In our in vitro experiments, EPS-induced M2 macrophages inhibit T cell 
responses via direct cell contact, suggesting that M2 macrophages traffic to 
inhibit T cell responses during disease.  We do not know if in vivo, these cells can 
produce soluble factors to inhibit cells.  TGF-β activation is not well understood 
and could occur differently in vivo compared to our in vitro co-culture 
conditions.  We do find increased serum levels of total TGF-β, suggesting that 
TGF-β may be cleaved from the surface of M2 macrophages in vivo.  We often 
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find increases in M2 macrophages in MLN and spleen following EPS treatment 
where they may interact with and inhibit T cells.  These T cells are recruited to 
the colon following epithelial damage induced by C. rodentium in the colon. 
Since we do not see infiltration into the mucosa in mice treated with EPS prior to 
C. rodentium infection, we hypothesize that M2 macrophages render the T cells 
inactive or anergic in the spleen or MLN, blocking recruitment to the colon.  
Additionally, damage caused by C. rodentium may enhance recruitment of M2 
macrophages to the spleen, MLN, or the colon where they directly inhibit 
inflammation.  We have preliminary evidence that an increase in Arg-1+ cells 
occurs in the colon of mice treated with EPS prior to infection compared to mice 
infected with C. rodentium alone.  We have not established if the Arg-1+ cells are 
macrophages, but these data suggest that M2 macrophages are recruited to the 
colon during enteric disease.     
Peritoneal cells administered by i.p. injection traffic to the spleen and 
MLN, and we expect that some EPS-induced M2 macrophages traffic to other 
organs following EPS injection.  In different diseases, damage in other organs 
could recruit EPS-induced M2 macrophages and lead to protection from other 
sources of inflammation.  The mechanisms of macrophage egress from the 
peritoneal cavity are not well defined.  A recent study identified a CD44-
dependent mechanism by which peritoneal macrophage are recruited to the liver 
following sterile inflammation (Wang & Kubes 2016).  This may be a relevant 
mechanism for direct influx into other organs from the peritoneum.  
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Interestingly, peritoneal macrophages upregulate CD44 following EPS treatment, 
suggesting EPS-induced M2 macrophage may use a similar mechanism to travel 
to the liver and perhaps other organs (Wonbeom Paik, unpublished 
observations).   
Alterations in T cell Responses by EPS-induced M2 Macrophages. 
M2 macrophages mediate an anti-inflammatory response not only by 
TGF-β and PD-L1, but also by arginase-1, IL-10, and PD-L2 (Huber et al. 2010; 
Gobert et al. 2004; Pesce et al. 2009; Yue et al. 2015).  Such molecules protect 
from colitis, promote tissue repair and metabolic homeostasis, and provide 
protective immunity to helminth infections (Little et al. 2014).  Even though EPS-
induced M2 macrophages produce multiple anti-inflammatory molecules, in our 
in vitro co-cultures of EPS-induced M2 macrophages and proliferating T cells, we 
find restoration of CD4+ T cell proliferation only by interfering with TGF-β.  In 
contrast, CD8+ T cell restoration occurs through PD-L1, as well as TGF-β. 
Inhibition of other molecules including arginase-1, PGE2, PD-L2 and IL-10 had 
no effect on T cell inhibition.  We conclude that TGF-β and PD-L1 are the main 
inhibitory factors of the EPS-induced M2 macrophages (Figure 4.3).  We cannot 
rule out the contribution of other factors, potentially contributing to protection in 
vivo.  Arginase-1 inhibits TCR signaling, but also promotes wound healing and 
fibrosis (Pesce et al. 2009), effects we have not examined following EPS 
treatment.  EPS-induced M2 macrophages increase expression of CD80, but 
decrease expression of CD86.  These molecules interact with CD28 to provide co-
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stimulation to T cells, but can also interact with CTLA-4 to strongly inhibit T cell 
responses (Figure 4.3).  Although these molecules don’t contribute in our in vitro 
T cell proliferation assay, further studies are needed to determine the importance 
of these molecules in our system with T cells and other cells.     
Programmed death-ligand 1.  T cells upregulate PD-1 following TCR 
stimulation. Its ligands, PD-L1 and PD-L2 are expressed on dendritic cells and 
macrophages.  These ligands serve as co-inhibitory receptors that are part of the 
Figure 4.3.  Interactions between effector molecules of EPS-
induced M2 macrophages and T cells.  M2 macrophages produce 
multiple factors to inhibit T cell responses (-), including arginase-1, PD-L1 and 
TGF-β. CD80 provides co-stimulation when it interacts with CD28 (+), but 
inhibits following interactions with CTLA-4.   
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immune checkpoint during T cell activation (Freeman et al. 2000).  PD-1 
pathway interactions limit the positive signals that T cells receive from CD28 and 
CD80/CD86.  PD-1/PD-L1 signaling reduces cytokine production and halts T cell 
proliferation by inducing T cell apoptosis and anergy (Freeman et al. 2000; Liang 
et al. 2003).  In studies of chronic viral infection, PD-1 is highly expressed on 
exhausted T cells, suggesting that this pathway also promotes T cell exhaustion 
(Barber et al. 2006).  CD8+ T cells are more sensitive to PD-1 ligation (Carter et 
al. 2002), which may explain why, in our system, that PD-L1 blockade increases 
proliferation of CD8+ T cells, but not of CD4+ T cells.  The levels of co-stimulatory 
and co-inhibitory molecules determine if the interaction leads to inhibition or 
activation.  EPS-induced M2 macrophage upregulate CD80 and downregulate 
CD86, both co-stimulatory molecule, and increase expression of inhibitory PD-
L1.  In our in vitro T cell proliferation assay, inhibition of CD8+ T cells occurs in 
an antigen-independent manner, but potentially inhibition could occur in an 
antigen-specific interaction.  EPS-induced M2 macrophages inhibit antigen-
specific CD4+ T cell proliferation, presumably through TGF-β, but we have not 
tested inhibition of CD8+ T cells in an antigen-specific system.  Understanding 
the balance of these signals from M2 macrophages will help us determine how 
EPS could be used in other disease states to inhibit CD4+ and CD8+ T cell 
responses.   
Transforming growth factor-β.  TGF-β inhibits T cell responses by 
inducing apoptosis and T cell anergy, but also promotes immune responses in 
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other cells (Gorelik & Flavell 2002).  As discussed above, although we see cell 
contact-dependent inhibition via TGF-β signaling in vitro, activation may occur 
differently in vivo.  Integrins, matrix metalloproteinases (MMPs), and other 
proteases present in the extracellular matrix activate TGF-β (Hyytiäinen et al. 
2004).  Peritoneal macrophages express integrins, including CD11b, and MMPs 
that may activate TGF-β, but some macrophage functions require tissue-specific 
signals for expression (Okabe & Medzhitov 2016).  It is unclear if TGF-β-
expressing macrophages interact with cells other than T cells in vivo.  If TGF-β is 
cleaved and activated from macrophages in vivo, it could act on a variety of 
downstream cells.  TGF-β signaling in DCs decreases maturation and antigen 
presentation and decreases cytokine production and cytotoxicity of NK cells.  
Additionally, it increases chemotaxis of eosinophils, granulocytes, mast cells, and 
monocytes and macrophages.  TGF-β also decreases activation, proliferation and 
survival in B cells, but interestingly, it promotes class switching to IgA (Gorelik & 
Flavell 2002).  This would be beneficial in C. rodentium infection, where IgA 
production is required for clearance of the pathogen.  This also supports the use 
of EPS treatment for disease in other mucosal tissues, such as the lung.  
Additionally, if EPS can promote class switch to IgA, it could prevent 
development of unwanted isotypes, such as IgE in the case of allergic responses, 
from being generated.  In certain diseases, decreased effector cell function as a 
result of EPS treatment would be detrimental and increase disease pathology.   
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Contribution of TGF-β signaling in vivo.  TGF-β and PD-L1 mediate 
the inhibitory effects of EPS-induced M2 macrophages in vitro, but do these 
molecules contribute to protection in vivo?  Mice deficient in TGF-β signaling die 
before birth and due to the wide-range of effects mediated by TGF-β, selective 
inhibition can greatly exacerbate disease, making studies of the in vivo relevance 
of the cytokine technically difficult. To determine if TGF-β also mediates T cell 
inhibition in vivo, we utilized the anti-CD3 model, where i.p administration of 
anti-CD3 causes a robust increase in serum TNFα and IL-2 within 2 hours of 
treatment.  We first tested if anti-TGF-β alleviates the protective effects of EPS, 
using mouse IgG1 as the isotype control. Although neutralization of TGF-β 
removes EPS-induced reduction in T cell cytokine production, the isotype control 
alone also increases cytokine production.  Therefore, it is difficult to determine 
the effect of anti-TGF-β on EPS inhibitory effects.  In contrast, mice administered 
mouse IgG1 isotype control prior to infection with C. rodentium had reduced 
disease, making it difficult to discern the effect of TGF-β neutralization following 
EPS treatment in this model.  This may be due to interactions between the mouse 
IgG1 and Fc receptors that generate some sort of protective immune response.  
Unfortunately, neutralizing antibodies to TGF-β raised in a different species are 
not available. 
We next tried inhibiting TGF-β through the TGF-β receptor kinase 
inhibitor SB-423512, or the vehicle control DMSO.  Unfortunately, this inhibitor 
is highly insoluble in anything but DMSO, and like the isotype control, the DMSO 
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control also abolished the protective effects of EPS in the anti-CD3 model.  
Similarly in the C. rodentium model, mice administered the TGF-β inhibitor had 
exacerbated disease, and control mice administered EPS and DMSO were no 
longer protected from disease.  These experiments demonstrate that inhibiting 
TGF-β in vivo is technically difficult and requires further optimization.  We have 
not tested the relevance of PD-L1 signaling in vivo, but this would require a CD8+ 
T cell-specific model since TGF-β also partially restores EPS-induced M2 
macrophage inhibition of CD8+ T cells.   
Regulatory T cell induction by B. subtilis EPS.  One of the well-
studied effects of TGF-β is the induction of Treg cells.  We do see an increase in 
Treg cells within the peritoneal cavity of EPS treated mice and in co-cultures of 
EPS-induced M2 macrophages, but how do CD4+ T cells contribute to protection 
from C. rodentium-induced disease?  Often times iTreg cells upregulate IL-10 to 
suppress immune responses.  In preliminary experiments, we do find 
upregulation of IL-10 in co-cultures of EPS-induced M2 macrophages and 
proliferating T cells, where we also see an increased percentage of Treg cells.  We 
have not yet found upregulation of IL-10 in vivo, or determined if EPS-induced 
Treg cells contribute to protection from C. rodentium-induced inflammation.   
Early in the search for the protective cell-type, we tested if CD4-/- mice are 
protected by EPS from disease.  CD4+ T cells drive much of the pathology of C. 
rodentium-induced inflammation, but CD4-/- mice still develop disease, including 
diarrhea and damage dependent on MyD88 signaling, but goblet cell-depletion 
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and extensive hyperplasia do not occur. We found that CD4-/- mice are not 
protected by EPS from disease, suggesting that CD4+ T cells are required for EPS-
mediated protection (Dr. Sara Jones-Burrage, unpublished observations).  EPS-
induced M2 macrophages are present around 2-4 days post-treatment.  Day 4 
post-EPS treatment, peritoneal cells still display an M2 macrophage phenotype 
and inhibit T cell proliferation compared to peritoneal cells from mice treated 
with ∆EPS.  C. rodentium first colonizes the cecal patch, then the colon and 
begins to induce inflammation 4-7 dpi, however, peak disease doesn’t occur until 
10 dpi.  EPS-induced M2 macrophages possibly inhibit early T cell recruitment to 
the colon, but Treg cells may limit later stages of disease around days 7-10 since 
the pathogen is still present at levels comparable to ∆EPS-treated mice.  This 
could be what occurs in CD4-/- mice that develop M2 macrophages 3 dpt, but still 
develop diarrhea by day 10 post-infection.  Reconstitution of CD4-/- mice with 
CD4+ T cells restores the protective benefits of EPS treatment during infection 
(unpublished observations), but since these experiments use total CD4+ T cells 
and make the equivalent of a wild-type mouse, we do not know if iTreg cells 
mediate this benefit.  In order to directly test the contribution of iTreg cells to 
EPS-mediated protection from inflammation, we will need to specifically deplete 
iTreg with anti-CD25 or use mice in which Treg cells can be inducibly-depleted 
with diphtheria toxin.   
Potential of Probiotics to Treat Human Diseases. 
Regulatory T cell induction by other commensals.  Several 
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commensal bacteria other than B. subtilis prevent inflammatory diseases by 
modulating the immune response (Table I).  The beneficial effects of commensals 
are described mostly for models of inflammatory bowel disease (IBD), where, 
with a few exceptions (Pagnini et al. 2010; Ivanov et al. 2009; Fanning et al. 
2012), protection appears to be mediated, in large part, by TLR2 signaling, iTreg 
cells, and IL-10.  For example, B. fragilis, Bifidobacteria infantis, and Clostridia 
species induce Treg cells that ameliorate disease in chemically-induced colitis 
models (Shen et al. 2012; Atarashi et al. 2011; O’Mahony et al. 2008; Round & 
Mazmanian 2010) and VSL#3 and Bifidobacterium breve induce IL-10-
producing Tr1 cells (Di Giacinto et al. 2005; Jeon et al. 2012).  B. subtilis EPS 
induces M2 macrophages that inhibit T cell responses through PD-L1 and TGF-β 
and have the capacity to induce Treg cells.  We conclude that B. subtilis EPS 
induces an anti-inflammatory response distinct from that of all previously 
described probiotics.   
With the exception of B. subtilis EPS, B. fragilis PSA and sphingolipids, 
and Faecalibacterium prausnitzii MAM protein (Mazmanian et al. 2008; Jones 
et al. 2014; Sokol et al. 2008; Quévrain et al. 2015; An et al. 2014), most of the 
bacterial molecule(s) responsible for protection have not yet been identified or 
purified.   
Therapeutic potential of probiotics outside the intestine.  While 
most known probiotics target gastrointestinal disease, many probiotics will likely 
be useful for treating or preventing other inflammatory diseases, including 
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diabetes, allergy and experimental autoimmune encephalomyelitis (EAE) (Stefka 
et al. 2014; Cao et al. 2014; J et al. 2010; Hu et al. 2015).  In fact, SFB-induced 
Th17 cells prevent the spontaneous development of type-1 diabetes in NOD mice 
(Kriegel et al. 2011).  Clostridia species alter innate lymphoid cells and prevent 
development of food allergy (Stefka et al. 2014), and B. fragilis PSA prevents 
development of EAE (J et al. 2010).  As our understanding of the mechanisms by 
which specific commensal bacteria modulate the immune system increases, we 
will likely identify more diseases for which these probiotics will be beneficial.   
Therapeutic Potential of B. subtilis EPS. 
Therapeutic administration of B. subtilis and EPS.  Because EPS 
and B. subtilis can elicit an anti-inflammatory response when administered 
through several different routes, we think that EPS and/or B. subtilis are good 
candidates as therapeutic agents for treating inflammatory diseases.  B. subtilis 
can be administered as spores that easily transit unharmed through the harsh 
conditions of the stomach and upper GIT to a nutrient-rich location in the colon 
where the spores can germinate express EPS.  Bacterial molecules such as EPS 
are attractive therapeutics given that many immunosuppressed individuals 
cannot tolerate the whole bacterium.  EPS induces M2 macrophages when 
administered by intraperitoneal or intravenous injection, but this would be a 
cumbersome way to treat humans outside of the clinic.  Ideally, EPS would be 
administered orally.  Administration of EPS by oral gavage did not protect mice 
from disease caused by C. rodentium (Dr. Sara Jones, unpublished observations).  
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We expect that stomach acid breaks down and inactivates EPS.  From early 
studies in our lab, we also know that B. subtilis needs to localize to a specific 
niche within the GIT to induce a protective response, as an immobile, flagella 
mutant strain does not prevent disease.  Encapsulating EPS would provide a 
vehicle for safe passage through the stomach, but might not ensure that it would 
reach the ideal location within the GIT.  Investigations of other types of 
administration and the elicited immune responses will be vital to translating this 
work to humans.       
Relevance of B. subtilis in humans.  Although purified EPS is our 
ideal therapeutic, until we determine the composition and have a more 
comprehensive purification process without contamination, EPS is unlikely to 
pass any sort of regulatory process for use in humans.  Probiotics in a number of 
countries already contain B. subtilis and it is regularly consumed in Natto and 
miso soup, proving the safety of spore consumption; but is it efficacious?  A 
member of our lab, Alexander Argianas, found that B. subtilis spores purified 
from Natto prevented C. rodentium-induced disease in mice (unpublished 
observations).  This study suggests that the B. subtilis strains used in Natto 
produces EPS.  We have shown that EPS induces an M2 macrophages phenotype 
in human macrophages similar to what we see in mouse, with increased 
expression of CD80 and PD-L1.  The M1/M2 macrophage paradigm has not been 
well characterized in humans.  Part of this is due to differences in marker 
expression, but regardless of phenotype, the functions are somewhat conserved 
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between mouse and human (Martinez et al. 2008).  We have not yet determined 
if these cells produce TGF-β or if they are functional, but these studies suggest 
that EPS may be beneficial in humans.       
Autoimmune disorders.  EPS promotes a balance following the 
inflammatory Th1 and Th17 insult that occurs during C. rodentium infection.  
EPS also decreases T cell responses following i.p. challenge with anti-CD3.  We 
hypothesize that EPS can suppress other T cell-mediated diseases, specifically 
autoimmune disorders.  Th1 and Th17 cells that target the CNS drive EAE 
pathology; and, both M2 macrophages and TGF-β-bearing CD4+ T cells alleviate 
disease symptoms, suggesting EPS may be a potential treatment for disease.  
Many other autoimmune diseases, including type 1 diabetes, rheumatoid 
arthritis, and systemic lupus erythematosus, are driven by T cells or can be 
treated by blocking T cell responses (Raphael et al. 2015), and are attractive 
candidates to test if EPS is useful in other disease states. 
Graft-versus-host disease.  Following allogeneic bone marrow 
transplants, recipients are at a high risk for acute and chronic graft-versus-host 
disease (GVHD).  During GVHD, T cells from the donor attack host tissues, often 
in an immunosuppressed patient (Hoffmann et al. 2002).  Macrophages are 
resistant to irradiation and we hypothesize that EPS treatment of the recipient 
patient prior to and following receiving the transplant may reduce pathology 
associated with GVHD. Suppression of T cell activation by EPS would be an 
attractive therapy for preventing the T cell attack of host tissues. 
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All of these diseases discussed thus far are driven by Type 1 immune 
responses, and we hypothesize that EPS balances this environment to create a 
homeostatic environment.  M2 macrophages are canonically thought to 
contribute to Type 2 immunity, but EPS-induced M2 macrophages inhibit Th2, as 
well as Th1 cytokine responses.  We hypothesize that EPS can contribute to the 
homeostatic balance of preventing hyper-th1 as well as hyper-Th2 responses.   
Allergic disease.  Children not exposed to certain bacteria early in life 
do not develop a proper Th1/Th2 balance resulting in allergy and asthma (La 
Rosa et al. 2003).  Allergic disease is caused by the immune system 
inappropriately reacting to innocuous substances.  The process of allergic 
sensitization is initiated by APCs (such as dendritic cells) that capture and 
internalize allergen.  APCs present antigen, especially to T cells which secrete 
cytokines, IL-4, IL-5 and IL-13 that help drive the inflammatory response (Galli & 
Tsai 2012).  IL-4 is critical for class switch to IgE, the immunoglobulin that 
mediates allergic symptoms.  Allergen-specific IgE is produced by B cells after 
encounter with helper Th2 cells.  Once allergen-specific antibodies are generated, 
they bind to mast cells and upon subsequent exposure, the allergen cross-links 
IgE, causing mast cell degranulation and rapid release of chemical mediator such 
as histamine, that recruit of Th2 cells, basophils and eosinophils that exacerbate 
the immune response.   
Dr. Julie Swartzendruber asked if EPS prevents allergic sensitization, a 
hyper-Th2 response, in a mouse model of IgE-mediated allergic sensitization to 
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ovalbumin (OVA).  In mice pre-treated with EPS, we find a decrease in OVA-
specific IgE induced by OVA/alum sensitization, suggesting that EPS prevents 
allergic sensitization.  A potential mechanism for this suppression is that EPS-
induced M2 macrophages inhibit the initial interaction between APCs and T cells, 
limiting production of IL-4 and production of IgE.  Additionally, TGF-β produced 
by M2 macrophages could induce class switch to IgA, instead of IgE.  
Alternatively, EPS-induced alterations in DCs mentioned earlier could alter the 
generation of a detrimental Th2 response.  This study demonstrates that EPS can 
prevent allergic sensitization but it is unclear if EPS can prevent allergy 
symptoms after sensitization has already occurred. 
It is possible that EPS may exacerbate symptoms through the induction of 
M2 macrophages.  For example, TGF-β increases chemotaxis of eosinophils and 
other granulocytes, suggesting that even though TGF-β inhibits Th2 cells, it may 
enhance disease by recruitment of other detrimental cells.   Future studies need 
to be done to test this hypothesis. 
Cell targets of EPS.  In our current studies, we identified modulation of 
macrophages by EPS and have hypothesized DCs may also respond EPS.  Both of 
these cells are, or can be, myeloid lineage cells (certain DC subsets have a 
lymphoid lineage), and are known to phagocytose antigens.  Since many of the 
signaling pathways overlap between macrophages and DCs, it’s reasonable that 
EPS acts exclusively on these cells types.  Much of this expectation is based on 
binding of EPS to macrophages and low levels of EPS binding to DCs.  We do not 
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see alterations in T cells following co-culture with CD4+ T cells and have not 
observed any changes directly on B cells.  We have not extensively ruled out 
effects of EPS on other cell types, which would be necessary for future studies in 
humans.   
M2 macrophages in health and disease.  M2 Macrophages promote 
wound healing and tissue repair.  Further, they provide immunity to helminth 
infections.  Arginase-1 and TGF-β mediate protective effects in both tissue 
homeostasis and immunity to helminths, suggesting that EPS treatment may 
enhance anti-helminth immunity or promote tissue repair.   
M2 macrophages also help maintain metabolic homeostasis by secreting 
anti-inflammatory cytokines and utilizing oxidative metabolism.  During obesity, 
M1 macrophages promote chronic inflammation in adipose tissue, which leads to 
insulin resistance (Castoldi et al. 2016).  A shift to an M1 macrophage phenotype 
is characterized by aerobic glycolysis.  We have not assessed the metabolic profile 
of EPS-induced M2 macrophages.  One interesting hypothesis is that 
macrophages metabolize EPS, driving M2 macrophage development.  The 
benefits of B. subtilis and EPS and their anti-inflammatory properties could 
extend to promoting a lean (non-obese) metabolism.  Future experiments will 
discern these possibilities.   
Treatment vs. prevention.  In many of the diseases discussed, we have 
used EPS as a preventative measure.  We do know that B. subtilis administered 
up to 3 dpi with C. rodentium still prevents disease (Figure 4.4).  B. subtilis-
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induced M2 macrophages are present at 4 dpt in the peritoneal cavity and 6 dpt 
in the MLN, suggesting the anti-inflammatory response induced by B. subtilis 
takes about 4 days to develop.  When mice were infected with C. rodentium 3 
days prior to B. subtilis treatment, the anti-inflammatory environment developed 
after inflammation had already begun (Figure 4.4).  In this study, therefore, B. 
subtilis treats, rather than prevents, C. rodentium-induced inflammation, but it is 
unclear if this occurs in other diseases with EPS.   
In humans, it’s not practical for EPS to be administered as a pretreatment 
for an unknown or unexpected disease.  In certain cases of autoimmunity, such as 
MS, the disease is diagnosed early, before much damage has occurred, but for the 
majority of diseases, we would use EPS to treat inflammation.  Future studies 
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Figure 4.4. Therapeutic window of B. subtilis EPS-induced anti-
inflammatory response. 
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testing the capacity of EPS to dampen down T cell responses once they have 
already been initiated are necessary to determine the true efficacy of EPS in 
humans.    
EPS: is there a downside?  EPS prevents inflammation in several 
different inflammatory conditions and is an exciting therapeutic option for many 
disorders.  But can otherwise beneficial effects of EPS be detrimental in certain 
situations?  The anti-inflammatory response induced by EPS is transient.  By 5 
days post-EPS treatment, peritoneal macrophages resemble those of an untreated 
mouse.  Further, splenic T cell responses are no different between EPS-treated 
mice than untreated mice.  We do not expect this transient anti-inflammatory 
response to induce detrimental effects.  In cases of cancer, however, increased 
immunosuppression could lead to tumor growth.  Tumor-associated 
macrophages (TAMs) bear many similarities to M2 macrophages, including TGF-
β expression.  TAMs produce anti-inflammatory cytokines and promote 
angiogenesis to bring nutrients to the tumor microenvironment, fostering tumor 
growth.  PD-L1 expression within tumors also promotes tumor growth.  Blockade 
of the PD-1 pathway has been a breakthrough treatment for many different types 
of cancers.  Although EPS treatment would be harmful for an established tumor, 
we do not know if repeated EPS treatment and maintenance of M2 macrophages 
would promote tumor development.   
Repeated doses of EPS might also generate EPS-specific antibodies.  These 
antibodies might induce an inflammatory response or block the induction of M2 
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macrophages.  Low dose inoculation of certain antigens has also been linked to 
induction of allergy.  In certain situations, commensal specific antibodies 
promote retention of the bacterium within the GIT.  Identification of the induced 
antibody isotypes, or the particular adaptive immune response elicited might lead 
to identification of other disease states in which this response could be beneficial.  
Additionally, in the case of B. subtilis, increased prevalence might block 
colonization of C. rodentium or other pathogenic bacteria.   
In other cases of inflammation such as viral infection, inflammation is 
necessary to clear the pathogen.  Inhibition of a viral specific response might 
render the host unable to clear the pathogen, allowing the virus to manifest in 
other organs and have deleterious effects.  As with C. rodentium infection, much 
of the disease symptoms induced by some viral infections, such as the common 
cold, are an exacerbated response to assure clearance of the pathogen.  A low 
dose of EPS may treat some of these symptoms and still allow the immune 
system to clear the infection.   
Concluding Remarks. 
Bacillus subtilis as a commensal.  Clearly, B. subtilis has evolved a 
complex interaction with the immune system; yet, B. subtilis is often overlooked 
and not considered a true commensal.  During these early stages of identifying 
mechanisms of immune-modulation by the microbiota, much attention has been 
placed on highly prevalent bacterial species.  Although B. subtilis is present a low 
levels in the GIT, it is detected in a many of the individuals surveyed (Benno et al. 
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1984; Benno et al. 1986; Qin et al. 2010).  One possibility is that EPS is composed 
of similar polysaccharides to another highly prevalent commensal, but such a 
commensal has not been identified since no other commensals have been shown 
to induce M2 macrophages.  
These studies emphasize the importance of organisms present at low levels 
and their important role in promoting a balance between the microbiota and the 
host.  The gut microbiota requires balance with the immune system and many 
unavoidable factors, whether environmental, antibiotics or infections, cause 
fluctuations in the microbiota and the balance between type 1 and type 2 immune 
responses. The hygiene hypothesis suggests that reduced exposure to 
microorganisms early in life leads to abnormal development of the immune 
system, providing an explanation for the rise in allergic disease, inflammatory 
disorders and autoimmunity.  The importance of commensal bacteria in shaping 
health is now widely recognized, and the potential therapeutic benefits of these 
bacteria are being explored in several diseases.  Regardless of the prevalence of 
certain organisms during homeostasis, individual organisms with the capacity to 
induce tolerance possess strong potential to be used as a probiotic to restore 
homeostasis when dysbiosis occurs (Figure 4.5). 
Probiotics are a multi-billion dollar industry world-wide.  Yogurts, pills, 
energy drinks, the products and benefits of a healthy microbiota are all over the 
news, advertising and day-to-day life.  But are these products actually eliciting a 
response?  Our study highlighting that the mechanism by which B. subtilis limits 
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inflammation caused by an enteric pathogen indicates probiotics do actually 
prevent disease. 
Many probiotics on the market are an undefined cocktail of bacteria; it is 
unclear what if any of the components are eliciting a positive effect.  More 
mechanistic studies are needed to identify which products actually contribute to 
human health.  
Figure 4.5.  Probiotics maintain balance between type 1 and type 2 
immunity.  Balance between Type 1 and Type 2 immunity is maintained by 
Treg cells, M2 macrophages, and tolerogenic DCs (A). When dysbiosis occurs, 
a skewing towards type 1 immunity results in increased autoimmune diseases 
and metabolic disorders (B), whereas an detrimental type 2 immune response 
drives allergy, asthma and fibrosis (C).  Probiotics and commensal bacteria 
maintain regulatory cells that drive homeostasis, allowing normal 
inflammatory processes to occur (D).    
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Trillions of bacteria inhabit the gastrointestinal tract; countless bacteria 
found in the environment exert beneficial effects as probiotics.  The precise 
mechanism by which these bacteria modulate the immune system to benefit the 
host has been identified for around a dozen of these bacteria.  Only four 
molecules (EPS, PSA, sphingolipids, and MAM) from three bacteria (B. subtilis, 
B. fragilis, and F. prausnitzii) have been identified to mediate these symbiotic 
effects.  This study highlights a unique mechanism by which a Gram (+) 
commensal exopolysaccharide induces an anti-inflammatory environment, as 
modeled in Figure 4.6.  EPS from B. subtilis, induces anti-inflammatory M2 
M2 
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Figure 4.6.  Model for EPS modulation of immune responses.  B. 
subtilis and purified EPS induce M2 Macrophages which inhibit CD4+ and 
CD8+ T cells through production of TGF-β and PD-L1 and potentially through 
induction of regulatory T cells. 
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macrophages in a TLR4-dependent manner.  These M2 macrophages produce 
multiple immune inhibitory molecules, including TGF-β, PD-L1 and arginase-1, 
all of which inhibit T cell responses and prevent inflammatory diseases.  
Undoubtedly, additional molecules from a large number of commensal bacteria 
will be found to regulate immune responses.  Understanding the mechanisms by 
which EPS and other molecules from commensal organisms regulate the immune 
system will lead to new rationally-designed and safe therapeutics for 
inflammatory diseases. 
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